Division of Extramural Activities 

Annual Report 2002 

National Institutes of Health 

National Cancer Institute 
Molecular Diagnosis of Cancer 

Gene expression profiling using DNA microarrays is a technology that arose as a consequence of 

the Human Genome Project. With DNA microarrays, it is possible to determine the activity 

(“expression”) of tens of thousands of genes in parallel on microarray plates. The expression of 

genes influences the biological behavior of a cell because it dictates which proteins the cell can 

make and gives cells their unique characteristics. In the DNA microarray images shown at the 

bottom of the cover illustration, each spot represents a different human gene. Red, yellow, and 

green spots indicate that a gene is expressed at high, intermediate, and low levels, respectively. 

The pattern of expression of all of the genes in a cell constitutes its gene expression “profile.” 

Using DNA microarrays, different types of normal and malignant cells can be distinguished from 

one another because they have distinct gene expression profiles. 

Shown at the top of the cover illustration are photomicrographs of lymph node biopsies from two 

patients with diffuse large B cell lymphoma. The tumor at the right belongs to the germinal 

center B cell-like subgroup of diffuse large B cell lymphoma. Patients with this lymphoma type 

have a relatively favorable 5-year survival rate of 59% following multi-agent chemotherapy. 

The tumor at the left belongs to the activated B cell-like subgroup of diffuse large B cell 

lymphoma. Patients with this lymphoma type have a less favorable 5-year survival rate of 31%. 

Although the tumors from these patients were indistinguishable histologically, they had striking 

differences in their gene expression profiles, as exemplified by the microarray images shown 

below each lymphoma subgroup. Gene expression profiling has therefore revealed that the 

diagnostic category of diffuse large B cell lymphoma actually harbors more than one molecularly 

distinct disease. DNA microarray technology holds great promise for classifying different 

cancers, defining molecular subtypes of a tumor, optimizing treatment strategies, and monitoring 

clinical response to treatment.

Cover Illustration:

Courtesy of Louis M. Staudt, M.D., Ph.D., Chief, Lymphoid 

Malignancies Section, Metabolism Branch, Center for Cancer 

Research, National Cancer Institute, National Institutes of 

Health. 

Reference: 

Staudt LM. Molecular diagnosis of the hematologic cancers. N 

Engl J Med 2003;348:1777-85. 
Foreword 

Since Congress passed the National Cancer Act in 1971, we have been 

experiencing exponential growth in our knowledge of cancer. That scientific knowledge base, which is a primary responsibility of the 

National Cancer Institute (NCI), is the first stage along a continuum of 

discovery, development, and delivery that will ultimately take us to the 

goal I have challenged myself and the entire cancer community to reach 

by the year 2015—the elimination of suffering and death from cancer. 

The know-ledge that we discover, whether at the level of the gene, 

molecule, cell, tissue, organ, individual, or population, feeds 

development—the process of creating tools and interventions to reduce the cancer burden—with 

the end result being delivery, the process of disseminating, facilitating, and promoting evidencebased prevention, detection, diagnosis, and treatment practices and policies. 

The NCI is committed to exploiting that discovery-development-delivery strategy to achieve the 

2015 challenge goal. In large measure, this will be accomplished through the efforts of 

outstanding NCI extramural scientists who have and will continue to enhance the scientific 

knowledge base. The NCI Division of Extramural Activities (DEA), carries a major responsibility for strengthening the scientific knowledge base by conducting the scientific review of 

applications for support of extramural research; managing and coordinating the Institute’s 

advisory activities, including the Presidentially appointed National Cancer Advisory Board and 

the Board of Scientific Advisors; formulating, coordinating, and disseminating operating policies 

pertaining to extramural programs; and analyzing and reporting on all extramural research 

programs funded by the NCI. 

The DEA Annual Report provides a comprehensive look at each of the major areas of 

responsibility within the DEA, including referral, review, advisory activities, information 

resources, portfolio tracking and analysis, management, and extramural policy. 

I am pleased to present this annual report, which not only describes the DEA’s activities and 

accomplishments and its work in the context of achieving the NCI’s overall scientific goal of 

reducing the burden of cancer, but also gratefully acknowledges the hundreds of researchers who 

have contributed to the success of our peer-review and advisory activities. 

Andrew C. von Eschenbach, M.D. 

Director, National Cancer Institute
Introduction 

The mission and responsibilities of the NCI Division of Extramural Activities (DEA) affect, in 

some way, all extramural scientists receiving research or training support from the NCI. The 

DEA is centrally involved in all aspects of grant development and tracking, from original 

conception of research and training programs for introduction in the extramural community, to 

issuance of announcements of such programs, to receipt and referral of incoming applications, to 

review and final approval of the applications, to coding and tracking after disbursement of funds. 

In brief, the DEA was established to: 

 Provide advice and guidance to potential applicants 

 Refer incoming grant applications to appropriate programs within the NCI 

 Provide the highest quality and most effective scientific peer review and oversight of 

extramural research 

 Coordinate and administer advisory activities, such as the National Cancer Advisory Board 

(NCAB) and Board of Scientific Advisors (BSA), related to the various aspects of the NCI 

mission 

 Establish and disseminate extramural policies and procedures, such as requirements for 

inclusion of certain populations in research, actions for ensuring research integrity, budgetary 

limitations for grant applications, and policies to expedite funding 

 Track the NCI research portfolio (more than 6,445 research and training awards) using 

consistent, budget-linked scientific information to provide a basis for budget projections and 

to serve as a resource for the dissemination of information about cancer. 

In essence, the DEA is the organizational component of the NCI that coordinates the scientific 

review of extramural research before funding and provides systematic surveillance of that 

research after awards are made. In this latter role, the DEA assists the NCI in its goal of 

achieving a balanced portfolio of research in biology, behavior, epidemiology, and cancer control, prevention, detection, diagnosis, and treatment, as well as long-term survival/survivorship, 

rehabilitation, and end-of-life issues. In addition, the DEA serves as a focal point for information 

about the NCI’s peer-review and grants policies. DEA maintains a comprehensive Web site 

providing detailed information and links to application procedures and to announcements 

regarding funding opportunities—see http://deainfo.nci.nih.gov/funding.htm.

*† 

* See Appendix A for a glossary of acronyms used in this report. 

† A directory of Cancer Information Sources on the Internet, including selected DEA and NCI Web sites, is included in 

 Appendix G.
Grant Referral: DEA as the First Point of Contact with 

the NCI 

In Fiscal Year (FY) 2002, the NCI received 9,346 grant applications for referral (see Table 1). 

These included applications for 43 different types of funding award mechanisms (see Appendix 

F), including Clinical Investigator Awards (K08), Research Program Projects (P01), Cancer 

Center Support Grants (CCSGs) (P30), Research Projects (R01), and Small Business Innovation 

Research (SBIR) Grants (R43). During FY2002, the Program Coordination and Referral 

Branch (PCRB) in the DEA was responsible for receipt, referral, and assignment of applications, 

as well as other program development functions. 

Upon receipt of a primary or secondary assignment to the NCI by the National Institutes of 

Health (NIH) Center for Scientific Review (CSR), the DEA Referral Officer (RO) assigns all 

incoming applications to one of the 45 NCI extramural research program areas. The RO also 

must track, in real time, the review status of all applications assigned to the NCI. The RO 

distributes all of the applications directly reviewed by the DEA for the NCI. These applications 

include P01 Program Projects, P30 Centers, P20 Planning Grants, P50 Specialized Centers, R13 

Conference Grants, R03 Small Grants, T32 Training Grants, certain R01 Research Project 

Grants, and U series Cooperative Agreement applications. These applications are sent to one of 

the three DEA Review Branches for assignment to individual Scientific Review Administrators 

(SRAs) and to one of the seven subcommittees of the NCI Initial Review Group (IRG) or to a 

Special Emphasis Panel (SEP), as described later. 

The DEA is often the first point of contact for applicants and the recipient of Letters of Intent 

from potential applicants for multiproject Program Grants (P01) and Conference Grants (R13). It 

is also the only point of receipt for distribution to program staff of Research Supplements for 

Underrepresented Minorities, Supplements to Promote Reentry Into Biomedical and Behavioral 

Research Careers, Research Supplements for Individuals with Disabilities, and Supplements for 

the Continuous Umbrella of Research Experience (CURE) program for underrepresented 

minorities (available for R25, K12, and P30 parent grants). In addition, the RO receives and 

distributes advance copies of applications from investigators submitting P01s or responding to 

Requests for Applications (RFAs) and certain Program Announcements (PAs). 

DEA Referral Officers serve as primary NCI contact persons for members of the extramural 

scientific community in need of information on a broad range of subjects, including application 

information, new initiatives announced as RFAs or PAs, and the review process. The ROs also 

provide “one-stop shopping” for applicants who are uncertain about who to contact and direct 

them to appropriate Program Directors or SRAs for information on the status of the review and 

award of their grants. In addition, the ROs assist members of the extramural community in 

navigating NIH and NCI Web pages to obtain current information, forms, and guidelines. 

Progress continued in FY2002 toward the objective of a paper-free referral system. Working 

with the NCI Office of Informatics and contractors, the staff of the DEA Applied Information 

Systems Branch (AISB) and the ROs have brought this project to the point where all referral 

actions—those done by the ROs as well as those done by program staff—are completed 

electronically using an efficient, user-friendly, Web-based system that maintains records of 

actions. The system, which is one of the functions of the new NCI Online Workplace (NOW), 

was put in place in FY2001. Amended and competing continuation (Type 2) applications are 

referred automatically to the cancer activity that accepted the previously submitted application. 
Electronic reports using data from Information for Management, Planning, Analysis, and 

Coordination (IMPAC II) have been developed and are available (using Oracle Discoverer) to 

meet the various RO requests. 
Peer Review—The Next Step 

Once applications are referred to the NCI and the appropriate program, they must be reviewed. 

The high caliber of NCI’s research is maintained through peer review and a quality control 

process in which experts in the field review and score proposals for research. The peer-review 

mechanism helps ensure that the NCI uses its resources wisely and funds research that has the 

potential to make a significant contribution to science and medicine. The NCI’s extramural 

programs and activities are funded primarily through peer-reviewed grants and cooperative 

agreements. Programs funded through research contracts are also subject to peer review, 

including contract-supported projects conducted within the intramural research program. 

The dual peer-review system of the NIH consists of two sequential levels of review mandated by 

statute. The first level of review is performed by either an NIH CSR study section or an NCI 

Initial Review Group (IRG) subcommittee or Special Emphasis Panel (SEP) whose primary 

purpose is to review and evaluate the scientific merit of research grant and cooperative 

agreement applications. The second level of review for program relevance is conducted by the 

NCAB. 

Most investigators are familiar with the NIH CSR study sections, which have primary 

responsibility for investigator-initiated Research Project (R01) grants and fellowships. It is less 

widely known, however, that applications representing more than 50 percent of the NCI’s 

extramural budget are reviewed by groups directly formed and managed within the NCI by the 

DEA. Routing for review to either the CSR or the DEA is usually decided by the choice of award 

mechanism. In either case, the NCAB, also managed by the DEA, has statutory responsibility to 

perform the second level of review, which considers additional factors of mission and relevance. 

The NCI has no direct input into the selection of reviewers who serve on CSR study sections. In 

contrast, members of the NCI IRG are selected by NCI review staff and approved by the 

Director, NCI, based on their knowledge in the various disciplines and fields related to cancer. 

The DEA-managed NCI IRG has seven specialized subcommittees for review of scientific areas. 

For example: Subcommittee A reviews Cancer Centers; Subcommittee D reviews Clinical 

Program Projects; and Subcommittee H reviews Clinical Cooperative Groups. (The current 

charter and membership of subcommittees may be found in Appendix B and at the following 

Internet address: http://deainfo.nci.nih.gov/advisory/irg.htm.) IRG members are appointed for 

varying terms of service, which may be up to 4 years on specific subcommittees. SEPs may be 

formed by the DEA to review RFAs or unique applications. Members of such panels are selected 

on a one-time, as-needed basis to review specific applications, proposals, or proposed 

solicitations. (Additional information about the NCI SEPs can be accessed at the following 

Internet address: http://deainfo.nci.nih.gov/advisory/sep.htm.) In addition, applications for 

Cancer Center, Cooperative Group, or Program Project support normally require a site visit to 

the applicant institution by members of the appropriate IRG subcommittee and ad hoc 

consultants. 

Both the SEPs and the IRG advise the Director, NCI, on the scientific and technical merit of 

applications for grants for research and research training as well as for research-related grants 

and cooperative agreements, and for contract proposals relating to scientific areas relevant to 

cancer. Government-employed SRAs within the DEA manage the scientific review of 
applications, including the selection of peer reviewers and the overall administration of the peerreview process. 

In FY2002, the DEA organized, managed, and reported the review of a total of 1,972 grant and 

cooperative agreement applications (see Table 2) and 151 contract proposals (see Table 17). 

Twenty meetings of the NCI IRG subcommittees were convened to review and evaluate grant 

applications of various types (see Table 3). In addition, there were 80 SEP meetings for review 

of grants or contracts, and 128 site visits. 

In FY2002, 2,465 reviewers served on 200 occasions on either the IRG or SEPs to review 

applications (see Appendix C). Members are selected because they are authorities in relevant 

fields of biomedical research or because they represent informed consumer perspectives. 

Peer Review Functions

The review units in the DEA are responsible for organizing, managing, and reporting the 

scientific peer review of applications for a wide variety of grant mechanisms. In the past, two 

Branches within the DEA managed peer-review activities for NCI-reviewed applications: the 

Grants Review Branch (GRB) and the Special Review and Logistics Branch (SRLB). During 

FY2002, the Grants Review Branch was reorganized into two branches in response to the 

Department of Health and Human Services and the NIH “delayering” initiative. The Resources 

and Training Review Branch (RTRB) has primary responsibility for review of applications for 

cancer centers, cancer training and career development, and cancer clinical trials, as well as for 

managing the corresponding four subcommittees of the NCI Initial Review Group (IRG) (see 

Table 3). The remainder of the GRB became the Research Programs Review Branch (RPRB), 

with primary responsibility for review of unsolicited applications for program project grants 

(P01s), for applications for Special Programs of Research Excellence (SPOREs) (P50s) in 

various organ sites, and for conference grant applications. The RPRB also manages the three 

subcommittees of the NCI IRG that are responsible for review of program project grant 

applications and the internal NCI R13 Review Committee. These branches are primarily 

responsible for the peer review of a variety of types of unsolicited multiproject and career 

development grant applications (see Table 2) and together manage the seven subcommittees of 

the NCI IRG (see Appendix B). The Special Review and Logistics Branch (SRLB) organizes 

and manages peer review primarily for grant applications in response to specific RFAs, Program 

Announcements with special receipt dates and Institute review (PARs), and contract proposals 

submitted in response to specific Requests for Proposals (RFPs); most of these reviews are 

conducted by SEPs. The review units in the DEA prepare the summary reports of the evaluations 

and recommendations for each site visit or review committee meeting and distribute these reports 

to program officials, the NIH data management system, and NCI’s Records Management Center. 

Details of the summary statements also are provided to the NCAB, as required. Each primary 

Principal Investigator applicant receives a report in the form of the summary statement. 

Many of the reviews conducted by the RPRB and the RTRB involve complex multidisciplinary 

applications. The review format for these applications usually involves a two-tier review. The 

first tier of the review is usually either a site visit to the applicants’ institution or a teleconference 

by an expert review panel; this provides an opportunity for the reviewers to question the 

applicants directly in order to clarify issues in the application, thereby enhancing the review 

process. The review panel members prepare a draft review report, which is then considered, 

along with the application, by the relevant subcommittee of the NCI IRG. Five of the seven NCI 
subcommittees of the NCI IRG serve as the “parent committees” for final scoring of applications 

after expert panel reviews: Subcommittee A is the “parent committee” for Cancer Center 

Support Grant (P30) applications; Subcommittees C, D, and E are the “parent committees” for 

Program Project (P01) grant applications; and Subcommittee H is the “parent committee” for 

review of Cooperative Clinical Trials (primarily U10) applications. The other two subcommittees, Subcommittees F and G, review all of the career development, training, and 

education grant applications submitted to the NCI. 

During FY2002, the seven subcommittees of the NCI IRG reviewed a total of 670 applications of 

various types with requests for a total of $341,368,677 in direct costs for the first year, and more 

than $1.802 billion for all years (see Table 3). The FY2002 workload of the subcommittees 

therefore represents an increase of approximately 5.7 percent in the number of applications 

reviewed by the subcommittees, due mainly to the increased number of program project applications for Subcommittee C and career development applications for Subcommittees F and G. 

A significant proportion of the effort of the Research Programs Review Branch during 

FY2002 was associated with the review of unsolicited P01 applications. The SRAs in the RPRB 

organized and managed the review of 117 new, recompeting, amended, and supplemental P01 

applications (see Table 4), a 23 percent increase over the number of P01 applications in FY2001. 

The 117 applications involved requested more than $151 million in direct costs for the first year 

(see Table 6). One hundred and four of the program project applications were reviewed by IRG 

Subcommittees C, D, and E, the three P01 subcommittees of the NCI IRG; 12 were reviewed by 

Special Emphasis Panels, due mainly to member conflicts with the IRG. Sixty-seven of the 

reviews involved site visits for new and recompeting applications (see Table 5). Five of the 

applications were amended applications submitted for Accelerated Peer Review (APR). The 

APR process allows eligible applicants, those whose applications received scores within a few 

points of the payline and that have very easily addressable problems, to submit a 20-page 

“response” to the previous critique. The APR response is evaluated at the very next review cycle, 

potentially saving several months in the review process for the applicants. The APR response 

counts as one of the two allowable revisions to an application. 

In all, almost 1,200 reviewers with expertise from the most basic cellular and molecular biology 

to the most clinical cancer research areas were required for all of the individual P01 review 

panels organized by RPRB SRAs. 

During FY2002, RPRB successfully continued several initiatives to improve review procedures 

for applications for program projects. The Deputy Chief of the Research Programs Review 

Branch, who is the P01 review coordinator for the DEA, and the SRAs for the IRG 

Subcommittees (C, D, and E) responsible for program project review organized the second 

annual joint orientation session for new members of the committees in August 2002. An 

orientation notebook, with policies, procedures, suggestions, and case studies, was provided for 

each new subcommittee member. This new member orientation was followed by a plenary 

session of all of the reviewers on these three subcommittees, which featured a keynote address 

by the NCI Director and several exercises, led by the subcommittee SRAs, which were designed 

to help the reviewers establish consistent scoring calibration standards that are applicable across 

the three committees regardless of scientific discipline. The outcomes of this plenary session 

were more consistent review practices and scoring patterns across the three subcommittees, and 

therefore better information for NCI program staff to base funding decisions for program project 
applications. This is important because support of P01s accounted for approximately 18 percent 

of the entire NCI extramural budget in FY2002. 

RPRB projects that the number of P01 applications will continue to increase, straining the 

resources of the DEA and requiring ever increasing numbers of senior scientists as reviewers. 

Therefore, as FY2002 drew to a close, RPRB staff were working closely with the Director, 

ORRPC, to convene an NCI working group on P01s, with representation from DEA and the four 

extramural program Divisions, to consider review options for P01s for the future. 

In FY2002, RPRB also had responsibility for the peer review of the applications received for the 

NCI Special Programs of Research Excellence (SPORE) program. These large, complex 

multidisciplinary P50 applications focus on translational research directly applicable to human 

disease in various organ sites. This important program is currently in the third year of a transition 

from an RFA-driven program to an investigator-initiated program; by 2005, there will be one 

receipt date each year for applications addressing each specific tumor site. During FY2002, the 

RPRB organized and managed Special Emphasis Panels for the review of a total of 51 SPORE 

applications for research in prostate cancer, gastrointestinal cancer, head and neck cancer, brain 

cancer, breast cancer, gynecologic cancers, and lymphoma, an 82 percent increase over the 

number of SPORE applications reviewed during FY2001. These 51 applications were requests 

for almost $93 million in direct costs for the first year of support. Based on the current schedule 

for SPORE application receipt in FY2003 and beyond, the RPRB expects the SPORE review 

workload to continue to increase at a rapid rate. 

The SRAs who organize the SPORE reviews routinely conduct orientation conference calls with 

all of the reviewers before the applications are sent to the reviewers to explain the special 

features of the SPORE program and the special review criteria for SPORE applications. 

During the summer of 2002, the Director of NCI convened a Working Group of senior 

extramural investigators to make recommendations concerning the Cancer Centers and the 

SPOREs. RPRB staff prepared information and presented SPORE review options for the 

P30/P50 Working Group. The recommendations of the Working Group will be the subject of 

additional RPRB activity in FY2003. 

During FY2002, the RPRB also continued to conduct the reviews for R13 applications for 

support for a wide variety of scientific conferences. Fifty-nine applications representing requests 

for more than $1.74 million in direct costs for the first year were reviewed by the NCI R13 

Review Committee, which is composed entirely of NCI extramural staff. This committee uses 

an innovative “virtual review” format to accomplish an accelerated review of the conference 

grant applications four times a year, so that conference organizers can plan more effectively. 

DEA also maintained a leadership role in the design and implementation of the Peer Review 

Module of the new central NIH extramural database, called IMPAC II, during FY2002. The 

Chief of the RPRB, an SRA from the SRLB, and a support staff member from the RPRB served 

on the IMPAC II Review Users’ Group (RUG) to test new programming for uploading final 

summary statements into the database. An RPRB SRA served on the task force to design and 

test a new internet-assisted review module that will be part of IMPAC II. This module will allow 

reviewers to log in through the NIH eRA Commons and post their preliminary critiques and 

preliminary scores on a secure Web site prior to the review meeting. This system will allow 

reviewers to preview the other critiques for their assigned applications and will focus the 

discussions during the review meeting more effectively. In addition, an RPRB support staff 
member continues to serve on the trans-NIH User Group for the Committee Management (CM) 

Module in the new NIH IMPAC II database system, and on the working group designing a Webbased upgrade to the CM module. The CM module is a critical element in preparing for and 

reporting on peer reviews, and the User Group has identified resolutions for problems and 

suggested several enhancements to the system. 

The Resources and Training Review Branch (RTRB), which administers four NCI IRG 

subcommittees (A, F, G, and H), has the responsibility for multidisciplinary cancer centers, 

cooperative clinical trials, institutional training and education grants, and career development 

awards. Staff of this branch also participate in the review of other funding mechanisms within 

the DEA. Although this change took place in mid-2002, the activities of the branches are 

described separately. 

The reviews conducted by the committees within RTRB are of two types. For the complex, 

multidisciplinary applications such as cancer center support grants (P30s) and multi-institutional 

clinical trial cooperative groups cooperative agreements (U10s), the review format generally 

involves a two-step initial review. The first step of the review has involved either a site visit to 

the applicant institution or a presentation to a committee in the Washington area. This group of 

experts serves as a fact-finding body to update the application and to clarify issues in the 

application based on discussion with the applicants. This first committee prepares a draft report 

that is presented, together with the full application, for discussion, evaluation, and final scoring 

by the appropriate parent committee—NCI IRG Subcommittee A for cancer centers and 

Subcommittee H for clinical trials. The scoring by a parent committee provides for a more 

uniform evaluation of applications than scoring by individual review teams. 

Shortly after his appointment as NCI Director, Dr. von Eschenbach established a P30/P50 

Working Group composed of leaders of the cancer research community, who are sensitive to 

issues facing both reviews and applicants, to study the P30 Cancer Center Support Grant together 

with the P50 SPORE award to determine how to continue supporting these important methods of 

funding translational research in a more restricted funding environment. A presentation was 

made to the Working Group on issues that the Committee is facing as applications for Cancer 

Center Support Grants grow in length, and there is an increase in numbers of research programs 

described, shared resources for which funding is proposed, and overall support requested. Means 

of streamlining the review process, without compromising the rigor of the review, also were 

discussed with the Committee. A final report is to be presented to the NCAB in early 2003. 

Subcommittees F and G review all education, training, and career development grant 

applications within the DEA. These applications include a large number of different funding 

mechanisms divided between Subcommittee F (T32, K01, K08, K22) and Subcommittee G (R25, 

K05, K07, K22, K23, K24). Each of these sets of applications is reviewed in one meeting by the 

chartered committee supplemented by temporary reviewers with appropriate expertise to ensure 

that every application is evaluated by experts in its field. 

The number of applications being reviewed in Subcommittees F and G has continued to grow. 

This is due, in part, to the increased number of mechanisms available and to the increased 

information disseminated about them. In addition to a number of procedures introduced last year 

to streamline the review process to reduce the burden on the review teams, a third committee is 

being formed to address unresolved issues. 
Another issue of concern with regard to the applications reviewed in Subcommittees F and G 

was the compression of scores. This made it more difficult for funding decisions to be made 

because many applications received scores that were very close to each other. In addition, it was 

misleading to applicants because scores that appeared numerically to be very favorable may in 

fact have been ranked in a low percentile of all the applications of its type. To address this 

concern, a new scoring paradigm was developed in which reviewers were asked to rate, across 

the full rating scale, each application on its merit relative to the full population of applications of 

its type. Reviewers also were encouraged to rate as unscored any application that they judged to 

be in the lower half of applications of its type. Although unscored applications received the 

reviewers’ comments, the applications were not discussed at the meeting, thereby shortening 

its duration. 

This problem of score compression and the proposed new procedure was explained to the 

reviewers in writing and in a teleconference with the reviewers prior to the review meetings, and 

discussed further at the beginning of the meeting. The median score for both committees 

improved significantly, with a fuller range of scores used, fewer applications were rated as better 

than 150, and a sufficient number were rated as unscored to shorten the duration of the meeting. 

The SRA for Subcommittee H (Clinical Cooperative Groups) continues to work closely with the 

staff of the Clinical Investigations Branch of the NCI Clinical Trials Evaluation Program (CTEP) 

on updating the Clinical Trials Cooperative Group Program Guidelines. In addition, the review 

of the U10 application submitted by the Children’s Oncology Group, which was recently formed 

through the merger of the four previous pediatric oncology groups, was successfully completed. 

Challenging to this review was the potential for conflicts of interest, as most pediatric oncology 

research clinicians in the United States, Canada, and Western Europe are members of the merged 

group. To reduce the reviewer burden of the current review format, the SRA has been actively 

involved in the pilot of a new review format for the Clinical Cooperative Groups. Two 

Cooperative Groups will take part in this pilot, which will involve a direct presentation by the 

group under review to Subcommittee H after an onsite review of their statistics and data 

management centers. 

The Special Review and Logistics Branch (SRLB) organizes and manages peer review 

primarily for grant applications submitted in response to specific NCI RFAs and most special 

PARs, and for contract proposals submitted in response to specific Requests for Proposals 

(RFPs); most of these reviews are conducted by SEPs. 

Each year, the National Cancer Institute identifies several broad priority areas that serve as the 

framework for strategic planning and budget development. Extraordinary Opportunities for 

Investment are areas of discovery that build upon the most important recent developments in 

knowledge and technology and hold promise for making significant progress against all cancers. 

NCI Challenges are areas of emphasis that focus investment on improving the resources and 

mechanisms available to support research, furthering the preparation of the people needed to 

conduct research, enhancing access to research information and technology, and maximizing the 

sharing of discovery and collaboration among researchers and clinicians. The “opportunities” 

and “challenges” are articulated in the NCI Bypass Budget that is sent to the President each year. 

For the FY2002 Bypass Budget, the Institute identified the following: 
Six areas of extraordinary opportunities:

 Genes and the Environment 

 Cancer Imaging 

 Defining the Signatures of Cancer Cells: Detection and Diagnosis 

 Molecular Targets of Prevention and Treatment 

 Research on Tobacco and Tobacco-Related Cancers 

 Cancer Communications. 

In addition, eight NCI challenges also were highlighted: 

 Investigator-Initiated Research 

 Centers, Networks, and Consortia 

 National Clinical Trials Program 

 Informatics and Information Flow 

 Emerging Trends in Cancer 

 Cancer Training and Career Development 

 Quality of Cancer Care (new for 2002) 

 Reducing Cancer-Related Health Disparities (new for 2002). 

These “opportunities” and “challenges” translated into a variety of initiatives in FY2002, not 

only for academic research centers, but also for the small business community. Following 

approval by the NCI Executive Committee and BSA (unlike RFAs, PAs are not approved by the 

BSA), program staff—assisted by the Program Coordination and Referral Branch—generate the 

initiatives that are published in the NIH Guide for Grants and Contracts.

* In an RFA, a specific, 

published dollar amount is set aside by the Institute, while in an Institute PAR (Institute 

Reviewed Program Announcement) there is no dollar set-aside and no requirement for BSA 

review. The reviews of all RFAs and PARs are managed by the SRAs of the DEA. Tables 7 

through 12 summarize the RFAs, PAs, and PARs published and the RFAs, PAs, and Master 

Agreements reviewed by the SRLB in FY2002. Table 12 represents those applications submitted 

in response to PAs, the review of which is shared by SRLB, RPRB, and RTRB. 

In February 2002, the NCAB concurred with the review results of 44 SRLB-reviewed initiatives, 

41 of which were directly related to the Bypass Budget; in June 2002, 20 of 26 RFA/PAR 

initiatives were related to the Bypass Budget; and in September 2002, 28 of 31 RFA/PAR 

initiatives were related to the Bypass Budget. In considering the specific initiatives, the 

breakdown for all of FY2002 is as follows:‡ 

* Because of the importance of allowing adequate time for the applicant community to respond to NCI’s initiatives, it is to be 

 expected that the results of some initiatives may be funded (or reviewed by the NCAB) in subsequent fiscal years. 

† Two multiproject initiatives were part of the RFAs. 

‡

 Tables 10 and 11 identify the “challenges” and “opportunities” as they relate to specific RFAs and PAs for FY2002. 
Research Opportunities†

 # of RFAs/PARs

01 Cancer Imaging ...................................................................... 0/7 

02 Defining the Signatures of Cancer Cells............................... 2/14 

03 Molecular Targets of Prevention and Treatment .................... 0/6 

04 Research on Tobacco and Tobacco-Related Cancers ............. 3/1 

05 Cancer Communications......................................................... 3/0 

Challenge Initiatives # of RFAs/PARs

C1 Investigator-Initiated Research .............................................. 0/2 

C2 National Clinical Trials Program in Treatment/Prevention.10/10 

C3 Studying Emerging Trends in Cancer .................................... 2/7 

C4 Cancer Training and Career Development ............................ 0/8 

C5 Quality of Cancer Care........................................................... 1/0 

C6 Reducing Cancer-Related Health Disparities......................... 4/0 

Breadth of Peer Review 

A general theme that has been applied to all recent NCI initiatives—PAs, RFAs, and Broad 

Agency Announcements (BAAs)—is that the widest possible net should be cast in the search for 

quality science. NCI IRG subcommittees increasingly serve as the locus for peer review of 

applications assigned to the NCI. In the past, most PAs for single-project research grant 

mechanisms (R01, R03, R21) were directed to the CSR for evaluation. Over the last several 

years, however, increasingly specialized requirements of NCI initiatives have led to the need for 

specific kinds of expertise not routinely found in depth in the standing CSR study sections. This 

has led to the issuance of more PARs for which ad hoc peer-review groups with the disciplineappropriate expertise (as provided by SEPs) are specifically recruited. Considerable effort is 

required to recruit the wide range of individuals with expertise to cover all aspects of an 

initiative. 

Highlights of SRLB reviews for FY2002 include two major initiatives. The first was the 

simultaneous release of five RFAs relating to the identification of molecular targets for cancer 

therapy. Because of the extent of the initiatives, three SRAs were assigned to conduct the peer 

review. By coordinating the review meeting dates, the SRAs were able to recruit not only for 

their own meetings, but also for the meetings of their two collaborating colleagues. An Internetaccessible database that listed all of the contacted reviewers, minimized the repetitive calling of 

the same potential reviewer. 

The other significant project was the BAA (a contract initiative) for Novel Technologies. This 

initiative was modeled after the long-range research projects of the Defense Advanced Research 

Projects Agency (DARPA), one of which developed into the Internet. To elicit participation of 

technology-oriented firms, measures were applied in accordance with the Procurement Integrity 

Act regarding the confidentiality of the information submitted. This made the initiative a 
hybrid—part investigator-initiated research and part contract—which complicated the review 

process and necessitated the use of a waiver from the usual conflict-of-interest provisions. 

In addition to the BAA described above, the Division reviewed nine RFPs (contract initiatives) 

and two Master Agreement Announcements (MAAs). RFPs are full proposals in which several 

elements of each proposal are individually evaluated and scored, with the combined score, 

indicating the overall merit. After negotiations, contract awards result from the RFP solicitation. 

The MAA is a mechanism by which offerors describe their capability to perform specified tasks. 

The review panel then determines whether they are qualified to perform the described tasks. 

Qualified offerors then are placed in a pool (of qualified offerors) from which the NCI can draw 

upon to perform tasks relevant to the MAA. The review of an RFP proposal is approximately 

five times more complicated than that of an MAA proposal. The list of RFPs and MAAs 

reviewed in FY2002 is shown in Table 17. 

Scanning of Applications Into Electronic Records To Increase Efficiency 

The DEA application scanning project highlighted in last year’s report has been completed. 

Applications submitted for the February 1, 2002, and later receipt dates were scanned by a 

central facility for all NIH Institutes and Centers. These electronic records are now added to the 

IMPAC II dataset, creating a more complete centralized, enterprise-wide, information repository. 

The DEA continues to fund some scanning for contract proposals that are not part of the IMPAC 

II dataset. 

Grant Funding 

In Table 13, a comparison is made of the average cost and number of NCI R01 and P01 grants 

awarded in FY2000, 2001, and 2002 according to extramural division. Table 14 presents a 

summary for FY2002 of total funding of NCI grant awards by mechanism. Trends in grant 

funding according to scientific area are described on page 25 and in Tables 15 and 16. 
Supporting Peer-Review Consultants 

Ensuring that highly qualified individuals are available for expert review of grant applications 

and contract proposals requires an efficient administrative support system. The DEA’s Scientific 

Review and Evaluation Award (SREA) Office, residing within the Committee Management 

Office (CMO), supports the NCI peer-review process by compensating consultants for their 

services on the NCI IRG or SEPs and by reimbursing them for their travel and other expenses 

(see Appendices B and C). The SREA Office also approves and processes payments for other 

activities related to review, including contract-supported ticketing services. During FY2002, the 

SREA Office authorized 3,215 consultant reimbursement vouchers and 578 nonconsultant other 

vouchers for travel ticketing, meeting room rental, and teleconferences. 

During FY2002, the SREA Office continued to work with a contractor to further develop the 

program that allowed retrieval of Financial Operating Plan (FOP) data from IMPAC II (an NIHwide committee management database). The IMPAC II Committee Management Voucher 

Module is now fully operational, and the SREA Office utilizes IMPAC II for the generation of 

all consultant and nonconsultant voucher reimbursements, FOPs, and Internal Revenue Service 

Form 1099 reports. Also, during FY2002, the SREA Office worked with the contractor to 

develop a program that will allow retrieval of financial and consultant reimbursement 

information from IMPAC II and streamline the reconciliation process. This process is in 

development. In addition, the SREA Office and the contractor are working with World Travel 

Services to develop a streamlined billing process to expedite the processing of travel invoices 

and eliminate the duplicative verification process that in the past caused severe backlogs. 

The SREA Coordinator worked with other NIH Institute SREA Offices to participate in the 

planning and establishment of the first NIH SREA Coordinating Committee. Their goal was 

twofold: (1) to act as an advisory body to the Director, Office of Federal Advisory Committee 

Policy (OFACP), senior NIH Management officials, and the SREA community on SREA policy; 

and (2) to ensure consistent administration of SREA policies and procedures across the NIH. 

This group meets monthly to discuss SREA procedures and is presently working on the first 

Standard Operating Procedure (SOP) for the NIH SREA community to standardize procedures 

and provide guidance and consistency within the SREA offices and among all of the Institutes. 

In addition, the SREA Office advises consultants, NCI staff, and the SREA trustee on policies 

and procedures; performs the administrative tasks related to setting up, managing, monitoring, 

and closing out accounts; and prepares expenditure reports, including those required by the NIH 

Office of Financial Management for 1099 tax forms and those requested by the CMO for the 

NCI FOP, consultant services, and financial management reports for IRG, SEP, and SREA. 

This little-known support function is critical to the success of the peer-review system because 

any error, inconvenience, or delay in reimbursement that reviewers experience is likely to 

discourage their future service. Excellent customer service remains a constant goal of the NCI 

SREA staff. 
DEA’s Role in Advisory Activities 

Beyond its central role in coordinating the peer review and referral of grants, perhaps the most 

far-reaching role the DEA plays across the NCI is the coordination and administration of NCI’s 

eight chartered Federal advisory committees (see Appendix B). The activities of these advisory 

bodies are coordinated by the Office of the Director, DEA, and the Committee Management 

Office, DEA. A primary responsibility of the DEA is coordination of the activities of the NCAB, 

whose members are appointed by the President and whose responsibilities include conducting the 

second-level review of grants and cooperative agreements, as well as advising the NCI Director 

on policy for the conduct of the National Cancer Program. The DEA also coordinates 

administration of the BSA, the body responsible for the oversight and concept review of the 

extramural programs and initiatives of the NCI. As such, the DEA plays a major role in the 

development and issuance of PAs, PARs, and RFAs, the major extramural program initiatives 

used by the NCI. The DEA Director serves as Executive Secretary to the NCAB, and the Deputy 

Director, DEA, serves as Executive Secretary to the BSA. (See Appendices D and E for 

highlights of the activities of these Boards in FY2002.) 

Each year, the NCI relies on hundreds of individuals with special expertise to advise and support 

staff in its mission to win the war against cancer. These individuals provide advice and guidance 

to NCI staff on countless research projects, scientific concepts, and programmatic and 

administrative issues relating to its research initiatives and priorities. During FY2002, 2,465 

consultants were asked to serve as standing, temporary, and ad hoc members on NCI’s advisory 

Boards and groups. These consultants participated in 125 committee meetings conducted by NCI 

staff. There were 142 site visits conducted under the NCI IRG subcommittees and Board of 

Scientific Counselors (BSC). The DEA performs a variety of administrative and management 

functions in support of these advisory committees and their members. Under the various 

chartered committees, working groups were formed to address several important areas of cancer 

research related to diverse populations, and cancer advocacy, treatment, prevention, 

communication, and education. (See Appendix C for a list of consultants.) 

Major NCI Advisory Bodies Administered by the DEA 

National Cancer Advisory Board. NCI’s principal advisory body is the presidentially 

appointed NCAB. The Board advises the DHHS Secretary and the NCI Director on issues related 

to the entire National Cancer Program and provides a second level of review for grant 

applications referred to the NCI. 

Board of Scientific Advisors. The BSA represents the scientific community’s voice in NCIsupported extramural science. The Board, composed of distinguished scientists from outside the 

NCI and representatives from the advocacy community, advises the NCI leadership on the progress and future direction of the Institute’s Extramural Research Program. The Board evaluates 

NCI extramural programs and policies and reviews ideas for new research opportunities and 

solicitations to ensure that a concept is meritorious and consistent with the Institute’s mission. 

The BSA believes it is important to interact with and receive feedback from the clinical, population science, and laboratory research communities affected by NCI policies. To this end, the NCI 

has established BSA-sponsored “NCI Listens” sessions at national association meetings (see 

Appendix B, p. 49). BSA members and NCI staff invite conference participants to join them for 
these sessions. A brief presentation is given by NCI staff emphasizing the status of grant funding, 

the Bypass Budget, and the status of several new initiatives. The brief presentation is followed by 

an open question-and-answer period. The NCI is committed to providing a written response to the 

scientific society hosting the meeting concerning issues raised during the session. The BSA hopes 

that conference participants will take advantage of this opportunity to raise their concerns. 

Board of Scientific Counselors. The BSC, managed through the OD, NCI, advises the Institute 

leadership on the progress and future direction of NCI’s Intramural Research Program residing in 

the Center for Cancer Research (CCR) and the Division of Cancer Epidemiology and Genetics 

(DCEG). This group of scientific experts from outside the NCI evaluates the performance and 

productivity of NCI staff scientists through periodic site visits to intramural laboratories and 

provides evaluation and advice on the course of research for each Laboratory and Branch. 

NCI Initial Review Group. The IRG, composed of seven subcommittees, reviews grant and 

cooperative agreement applications for centers, research projects, and research training activities 

in the areas of cancer cause, diagnosis, treatment, and prevention, as well as contract proposals 

relating to all facets of cancer. Members may be appointed as standing committee members with 

overlapping terms of up to 4 years or as “temporary” members with all the rights and obligations 

of committee membership, including the right to vote on recommendations in which the 

individual fully participated as a reviewer for a specific meeting. Consultants also may be invited 

to serve as special experts or ad hoc members to provide information or advice. These 

individuals generally serve in site visit groups, providing critical information to the chartered 

advisory committees responsible for initial peer review. 

NCI Special Emphasis Panels. The SEPs advise the Director, NCI, and the Director, DEA, 

regarding research grant and cooperative agreement applications, contract proposals and concept 

review relating to basic and clinical sciences, and applied research and development programs of 

special relevance to the NCI. Membership of an SEP is fluid, with individuals designated to 

serve for individual meetings rather than for fixed terms. These individuals have all of the rights 

and obligations of committee membership, including the right to vote on recommendations. 

Program Review Groups. As part of an ongoing process of review and revitalization, the NCI 

instituted a series of external reviews to guide it in strengthening major research support programs. Program Review Groups, coordinated by the DEA as an activity of the BSA, examine the 

NCI extramural programs and their infrastructures to evaluate whether changes are necessary for 

the Institute to be in a position to effectively guide and administer the needs of the science in the 

foreseeable future. (See http://deainfo.nci.nih.gov/advisory/bsa/bsa_program/bsaprgr.htm.) 

Progress Review Groups. As part of its overall responsibilities for committee management 

functions and coordination of advisory groups, the DEA assists other NCI offices with additional 

types of oversight activities. Progress Review Groups, managed by the Office of Science 

Planning and Assessment within the OD, NCI, are created to provide their expertise, biomedical 

research information, and assistance to NCI chartered advisory committees in defining and 

prioritizing the national research agenda for particular cancers—including breast, prostate, 

colorectal, brain, pancreatic, leukemia, lymphoma, myeloma, and lung—by: (1) identifying new 

or unmet scientific opportunities; (2) reviewing an NCI analysis of its current research program; 

and (3) using the ongoing activities as a baseline, providing expert opinions on how to address 

the opportunities and hasten progress against the disease. These groups report through a chartered 

Federal advisory committee. (See http://deainfo.nci.nih.gov/advisory/pog/progress/index.htm.) 
Committee Management Activities 

The Committee Management Office (CMO) is the DEA administrative unit that coordinates the 

general administration of the NCI’s chartered Federal advisory committees. The CMO provides 

advice related to the provisions of the Federal Advisory Committee Act and other Federal, 

Department of Health and Human Services (DHHS), and NIH regulations governing the actions 

of NCI staff who manage advisory committees. It coordinates the activities of advisory 

committees across the NCI and ensures that NCI staff comply with Federal advisory committee 

policy. Additionally, the Office of the Director (OD), DEA, and the CMO provides guidance and 

information to staff and external groups on specific NIH policies related to the operation of 

working groups and ad hoc consultants operating under the direction of some of NCI’s chartered 

Federal advisory committees. NCI working groups provide scientific expertise through chartered 

committees to the NCI Director and Division Directors on a range of matters related to the 

National Cancer Program. The Office works closely with the other DEA offices to coordinate 

activities with NCI advisory committees; implements policies and procedures designed to avoid 

conflicts in the nomination and selection of board members; implements policies and procedures 

to ensure compliance with DHHS and NIH regulations governing the operation of chartered 

advisory bodies; advises on issues related to conflicts of interest, selection and recruitment of 

viable committee members, and management of committee records; provides logistical support 

for NCAB meetings; and facilitates committee-related travel. 

CMO staff continue to participate in various NIH-wide Information for Management, Planning, 

Analysis, and Coordination (IMPAC II) software application user group meetings and pilots, 

including participation on the NIH Committee Management-Joint Application and Development 

Group (CMJAD) slated to provide advice on the redesign of the Committee Management 

Module. The IMPAC II Module is being redesigned as a Web-based application and will be a 

more user-friendly and intuitive system. In FY2002, the CMO continued to develop in-house 

IMPAC II training information, developed new guidelines geared towards assisting NCI staff in 

efficiently using the IMPAC II system, and conducted training for users of the system. 

In concert with the automation of the NIH-wide committee management functions, the CMO 

continued to work closely with other DEA staff to streamline general committee management 

and review procedures related to member travel and vouchering and mail review and 

teleconference reimbursements. The same procedures were used to facilitate more effective 

management of all other NCI chartered advisory committees. 

In addition, the DEA CMO continued to conduct briefings with the NCI Divisions; the Offices of 

Liaison Activities, and NCI management on the use of working groups associated with chartered 

committees. The CMO was actively involved in the guidance and support of various NCI 

working groups and NIH employee working groups related to the IMPAC II Module, the Data 

Quality and Control Initiative, and the SREA Coordinating Committee. Additionally, CMO staff 

participated in NIH Committee Management work groups and the Committee Management 

Users Group charged to redesign the IMPAC II Module. 
Extramural Policy and Program Development 

An important part of DEA’s mission is providing effective and timely coordination of program 

initiatives from the initial concept stage through publication of RFAs, PAs, and RFPs and, 

finally, through the peer review of grant applications and contract proposals. The NCI’s activity 

in this arena has grown, in proportion to the generous budget increases received by the Institute, 

to the point where a central unit, the Office of Referral, Review, and Program Coordination

(ORRPC), was established within DEA for coordination of program development, issuance, and 

review activities. The Associate Director, Ms. Diane Bronzert, serves as the overall coordinator 

for peer review functions for the Institute. ORRPC is responsible for (1) the coordination and 

management of review activities for grants, cooperative agreements, and contracts for the 

Institute; (2) the development of NCI policies and procedures as related to review of grants and 

contracts; (3) coordination of the second level of review with the National Cancer Advisory 

Board; (4) development of referral guidelines and grant referral to NCI programs; and 

(5) coordination of the development, preparation, clearance, and issuance of special NCI 

initiatives, including program announcements, requests for applications, and extramural policy 

statements through the NIH Guide to Grants and Contracts. ORRPC coordinates the activities 

of the Program Coordination and Referral Branch and the three review branches, Special Review 

and Logistics Branch, Resources and Training and Review Branch, and Research Programs 

Review Branch. At each stage of the development of new initiatives, DEA’s ORRPC facilitates 

this coordination across the NCI’s extramural Divisions, other NIH Institutes, and other relevant 

agencies of the Federal Government. 

The DEA manages and coordinates the BSA, which is charged with the concept review of all 

new and reissued RFAs and RFPs (see Appendix E). In addition, the DEA tracks new initiatives 

proposed by other Institutes and agencies to consider possible NCI participation. The success of 

this operation is dependent on the development of clear Institute referral guidelines, also a DEA 

responsibility. Before the publication of an initiative, the DEA negotiates with the CSR, DEA 

review units, and other offices to coordinate scheduling, timelines, and workloads. Concepts for 

PAs do not require BSA approval, but are considered instead by the NCI Extramural Division 

Directors Committee. 

Through the OD, the DEA conducts continual evaluation of program initiatives and coordinates policies and procedures to ensure that all aspects are as clear and accessible as 

possible to staff, advisory groups, and applicants. To facilitate this evaluation, the ORRPC, 

with the technical assistance of Applied Information Systems Branch (AISB), manages 

Web-based information systems to provide key information on new initiatives. This Web-based 

information system includes early notice of approved concepts, listings of active PAs and 

recently published RFAs, and policies related to the clearance of new program initiatives. This 

information is provided in both public Internet and NCI limited-access Intranet versions 

(http://deainfo.nci.nih.gov/funding.htm). 
Tracking and Coordinating Program Activities 

The program coordination responsibilities of the DEA, in cooperation with NCI Extramural 

Program Divisions, extend to the development of all new extramural program guidelines. The 

DEA manages this activity in communication with the originating NCI program and the NIH 

Office of Extramural Research. To maintain consistency and completeness, all new NCI 

guidelines are centrally edited and cleared through the DEA before being forwarded for NIH 

approval and publication in the NIH Guide for Grants and Contracts. Because most program 

staff have limited experience in crafting an initiative in the precise format required by the Public 

Health Service (PHS) rules and regulations, the services provided by the DEA in preparing such 

announcements materially speeds their release, often eliminating a month or more from the 

process. Another program coordination activity is the development of referral guidelines for 

assignment of grant applications to the NCI. These guidelines, included in the Referral 

Guidelines for Funding Components of PHS, are critical to the development of program 

initiatives across the NIH, as well as to the prompt referral of unsolicited grant applications to 

the NCI. These guidelines differ from the internal referral guidelines, which also are coordinated 

by the ORRPC. The internal referral guidelines are vital to the prompt referral of grant 

applications to the appropriate NCI program area. 

In addition to program coordination, the DEA has developed and maintained a Web-based 

information tracking system to provide staff with all essential information on program initiatives, 

from concept through publication of the full text, with the ultimate goal of tracking outcomes. In 

addition to the Intranet version for NCI staff, extramural scientists have access to an Internet 

version of published initiatives. 
Information Resources Management 

The Applied Information Systems Branch (AISB) provides integrated computer support, 

applications, and information systems development to the DEA. The AISB monitors the DEA 

Web Site, supports the Division’s Intranet server, designs and maintains Division-specific 

software applications, provides oversight of hardware and connectivity, and serves as liaison 

with the Center for Information Technology (CIT) and NCI central units. Its mission is critical to 

the future of the Division in communicating both internally and externally current information 

technology activities and new developments with all components of the NCI, NIH, and reviewer 

and applicant communities. 

All of the Division’s Information Technology and Information Systems contracts are 

consolidated under the AISB. The AISB operates a computer support help desk to track staff 

requests, manage the Division’s computer equipment inventory, and provide computer-related 

training, as needed. Specific projects utilizing the technologies and services provided by the 

AISB are described under the appropriate functions of the DEA throughout this report. For 

FY2002, the following specific accomplishments are highlighted: 

 Enhanced the Extramural Science Administrator Training Tracking System (ESATTS) to 

permit NCI extramural staff the ability to enter their training data 

 Completed redesign and development of a new DEA Intranet Web Site, which includes a 

search engine 

 Developed a prototype Web-based software application for use by DEA review staff to 

enable the merging of IMPAC II data into MS Word or Corel WordPerfect documents 

 Converted the Fiscal-Linked Analysis of Research Emphasis (FLARE) application to Java 

and added several features, which has resulted in a higher level of stability and performance. 

FLARE is being used by RAEB for coding grants, searching, and reporting. 

 Completed development of a Web-based application to automate the process of assigning 

Special Interest Category (SIC) and Organ SITE codes for U10 and U30 grants 

 Developed a Compact Disc version of the IRG reports for use by DEA staff at NCAB 

meetings and for archival purposes 

 Developed an application to search PDF files on CD containing the listing of names and 

biographical information on members of the Consumer Advocates in Research and Related 

Activities (CARRA) 

 Developed a Web-based application to allow Review Staff to create customized CDs 

containing grant applications and other materials for the reviewers. This has helped to 

reduce the volume of paper being sent to the reviewers. 

 Created a Project Management and Systems Documentation Web Site to enhance 

communications among AISB Staff and Contractors. 
 Enhanced the annual BSA report on RFA and PA Concepts to include additional information 

and graphics. 

AISB staff are involved with many NCI and NIH information systems and information 

technology groups and organizations, including: 

 NCI Office of Information Systems and Computer Services 

 NCI Institute Information Systems Advisory Group 

 NCI Change Management Group 

 NIH Electronic Council Book Steering Committee 

 IMPAC II Joint Applications Development and Critical Design Review Groups 

 NIH Automatic Data Processing Extramural Coordination Committee. 
Portfolio Tracking and Analysis 

The DEA’s Research Analysis and Evaluation Branch (RAEB) serves as the officially 

designated locus and contact for scientific information associated with NCI-supported research. 

The NCI needs consistent budget-linked scientific information across all its scientific programs 

to facilitate analysis of the Institute’s portfolio, provide a basis for budget projections, and serve 

as a resource for the NCI to disseminate information about cancer. The DEA conducts analyses 

to project future NCI research expenditures and to provide budget justifications to Congress. The 

work of the RAEB allows the DEA to respond immediately to daily requests for information 

from NCI staff, the broader NIH community, and requesters worldwide. The Branch also 

performs specialized custom searches on request. 

These capabilities are based on a sophisticated system of indexing, in which Research 

Documentation staff analyze grant applications to classify each project for its degree of 

relevance to Special Interest Category (SIC) and Organ Site Codes. The number of categories 

assigned to an individual grant varies from fewer than 10 to more than 50. SIC Codes are meant 

to describe in a consistent way the major scientific disciplines that are of stated or growing 

interest to the NIH, DHHS, Congress, and the public. SIC Codes are added throughout the year 

to retain currency with these interests. In FY2002, RAEB added new SIC Codes for Breast 

Cancer Early Detection, Childhood Leukemia, Chronic Myeloproliferative Disorders, Food 

Safety, Pediatric Research, and Virus-SV40. The single SIC Code Virus-Hepatitis B & C was 

divided into two separate SIC Codes. A critical characteristic of these data is comparability from 

one fiscal year to the next. Changes in funding between FY2001 and FY2002 for selected SIC 

Codes and organ sites are presented in Tables 15 and 16. In FY2002, RAEB indexers profiled 

more than 2,900 unfunded applications. The process of indexing unfunded applications, begun in 

FY1999, has greatly expanded the potential for analysis of the major categories 

found in these applications. RAEB staff profiled more than 2,700 funded grants and contracts in 

FY2002. The Branch now documents researchers’ use of radioisotopes. 

The Technical Operations staff manage RAEB Fiscal-Linked Analysis of Research Emphasis 

(FLARE) grants management database, assuring the reliability and complete-ness of its contents. 

The staff continued to work with contractors and AISB to refine the FLARE computer 

application in FY2002, managed the FLARE module for computerized calculation of indexing 

for Clinical Cooperative groups, Community Clinical Oncology Program, and P30 Centers 

grants, and assumed a number of maintenance tasks from the FLARE contractor in FY2002, 

including rollover of grant data from FY2002 to FY2003. 

Highlights of FY2002 include:

 RAEB is now responsible for indexing all extramural AIDS grant applications. 

 RAEB indexers profiled more than 2,900 unfunded applications. 

 RAEB staff indexed more than 2,700 funded grants and contracts. 

 RAEB added new Special Interest Categories:

  Breast Cancer Early Detection 
 Childhood Leukemia 

 Chronic Myeloproliferative Disorders 

 Food Safety 

 Pediatric Research 

 Virus-SV40 

 RAEB now documents the use of radioisotopes in connection with grant applications. 

 RAEB, with AISB, assumed most maintenance functions of the FLARE computer 

application. 
Special Activities in the Office of the Director, DEA 

In addition to managing and coordinating the various activities described in this report, the DEA 

Office of the Director (OD) has specific additional responsibilities to the NCI. First, the OD 

serves as a focal point and repository of information related to various funding mechanisms for 

grants, staff and awardee responsibilities, eligibility require-ments, receipt dates for all granting 

mechanisms, and special programs. The DEA serves as the coordinating center for submission of 

applications for special NIH-wide awards such as the James A. Shannon Director’s Award, the 

Academic Research Enhancement Awards (AREAs), the Institutional Development Awards 

(IDeAs), and the Research Enhancement Awards Program (REAP). 

Second, the DEA OD plays a critical role in the NCI’s efforts to promote increased participation 

of women, children, and members of minority and medically underserved populations in the 

research areas of cancer cause, prevention, control, diagnosis, and treatment. The NCI 

Revitalization Act of 1993 mandates that women and members of minority groups be included as 

subjects in each research project, unless there are clear scientific or ethical reasons that inclusion 

is inappropriate with respect to the health of the subject or the purpose of the research. 

Administrative procedures allow NCI staff to resolve inclusion problems after initial review of 

applications that are otherwise highly meritorious. In the event a grantee believes the proposed 

study does not warrant or require inclusion of women or minority groups, he or she can apply for 

a waiver of this requirement. The Director of the DEA has the authority to grant this waiver. In 

FY2002, 69 applications with preliminary bars to award were received by the DEA. Through 

corrective action, all were brought into compliance before award. 

Third, the DEA Director serves as the locus for implementation and oversight of NCI policies 

concerning extramural research integrity and serves as a resource to all NCI staff with questions 

in this area. In this role, the DEA OD works to address concerns about scientific misconduct, 

misuse of human and animal research subjects, financial mis-management, and financial conflict 

of interest involving NCI-supported research. Thus, the DEA Director functions as the NCI 

Research Integrity Officer and receives from the appropriate sources all documents related to 

misconduct for transmittal and reporting to relevant sources. In FY2002, seven cases of alleged 

scientific misconduct were opened by the Office of Research Integrity and referred to the 

Director, DEA. Nine cases were closed, and two were found to involve misconduct. 

Other major policy developments managed by the Office of the Director, DEA, in FY2002 

included the implementation and rollout of issues as diverse as: 

 A76 Study of extramural support positions 

 Implementation of data-sharing requirements on awards over $500,000 D.C. 

 Study of R21 and R03 grant award mechanisms 

 Evaluation of policies for grants supporting new R01 investigators 

 Control of cost increases on Type 2 competing continuation requests 

 Modifications to NCI Accelerated Executive Review of R01 applications 

 Implementation of policies governing human embryonic stem cell research 

 Recognition of NCI R37 Merit Awardees 
 Funding Policy for research project grant mechanisms 

 Evaluation of NCI large-scale award mechanisms for IOM Study. 

A major policy undertaking was initiated in FY2002 in conjunction with the duties of the 

Director as Executive Secretary of the NCAB. This was to launch, at the direction of the 

Director, NCI, a review of the NCI P30 Cancer Center Support Grant and the P50 Specialized 

Center of Research Excellence (SPORE) programs. A blue ribbon panel co-chaired by Drs. 

Arthur Nienhuis and Joseph Simone was established to examine the utility and efficacy of these 

key programs, and how best to position them to play a leading role in the 21st century in 

continuing to increase the pace of discovery, development, and delivery of the promise of cancer 

research. The final report is ex-pected by spring of 2003. Information can be found on the NCI 

Web Site at: http://deainfo.nci.nih.gov/advisory/ncab/p30-p50/index.htm. 
Organizational Structure of the Division of Extramural 

Activities 

Office of the Director 

 Directs and administers the operations of the Division, including those activities relating to 

grant review and administration and contract review, as well as Advisory Committee and 

Board activities. 

 Coordinates and manages the NCAB and the BSA. 

 Initiates, coordinates, and implements Institute policies and procedures relating to grants and 

contracts review. 

 Implements the NCI policies regarding extramural research integrity. 

 Represents the NCI on extramural policy issues to the NIH. 

 Advises the Executive Committee, NCI, on extramural implementation strategies. 

 Coordinates with the NIH for all NCI extramural staff training requirements. 

Marvin Kalt, Ph.D..............................Director 

Paulette Gray, Ph.D............................Deputy Director and Associate Director, 

Extramural Applications 

Diane Bronzert...................................Associate Director, Referral, Review, and Program 

Coordination 

Cedric Long, Ph.D. ............................Assistant Director 

Christopher Hatch, Ph.D....................Senior Assistant to the Director 

Elise Kreiss ........................................Senior Program Analyst 

Patricia Marek....................................Program Analyst 

Carolyn Craig* ..................................Program Analyst 

Bernadette Monacelli.........................Secretary 

Donyelle Parrish.................................Secretary 

Wendy Jones ......................................Secretary 

Jasen Converse...................................Receptionist 

Joshua Rhoderick*.............................Receptionist 

* Joined in 2002.
Office of Referral, Review, and Program Coordination, OD 

 Coordinates program concept development; publication functions; and receipt, referral, and 

assignment of all applications. 

 Coordinates activities of the SRLB, RTRB, RPRB, and PCRB. 

Diane Bronzert...................................Associate Director 

Catherine Battistone...........................Program Analyst 

Alma Carter........................................Technical Assistant 

Angela Greer......................................Secretary 
Committee Management Office, OD 

 Coordinates functionally related advisory activities across the Institute to ensure that 

appropriate policies and procedures are in place to conduct its mission and ensure the 

synthesis, integration, and documentation of these activities. 

 Provides consultation services to NCI staff on administrative and technical aspects of 

committee management; coordinates activities with all other NCI advisory committees; 

implements policies and procedures designed to avoid conflicts in the nomination, selection, 

and recruitment of board members; implements CM IMPAC II guidelines and procedures to 

ensure that all committee-related data is correctly entered into the database for preparation 

and submission of required annual reports to the President, DHHS, and NIH; provides 

logistical support for NCAB and BSA meetings; and facilitates NCAB and BSA committeerelated travel. 

 Provides administrative support for the peer-review system by compensating consultants for 

their services on NCI IRG subcommittees and SEPs; reimbursing consultants for travel and 

other expenses; and approving and processing payments for other activities related to review 

such as meeting room rental and teleconferencing. 

Claire Benfer* ...................................Committee Management Officer 

Linda Coleman...................................Committee Management Specialist 

Andrea Collins ...................................Deputy Committee Management Officer 

Earline Jackson ..................................Administrative Technician 

Hing Lee.............................................Accounting Technician 

April Mellinger* ...............................Committee Management Specialist 

Kerry Peasland...................................Program Specialist 

Lisa Rustin .........................................Committee Management Specialist 

* Joined in 2002.
Special Review and Logistics Branch 

 Plans, manages, and assists in the scientific merit review of special grant and cooperative 

agreement applications (RFAs and PAs) and the technical merit review of contract proposals 

(RFPs). 

 Arranges for and participates in onsite assessments of the research capabilities and facilities 

of selected applicants. 

 Identifies and recommends appropriate review committee members and site visitors, as 

required for the review of assigned applications and proposals. 

 Provides the SRA and other support staff to the technical review committees. 

 Serves as the information and coordination center for all grant applications and contract 

proposals pending review by the Branch. 

 Provides input and advice on grant and contract review policy and procedures, application 

and proposal patterns, and research trends and other related information, as required. 

 Coordinates secondary-level review activities of the NCAB with staff of other NCI 

Divisions, other Branches of the Division, the Research Contracts Branch, and the Grants 

Administration Branch. 

 Provides logistical support for primary- and secondary-level review activities in support of 

other Division and Institute units. 

Kirt Vener, Ph.D. ...............................Chief 

Special Review Unit 

Kenneth Bielat, Ph.D. ........................Scientific Review Administrator 

Jennifer DeGroff ................................Program Support Assistant 

Juana Diaz..........................................Program Support Assistant 

Kimberly Farrall-Cragg* ..................Program Support Assistant 

Paul Gallourakus................................Program Support Assistant 

Angela Gantt‡ ..................................Review Technical Assistant 

Sherwood Githens, Ph.D....................Scientific Review Administrator 

Madeleine Hemmings ........................Program Support Assistant 

Marcus Johnson‡ .............................Review Technical Assistant 

C. Michael Kerwin, Ph.D., M.P.H.....Scientific Review Administrator 

Sarah King-Mitchell...........................Contracts Technical Assistant 

Allonda Lord† ...................................Program Support Assistant 

Gerald Lovinger, Ph.D.......................Scientific Review Administrator 

* Left in 2002. 

† Joined in 2002. 

‡ Contractor.
John Makulowich* ............................Program Support Assistant 

Timothy Meeker, M.D. ......................Scientific Review Administrator 

Laura Monzon....................................Program Support Assistant 

Thu Nguyen .......................................Program Support Assistant 

Lalita Palekar, Ph.D. ..........................Scientific Review Administrator 

Joyce Pegues, Ph.D............................Scientific Review Administrator 

Phuong Pham .....................................Program Analyst 

Mary Jane Slesinsky, Ph.D. ...............Scientific Review Administrator 

Latasha Stevens‡ ..............................Review Technical Assistant 

Iliana Valencia‡ ...............................Review Technical Assistant 

Thomas Vollberg, Ph.D. ....................Scientific Review Administrator 

Review Processing and Distribution Unit 

Barbara Beckwith* ............................Grants Technical Assistant 

Adrian Bishop ....................................Mail and File Clerk 

Robert Kruth ......................................Mail and File Clerk 

Clara Murphy.....................................Program Assistant 

Michael Shatarsky..............................Grants Management Analyst 

* Left in 2002. 

‡ Contractor.
Program Coordination and Referral Branch 

 Serves as the information and coordinating point within the NCI for the clearance and 

tracking of all NCI extramural program initiatives. 

 Coordinates the shared interests of all trans-NCI program initiatives through the CSR and 

other NIH Institutes and Centers. 

 Coordinates clearance and publication of all RFAs, PAs, and Notices in the NIH Guide for 

Grants and Contracts. 

 Coordinates the clearance of all NCI grant mechanism guidelines and policies through the 

NIH Office of Extramural Research. 

 Serves as the NCI contact point for approval of the use of cooperative agreement 

mechanisms and for conversion of grants to cooperative agreements. 

 Serves as liaison to the CSR, NIH, to ensure appropriate referral of applications to the Institute and 

their distribution and assignment to appropriate program units within the NCI. 

 Coordinates development of referral guidelines within the NCI for internal and external use. 

 Receives and distributes advance copies of applications for Program Project grants and 

applications submitted in response to RFAs and PAs, and coordinates this information with 

review and program staff. 

 Receives letters of intent from principal investigators intending to submit large budget grants 

and from prospective R13 (conference grants applicants). Maintains a database of prospective large budget grants applicants. 

 Processes ARAs (Awaiting Receipt of Application) through the NOW system to CSR. 

 Automatically refers amended and competing continuation (Type 2) applications to the 

cancer activity that accepted the previously submitted application. 

 Serves as the primary NCI information referral point for the extramural scientific community 

on a broad range of subjects, including grant guidelines, application information, new 

initiatives announced as RFAs or PAs, and the review process. 

 Assists the extramural community in navigating the NIH and NCI Web pages to obtain 

current information, forms, and guidelines. 

 Directs applicants to the appropriate Program Directors and SRAs for information on the 

status of the review and award of their grant applications. 

 Tracks and analyzes trends of CSR referral to study sections and resultant review outcomes. 

 Works with NCI program staff to address unresolved review and referral issues with the CSR 

and other Institutes and Centers. 

 Coordinates requests from program staff for application status changes and for acceptance of 

grant assignments. 
Ray Bramhall, Ph.D. ..........................Chief (CSR Referral Liaison) 

David Contois ....................................Referral Officer 

Rashmi Gopal-Srivastava, Ph.D. .......RFA/PA Coordinator 

Leota Hall...........................................Referral Officer 

Florence Hoffmann/Pedersen.............Referral Officer (CSR Referral Liaison) 

Natacha P. Lassègue ..........................Program Analyst 

Michelle Trout* ................................Program Support Assistant 

Deborah Bielat ...................................Program Support Assistant 

* Left in 2002.
Research Analysis and Evaluation Branch 

 Serves as the Institute’s officially designated centralized source of scientific information and 

science-based budget information on NCI-supported research projects. 

 Analyzes and classifies the science content of all Institute-supported projects. 

 Prepares analyses comparing the distribution of funds among research areas; these analyses 

serve as a basis for budget projections. 

 Prepares special and routine reports and analyses and answers inquiries concerning the 

scientific and budgetary aspects of Institute-funded research, including research grants, 

center grants, and research contracts. 

 Maintains liaisons with other organizations involved in related classification activities. 

 Documents the need for proposed RFAs by comparing RFA concepts with existing NCIsupported research and with unsolicited applications. 

Rosemary Cuddy................................Branch Chief 

Marilyn Gaston ..................................Deputy Branch Chief 

Inquiry and Reporting Team 

 Responds to generalized data requests. 

 Plans, coordinates, and evaluates dissemination of extramural and intramural research data. 

 Conducts in-depth analyses of extramural research data. 

 Answers inquiries from Congress, the public, the press, and others concerning any phase of 

Institute-supported work. 

 Identifies emerging priority areas for data collection and analysis. 

 Conducts economic analysis of funded research; establishes consensus-building processes 

with programs, financial data operations, and others, including the private sector; identifies 

priority data gaps on funded research activities; and recommends solutions to fill these gaps. 

 Evaluates user needs, conducts formalized user surveys, as needed, and translates these needs 

into NCI research reports and dissemination plans. 

 Provides specialized data querying, archiving, and reporting functions for the Division, the 

Financial Management Branch, and the Institute. 

 Directs and conducts the grant, contract, and reporting data file release program, including 

data editing, review, and documentation. 

 Provides consultation services and writes scientific search formulation instructions to 

customers’ specifications to facilitate standardized data preparation. 

 Coordinates the design, development, and implementation of automated systems for award 

data dissemination. 

Marilyn Gaston ..................................Team Leader 

Stacy Harper-Avilla ...........................Technical Information Specialist 
Research Documentation Team 

 Analyzes and indexes grants and contracts for the Branch’s computerized systems. 

 Ensures that terms and categories for indexing are updated and reflect current trends in 

cancer research, and maintains a thesaurus of term definitions. 

 Analyzes extramural projects for relevance to SICs and Anatomic Sites to determine the 

officially reported figures for Institute support and provide a basis for budget projections. 

 Maintains liaison with other offices within the Institute to ensure consistent reporting of data. 

 Monitors the results of Institute grant-supported research through the literature surveillance 

program. 

Vacant ................................................Team Leader 

Lisa Krueger* ....................................Biologist 

Edward Kyle ......................................Biologist 

Nancy Lohrey.....................................Biologist 

Tyrone Wilson ...................................Biologist 

Technical Operations Team 

 Oversees Information Resource Management (IRM) for the Branch. 

 Manages RAEB’s FLARE grants documentation and indexing database, ensuring reliability 

and completeness of its contents. 

 Performs computerized searches for ad hoc information requests to the Branch. 

 Tracks documentation for grant applications, summary sheets, contract proposals, etc., in 

both physical and computerized formats. 

 Prepares documentation for indexing by the Research Documentation Section. 

 Maintains and updates archival document files, including transferring physical files to 

computer media. 

 Serves as the liaison with contractors and AISB to resolve FLARE computer applica-tion 

problems for the Branch. 

 Works with contractors and AISB to refine RAEB’s computer applications to meet the 

Branch’s needs. 

 Manages RAEB’s personnel support functions. 

Dianne Ostrow ...................................Team Leader 

Gail Blaufarb......................................Technical Information Specialist 

Linda Brown ......................................Computer Assistant 

David Hyde* .....................................Technical Information Specialist 

* Joined in 2002.
Applied Information Systems Branch

 Satisfies the information requirements of the Division and coordinates IRM activities with 

other relevant NCI and NIH units and provides high-quality information analysis, design, 

development, and coordination of applications in support of Divisional business processes. 

 Serves as the focal point for the Division in the development, deployment, and application of 

specialized software and databases required for the conduct of review, referral, coding, 

advisory, and other extramural applications. 

 Serves as the liaison with NCI Information Services Technology Branch (ISTB); other NCI 

computer professionals; other NCI units charged with execution of extramural IRM 

functions; other trans-NIH functional units such as the CSR, Office of Policy for Extramural 

Research Administration (OPERA), and Office of Extramural Research (OER); and the 

IMPAC II and eRA (Electronic Research Administration) systems. 

 Supports resources and Internet and Intranet applications connectivity and design. 

 Establishes, administers, and monitors contracts to provide design, production, and maintenance for microcomputer equipment and information storage and retrieval systems not 

covered by Core Services of the NCI. 

 Formulates DEA-specific office automation policy. 

 Provides staff/lead users with technical support and training for DEA applications. 

 Coordinates general use/support and training with Core Services. 

 Provides Division-specific applications of video teleconferencing and audiovisual services in 

support of review and Board activities. 

 Provides management with recommendations for establishing and implementing policies for 

conducting Divisional computer-assisted presentations, as necessary. 

 Reviews user-created applications and recommends and/or designs changes to improve 

efficiency and effectiveness. 

James W. Seach .................................Chief 

Application Development and Operations Team 

 Analyzes and coordinates life-cycle development of software for the Division; develops and 

designs applications to support the Division’s business practices, including user guides. 

 Develops, administers, and monitors contracts for acquisition, support, and maintenance of 

database systems. 

 Administers office automation contracts as well as DEA-wide Blanket Purchase Agreements 

for microcomputer equipment maintenance and supplies. 

 Formulates office automation policy, system development, and IMPAC II operations. 

 Coordinates internal user groups and the provision of training for specific DEA applications 

and the use of office automation equipment technology. 
Gregory Fischetti ...............................Team Leader 

Deborah Buranich ..............................Information Technology Specialist 

Charles Conley...................................Information Technology Specialist 

Teresa Park.........................................Information Technology Specialist 

Hector Reyes......................................Information Technology Specialist 

Information Management Team 

 Designs and maintains the Division’s Intranet and Internet and identifies documents to be 

placed on the NCI Web Site to make Division information more accessible to the public. 

 Develops new Web-based software applications that will enhance the productivity and 

efficiency of extramural processes within the DEA and the distribution of Division 

information throughout the NCI. 

 Establishes partnerships and ongoing communications with staff and external customers to 

allow openness and collaboration in accomplishing the information initiatives of the 

Division. 

 Works with staff to ensure the current utility and linkages of documents placed on the Web. 

Amir Sahar-Khiz................................Team Leader 

Kichelle Green ...................................Management Assistant 

Lorrie Smith.......................................Information Technology Specialist 

Elaine Taylor......................................Information Technology Specialist 
Research Programs Review Branch 

 Plans, coordinates, and manages the scientific merit review of program project grants, 

specialized centers, and other grant mechanisms, as necessary, by chartered review committees and special emphasis panels. 

 Arranges for and participates in onsite assessments of the research capabilities and facilities 

of selected applicants. 

 Identifies and recommends appropriate review committee members and site visitors, as 

required, for the review of assigned applications. 

 Provides input and advice on grant review policy and procedures, application patterns, 

research trends, and other related information, as required. 

 Coordinates grant review activities with staff of other NCI Divisions and other DEA 

Branches. 

Olivia Bartlett, Ph.D. .........................Chief 

Virginia Wray, Ph.D. .........................Deputy Chief 

Shakeel Ahmad, Ph.D........................Scientific Review Administrator 

Courtney Banks..................................Program Support Assistant 

Renee Brooks.....................................Program Support Specialist 

Mary Fletcher, Ph.D...........................Scientific Review Administrator 

Monica Green.....................................Program Support Assistant 

Michelle Higginbottom‡ ..................Review Technical Assistant 

Tiffany Jenifer....................................Program Specialist (Instructor) 

Willie Johnson ...................................Program Specialist 

Deneen Mattocks ...............................Program Support Assistant 

William Merritt, Ph.D........................Scientific Review Administrator 

Bratin Saha, Ph.D...............................Scientific Review Administrator 

Joyce Simms ......................................Program Support Assistant 

Michael Small, Ph.D..........................Scientific Review Administrator 

Cheryl Smith ......................................Program Support Assistant 

Patricia Stream‡ ...............................Review Technical Assistant 

Kimberly Walsh‡ .............................Review Technical Assistant 

Peter Wirth, Ph.D...............................Scientific Review Administrator 

Brian Wojcik, Ph.D............................Scientific Review Administrator 

‡ Contractor.
Resources and Training Review Branch 

 Plans, coordinates, and manages the scientific merit review of cancer center, clinical cooperative group, training, and education grant and cooperative agreement applications by 

chartered review committees and special emphasis panels. 

 Arranges for and participates in onsite assessments of the research capabilities and facilities 

of selected applicants. 

 Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications. 

 Provides input and advice on grant review policy and procedures, application patterns, and 

research trends and other related information, as required. 

 Coordinates grant review activities with staff of other NCI Divisions, other DEA Branches, 

and the Center for Scientific Review. 

David E. Maslow, Ph.D. ....................Chief and Scientific Review Administrator 

Mary Bell, Ph.D. ................................Scientific Review Administrator 

Robert Bird, Ph.D. .............................Scientific Review Administrator 

Danielle Brown ..................................Program Support Assistant 

Gail Bryant, M.D. ..............................Scientific Review Administrator 

Linda Edwards ...................................Grants Technical Assistant 

Stephanie Glynn‡ .............................Review Technical Assistant 

Deborah Jaffe, Ph.D...........................Scientific Review Administrator 

Raymond Petryshyn, Ph.D.................Scientific Review Administrator 

Linda Southworth...............................Program Support Assistant 

Harvey Stein, Ph.D. ...........................Scientific Review Administrator 

Zenia Vilensky...................................Lead Grants Technical Assistant 

Chanee Williams................................Grants Technical Assistant 

‡ Contractor.
ACRIN American College of Radiology Imaging 

 Network 

AISB Applied Information Systems Branch 

APR Accelerated Peer Review 

ARA Awaiting Receipt of Application 

AREA Academic Research Enhancement Award 

ATA Academic/Teacher Award 

BAA Broad Agency Announcement 

BSA Board of Scientific Advisors 

BSC Board of Scientific Counselors 

CARRA Consumer Advocates in Research 

and Related Activities 

CCR Center for Cancer Research 

CCSG Cancer Center Support Grant 

CD Compact Disk 

CECCRS Centers of Excellence in Cancer 

 Communications Research 

CISNET Cancer Intervention and 

SurveillanceMonitoring Network 

CIT Center for Information Technology 

CM Committee Management 

CMO Committee Management Office 

CSR Center for Scientific Review 

CTEP Cancer Therapy Evaluation Program 

CURE Continuous Umbrella of Research Experience 

DARPA Defense Advanced Research Projects Agency 

DCB Division of Cancer Biology 

DCCPS Division of Cancer Control and Population 

 Sciences

DCEG Division of Cancer Epidemiology and Genetics 

DCP Division of Cancer Prevention 

DCTD Division of Cancer Treatment and Diagnosis

DEA Division of Extramural Activities 

DEAIS DEA Information System 

DHHS Department of Health and Human Services 

ER Estrogen Receptor 

ERA Electronic Research Administration Training 

Tracking System 

ESATTS Extramural Science Administrator Traing 

Traching System 

FIRST First Independent Research Support and 

 Transition Award 

FLARE Fiscal Linked Analysis of Research Emphasis 

FOP Financial Operating Plan 

GRB Grants Review Branch 

IC Institute/Center 

ICMIC In Vivo Cellular and Molecular Imaging 

Center 

IDeA Institutional Development Award 

IMPAC Information for Management, Planning, 

 Analysis, and Coordination – database 

Appendix A: Glossary of Acronyms
IOM Institute of Medicine 

IRG Initial Review Group 

IRM Information Resources Management 

ISTB Information Services Technology Branch 

JAD Joint Application and Development 

MAA Master Agreement Announcement 

MBRS Minority Biomedical Research Support 

MERIT Method to Extend Research in Time 

NCAB National Cancer Advisory Board 

NCI National Cancer Institute 

NCRR National Center for Research Resources 

 (NIH) 

NIH National Institutes of Health 

NOW NCI Online Workplace 

NRSA National Research Service Award 

NTROI Network for Translational Research in Optical 

 Imaging 

OD Office of the Director 

OER Office of Extramural Research (NIH) 

OFACP Office of Federal Advisory Committee Policy

OPERA Office of Policy for Extramural Research 

 Administration (NIH) 

ORRPC Office of Referral, Review, and Program 

 Coordination 

PA Program Announcement 

PAR Reviewed Program Announcement 

PCRB Program Coordination and Referral Branch 

PHS Public Health Service (DHHS) 

PRG Progress Review Group 

RAEB Research Analysis and Evaluation Branch 

RAID Rapid Access to Intervention Development 

REAP Research Enhancement Awards Program 

RFA Request for Applications 

RFP Request for Proposals 

RO Referral Office 

RPG Research Program Grant 

RPRB Research Programs Review Branch 

RTRB Resources and Training Review Branch 

RUG Review Users’ Group 

SBIR Small Business Innovation Research 

SBRB Special Review and Resources Branch 

SEER Surveillance, Epidemiology and End Results 

SEP Special Emphasis Panel 

SIC Special Interest Category 

SOP Standard Operating Procedure 

SPORE Specialized Program of Research Excellence 

SRA Scientific Review Administrator 

SREA Scientific Review and Evaluation Award 

SRLB Special Review and Logistics Branch 

STTR Small Business Technology Transfer Research 

Appendix A: Glossary of Acronyms
Appendix B: List of Chartered Committees, FY2002 

President’s Cancer Panel 

Chair 

LaSalle D. Leffall, Jr., M.D. .........Howard University College of Medicine, Washington, DC 

Past Chair & Member 

Harold P. Freeman, M.D............................................. North General Hospital, New York, NY 

Members 

Lance E. Armstrong..................................................................... Lance Armstrong Foundation 

Dennis J. Slamon, M.D., Ph.D....University of California at Los Angeles, School of Medicine 

Frances M. Visco, Esq. ............................. National Breast Cancer Coalition, Washington, DC 

Executive Secretary 

Maureen O. Wilson, Ph.D................................................................... National Cancer Institute 

National Cancer Advisory Board 

Chair 

John E. Niederhuber, M.D. . ................................University of Wisconsin School of Medicine 

Past Chair 

Phillip A. Sharp, Ph.D....................................................Massachusetts Institute of Technology 

Members 

Samir Abu-Ghazaleh, M.D. .................................................................... Avera Cancer Institute 

James O. Armitage, M.D. ...................................................................... University of Nebraska 

Richard J. Boxer, M.D. ...............................................................Medical College of Wisconsin 

Moon S. Chen, Jr., M.P.H., Ph.D.......................University of California, Davis Cancer Center 

Kenneth H. Cowan, M.D., Ph.D. University of Nebraska, Eppley Institute for Cancer Research 

Jean B. deKernion, M.D. ...........University of California at Los Angeles, School of Medicine

Stephen C. Duffy ................ American Academy of Facial Plastic and Reconstructive Surgery 

Ralph S. Freedman, M.B.B.Ch., Ph.D.The University of Texas M.D. Anderson Cancer Center 

James H. French, Jr., M.D. .........................................................The Center for Plastic Surgery 

Elmer E. Huerta, M.D., M.P.H. .....................................................Washington Hospital Center 

Howard K. Koh, M.D. .......................................... Massachusetts Department of Public Health 

Frederick P. Li, M.D.....................................................................Dana-Farber Cancer Institute 

Susan M. Love, M.D...................University of California at Los Angeles, School of Medicine 

The Honorable James E. McGreevey ................... Mayor, Woodbridge Township, New Jersey 

Sandra Millon-Underwood, R.N., Ph.D.........................University of Wisconsin at Milwaukee
Arthur W. Nienhuis, M.D. ..............................................St. Jude Children’s Research Hospital 

Larry Norton, M.D.................................................... Memorial Sloan-Kettering Cancer Center 

Amelie G. Ramirez, Dr.P.H............................................................Baylor College of Medicine 

Ivor Royston, M.D. .............................................................. Forward Ventures, San Diego, CA 

Lydia G. Ryan, M.S.N., P.N.P. ............................................................. AFLAC Cancer Center 

Ellen L. Stovall ...................................................... National Coalition for Cancer Survivorship 

Ex Officio Members of the National Cancer Advisory Board 

The Honorable Elaine Chao, M.B.A. ................................................U.S. Department of Labor 

The Honorable J. Jarrett Clinton, M.D., M.P.H............................. U.S. Department of Defense 

Lester Crawford, D.V.M., Ph.D. .......................................U.S. Food and Drug Administration 

Thomas L. Garthwaite, M.D.....................................................Department of Veterans Affairs 

John Howard, M.D., M.P.H., J.D., LL.M. National Institute for Occupational Safety and Health 

Rachel Levinson.......................... Office of Science and Technology Policy, The White House 

Thomas Moore, J.D....................................................... Consumer Product Safety Commission 

Kenneth Olden, Ph.D. .....................National Institute of Environmental Health Sciences, NIH 

Ari Patrinos, Ph.D............................................................................U.S. Department of Energy 

The Honorable Tommy Thompson.........................Department of Health and Human Services 

The Honorable Christine Todd Whitman .............................Environmental Protection Agency 

Elias A. Zerhouni, M.D. ................................................................ National Institutes of Health 

Alternates to Ex Officio Members of the National Cancer Advisory 

Board 

Stephen K. Akiyama, Ph.D.............National Institute of Environmental Health Sciences, NIH 

Michael A. Babich, Ph.D. ..................................... U.S. Consumer Product Safety Commission 

Raye-Ann Dorn, M.P.H. ...................................................U.S. Department of Veterans Affairs 

Peter Kirchner, Ph.D........................................................................U.S. Department of Energy 

Ruth L. Kirschstein, M.D............................................................... National Institutes of Health 

Alison Martin, M.D............................................................U.S. Food and Drug Administration 

Hugh W. McKinnon, M.D. ...........................................U.S. Environmental Protection Agency 

T. G. Patel, M.D................................................................U.S. Department of Veterans Affairs 

Richard Pazdur, M.D. .......................................................U.S. Food and Drug Administration 

John M. Powers, M.D. ................................................................... U.S. Department of Defense 

George Ruby, M.D.............................................................................U.S. Department of Labor 

Anita L. Schill, Ph.D., M.P.H., M.A., R.N.National Institute for Occupational Safety and Health 

Eugene Schwartz, M.D. .....................................................................U.S. Department of Labor 

Executive Secretary 

Marvin R. Kalt, Ph.D. ......................................................................... National Cancer Institute 

Appendix B: List of Chartered
NCI Advisory Committee to the Director 

Chair 

Andrew C. von Eschenbach, M.D. .................................................... National Cancer Institute 

Members 

Frederick R. Appelbaum, M.D. ................................ Fred Hutchinson Cancer Research Center 

Waun Ki Hong, M.D...........................The University of Texas M.D. Anderson Cancer Center 

Michael B. Kastan, Jr., M.D., Ph.D. ...............................St. Jude Children’s Research Hospital 

Barbara K. LeStage, M.S.H.P............................................................ American Cancer Society 

John E. Niederhuber, M.D. . ................................University of Wisconsin School of Medicine 

Phillip A. Sharp, Ph.D....................................................Massachusetts Institute of Technology 

Craig A. Thompson, M.D. ...............................................................University of Pennsylvania 

Ex Officio Members 

Marvin R. Kalt, Ph.D. ......................................................................... National Cancer Institute 

Alan S. Rabson, M.D. ......................................................................... National Cancer Institute 

Robert E. Wittes, M.D. ....................................................................... National Cancer Institute 

Executive Secretary 

Lisa Stevens, Ph.D. ............................................................................ National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
NCI Board of Scientific Advisors 

Chair 

Frederick R. Appelbaum, M.D. ................................ Fred Hutchinson Cancer Research Center 

Members 

David B. Abrams, Ph.D. ............................................ The Miriam Hospital, Brown University 

David S. Alberts, M.D. ................................... The University of Arizona College of Medicine 

Hoda A. Anton-Culver, Ph.D..................................................University of California at Irvine 

Esther H. Chang, Ph.D................................................. Georgetown University Medical Center 

Neil J. Clendeninn, M.D., Ph.D. ................................................ Drug Development Consultant 

Tom M. Curran, Ph.D. ....................................................St. Jude Children’s Research Hospital 

Mary Beryl Daly, M.D., Ph.D.............................................................Fox Chase Cancer Center 

Suzanne W. Fletcher, M.D................................................................... Harvard Medical School 

Waun Ki Hong, M.D...........................The University of Texas M.D. Anderson Cancer Center 

Susan B. Horwitz, Ph.D. ................................................... Albert Einstein College of Medicine 

Tyler Jacks, Ph.D. ..........................................................Massachusetts Institute of Technology 

William G. Kaelin, Jr., M.D...........Dana-Farber Cancer Institute and Harvard Medical School 

Kenneth W. Kinzler, Ph.D. ..................................................... Johns Hopkins Oncology Center 

Herbert Kressel, M.D..................................................... Beth Israel Deaconess Medical Center 

Amy S. Langer, M.B.A................................National Alliance of Breast Cancer Organizations 

Caryn E. Lerman, Ph.D....................................................................University of Pennsylvania 

W. Gilles McKenna, M.D., Ph.D.................... University of Pennsylvania School of Medicine 

Christine A. Miaskowski, R.N., Ph.D., F.A.A.N.......University of California at San Francisco 

Enrico Mihich, M.D.....................................................................Roswell Park Cancer Institute 

John D. Minna, M.D. .................................. University of Texas Southwestern Medical Center 

Nancy E. Mueller, Sc.D. ......................................................... Harvard School of Public Health 

Franklyn. G. Prendergast, M.D., Ph.D............................................................Mayo Foundation 

Richard L. Schilsky, M.D. .......................................................................University of Chicago 

Ellen Sigal, Ph.D............................................................................. Friends of Cancer Research 

Joseph V. Simone, M.D. ...............................................................................Simone Consulting 

Louise C. Strong, M.D........................The University of Texas M.D. Anderson Cancer Center 

Peter K. Vogt, Ph.D. ...................................................................The Scripps Research Institute 

Daniel D. Von Hoff, M.D. ......................................................................Arizona Cancer Center 

Barbara L. Weber, M.D. ................................. University of Pennsylvania School of Medicine 

Alice S. Whittemore, Ph.D. .........................................................................Stanford University 

William C. Wood, M.D.................................................................... Emory University Hospital 

Robert C. Young, M.D........................................................................Fox Chase Cancer Center 

Elias A. Zerhouni, M.D.............................. The Johns Hopkins University School of Medicine 

Executive Secretary 

Paulette S. Gray, Ph.D. ....................................................................... National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
NCI Listens: BSA at National Association Meetings 

American Society of Preventive Oncology (ASPO)

Bethesda, MD, March 10-12, 2002 

NCI Listens, Monday, March 11, 2002

Mary Beryl Daly, M.D., Ph.D. (Chair)...............................................Fox Chase Cancer Center 

Peter Greenwald, M.D. ....................................................................... National Cancer Institute 

Paulette S. Gray, Ph.D. ....................................................................... National Cancer Institute 

Caryn E. Lerman, Ph.D. (Chair)..............................University of Pennsylvania Health System 

Nancy E. Mueller, Sc.D.. ..............................................................Dana-Farber Cancer Institute 

and Harvard School of Public Health 

Barbara K. Rimer, Ph.D...................................................................... National Cancer Institute 

American Association for Cancer Research (AACR) 

San Francisco, CA, April 6-10, 2002 

NCI Listens, Tuesday, April 9, 2002

Enricho Mihich, M.D. (Chair)........................... SUNY/Buffalo-Roswell Park Cancer Institute 

Hoda Anton-Culver, Ph.D.......................................................University of California at Irvine 

Ellen G. Feigal, M.D........................................................................... National Cancer Institute 

Paulette S. Gray, Ph.D.. ...................................................................... National Cancer Institute 

Marvin R. Kalt, Ph.D.. ........................................................................ National Cancer Institute 

Brian W. Kimes, Ph.D. ....................................................................... National Cancer Institute 

Dinah Singer, Ph.D. ............................................................................ National Cancer Institute 

Louise C. Strong, M.D................................................................M.D. Anderson Cancer Center 

W. Gillies McKenna, M.D., Ph.D........................... Hospital of the University of Pennsylvania 

Andrew C. von Eschenbach, M.D... ................................................... National Cancer Institute 

Oncology Nursing Society (ONS) 

Washington, DC, April 18-21, 2002 

 NCI Listens, Friday, April 19, 2002

Christine Miaskowski, R.N., Ph.D., F.A.A.N. (Chair)University of California at San Francisco 

Paulette S. Gray, Ph.D. ....................................................................... National Cancer Institute 

Mary McCabe, R.N., M.S.N. .............................................................. National Cancer Institute 

Cold Spring Harbor Laboratories (CSHL) 

Cold Spring Harbor, NY, August 14-18, 2002 

NCI Listens, Friday, August 16, 2002

William G. Kaelin, Jr., M.D. (Chair) ...........................................Dana-Farber Cancer Institute 

and Harvard Medical School 

Paulette S. Gray, Ph.D. ....................................................................... National Cancer Institute 

Dinah Singer, Ph.D. ............................................................................ National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
NCI Board of Scientific Counselors 

NCI/BSC Subcommittee A—Clinical Sciences and Epidemiology 

Chair 

Michael B. Kastan, M.D., Ph.D. .....................................St. Jude Children’s Research Hospital 

Members 

Carlos L. Arteaga, M.D.............................................................................Vanderbilt University 

Leslie Bernstein, Ph.D. ..........................................................University of Southern California 

Martin A. Cheever, M.D.............................................................................. Corixa Corporation 

Michael L. Cleary, M.D.............................................. Stanford University School of Medicine 

Ms. Deborah E. Collyar ................................................... PAIR-Patient Advocates in Research 

Chi V. Dang, M.D., Ph.D........................... The Johns Hopkins University School of Medicine 

Timothy Eberlein, M.D..........................................Washington University School of Medicine 

Elizabeth T. Fontham, D.P.H......................Louisiana State University Health Sciences Center 

Stanley R. Hamilton, M.D. ........................University of Texas M.D. Anderson Cancer Center 

Elizabeth Holly, Ph.D. ...............................................University of California at San Francisco 

David J. Hunter, Sc.D. ............................................................ Harvard School of Public Health 

Laurence N. Kolonel, M.D., Ph.D. ............................................................University of Hawaii 

Frank McCormick, Ph.D............................................University of California at San Francisco 

Daniel M. Medina, Ph.D.................................................................Baylor College of Medicine 

Beverly S. Mitchell, M.D..... University of North Carolina at Chapel Hill, School of Medicine 

James J. Mule, Ph.D..................................................... University of Michigan Medical Center 

Olufunmilayo F. Olopade, M.B.B.S. ............................. University of Chicago Medical Center 

Richard J. O’Reilly, M.D.......................................... Memorial Sloan-Kettering Cancer Center 

Alice P. Pentland, M.D. ................. University of Rochester School of Medicine and Dentistry 

Arthur T. Porter, M.D. ................................... Wayne State University, Detroit Medical Center 

David A. Savitz, Ph.D................................................................... University of North Carolina 

David T. Scadden, M.D. ..................................................................... Harvard Medical School 

Steven G. Self, Ph.D. ................................................ Fred Hutchinson Cancer Research Center 

Margaret A. Tempero, M.D. .................University of California, San Francisco Cancer Center 

Michael Thun, M.D............................................................................ American Cancer Society 

Executive Secretary 

Abby B. Sandler, Ph.D........................................................................ National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
NCI/BSC Subcommittee B—Basic Sciences 

Chair 

Craig B. Thompson, M.D. .......................................University of Pennsylvania Cancer Center 

Members 

Rafi Ahmed, Ph.D.......................................................... Emory University School of Medicine 

Frederick W. Alt, Ph.D. ........................................................................The Children’s Hospital 

Jon C. Clardy, Ph.D. ......................................................................................Cornell University 

Gideon Dreyfuss, Ph.D. .................................. University of Pennsylvania School of Medicine 

E. Peter Geiduschek, Ph.D.............................................. University of California at San Diego 

Sankar Ghosh, Ph.D...........................................................Yale University School of Medicine 

Stephen P. Goff, Ph.D................................................................................Columbia University 

Beatrice H. Hahn, M.D. ..........................................................................University of Alabama 

Stephen S. Hecht, Ph.D................................................ University of Minnesota Cancer Center 

Nouria T. Hernandez, Ph.D.......................................................Cold Spring Harbor Laboratory 

David Housman, Ph.D. ..................................................Massachusetts Institute of Technology 

Thomas J. Kelly, M.D., Ph.D..................................................... The Johns Hopkins University 

Richard D. Kolodner, Ph.D............................................. University of California at San Diego 

John Kuriyan, Ph.D............................................................University of California at Berkeley 

Dan R. Littman, M.D., Ph.D........................................... New York University Medical Center 

Guillermina Lozano, Ph.D. .......................University of Texas M.D. Anderson Cancer Center 

Brooke T. Mossman, Ph.D................................... University of Vermont, College of Medicine 

Dinshaw J. Patel, Ph.D.............................................. Memorial Sloan-Kettering Cancer Center 

Suzanne B. Sandmeyer, Ph.D. ................................................University of California at Irvine 

Andrey S. Shaw, M.D............................................................................ Washington University 

Harinder Singh, Ph.D.......................University of Chicago, Howard Hughes Medical Institute 

Ronald I. Swanstrom, Ph.D....................................University of North Carolina at Chapel Hill 

Thea D. Tlsty, Ph.D. ..................................................University of California at San Francisco 

Gregory L. Verdine, Ph.D.............................................................................Harvard University 

Inder M. Verma, M.S.C., Ph.D. ......................................... Salk Institute for Biological Studies 

Cheryl L. Walker, Ph.D. ...................... The Univerity of Texas M.D. Anderson Cancer Center 

Eileen White, Ph.D. .............................................................. Howard Hughes Medical Institute 

Executive Secretary 

Florence E. Farber, Ph.D..................................................................... National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
NCI Director’s Consumer Liaison Group 

Chair 

Barbara K. LeStage, M.S.H.P............................................................ American Cancer Society 

Members 

Vernal Branch ...................................................................................... Vista Community Clinic 

Susan Lowell Butler, M.P.H., PH.D. ...................................Ovarian Cancer National Alliance 

Kathy Giusti, M.B.A. .................................................Multiple Myeloma Research Foundation 

Michael Katz, M.B.A.......................................................... International Myeloma Foundation 

Paula K. Kim................................................................Pancreatic Cancer Action Network, Inc. 

Ruth Lin, R.N............................................................................ Morristown Memorial Hospital 

Gena Love..........................................................................People Living Through Cancer, Inc. 

Christopher Pablo....................................................................... Kaiser Foundation Health Plan 

Karen G. Packer.............................................................Marshalltown Cancer Research Center 

Henry A. Porterfield..................................................................................Us Too! International 

Nyrvah Richard......................................Self-Help for Women With Breast or Ovarian Cancer 

Doug E. Ulman ............................................................................ Lance Armstrong Foundation 

Marissa Weiss, M.D. ...................................................................Living Beyond Breast Cancer 

Brad Zebrack, M.S.W., M.P.H., Ph.D. .................. National Coalition for Cancer Survivorship 

Executive Secretary 

Elaine Lee ........................................................................................... National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
NCI Initial Review Group Scientific Review Committees 

Subcommittee A—Cancer Centers 

Chair 

Harold L. Moses, M.D. ..........................................................Vanderbilt-Ingram Cancer Center 

Members 

Stephen B. Baylin, M.D. .................................. Johns Hopkins University School of Medicine 

Deborah J. Bowen, Ph.D........................................... Fred Hutchinson Cancer Research Center 

Michael A. Caligiuri, M.D......................Ohio State University Comprehensive Cancer Center 

William L. Carroll, M.D. .......................Ohio State University Comprehensive Cancer Center 

Graham A. Colditz, M.D., Ph.D. .....................Harvard Medical School, Channing Laboratory 

Walter J. Curran, Jr., M.D. ........................................................... Thomas Jefferson University 

Julie Y. Djeu, Ph.D. .......................................University of South Florida College of Medicine 

Janice P. Dutcher, M.D................................................................... New York Medical College 

Judith C. Gasson, Ph.D. ............................................... University of California at Los Angeles 

William N. Hait, M.D., Ph.D. .............................................The Cancer Institute of New Jersey 

Janet A. Houghton, Ph.D. ..............................................St. Jude Children’s Research Hospital 

Candace S. Johnson, Ph.D. ........................................ University of Pittsburgh Cancer Institute 

Wen-Hwa Lee, Ph.D...............................................University of Texas Health Science Center 

Michael W. Lieberman, M.D., Ph.D...............................................Baylor College of Medicine 

Debra G. Lillegard, MA .............................................................. Park Nicollet Health Services 

Robin J. Mermelstein, Ph.D. ...................................................University of Illinois at Chicago

Raymond E. Meyn, Jr., Ph.D. .............The University of Texas M.D. Anderson Cancer Center 

David M. Ota, M.D. ...................................................................Medical College of Wisconsin 

Electra D. Paskett, M.P.H., Ph.D............Ohio State University Comprehensive Cancer Center 

Jill C. Pelling, Ph.D. .......................................................University of Kansas Medical Center 

Nancy J. Raab-Traub, Ph.D. ..................................University of North Carolina at Chapel Hill 

Derek Raghavan, M.D., Ph.D. ...............................................University of Southern California 

Catalina Ramos, M.D............................................ Y-ME National Breast Cancer Organization 

Joan H. Schiller, M.D. ..................... University of Wisconsin, Comprehensive Cancer Center 

Thomas A. Sellers, Ph.D........................... Mayo Cancer Center, Mayo Clinic and Foundation 

Marc A. Shuman, M.D. .............................................University of California at San Francisco 

Jean Y. Wang, Ph.D........................................................ University of California at San Diego 

David A. Williams, M.D........................Indiana University Cancer Center, Indiana University 

James K. Wilson, M.D...........................................................Case Western Reserve University 

David W. Yandell, Sc.D. ........................................................................ University of Vermont 

Scientific Review Administrator 

David Maslow, Ph.D........................................................................... National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
Subcommittee C—Basic and Preclinical 

Chair 

William F. Morgan, Ph.D. .................................... University of Maryland School of Medicine 

Members 

Dafna Bar-Sagi, Ph.D. ...................................... State University of New York at Stony Brook 

Olivera J. Finn, Ph.D............................................ University of Pittsburgh School of Medicine 

Denise A. Galloway, Ph.D........................................ Fred Hutchinson Cancer Research Center 

Mien-Chie Hung, Ph.D. ......................The University of Texas M.D. Anderson Cancer Center 

Ronald C. Kennedy, Ph.D. ...............................Texas Tech University Health Sciences Center 

Howard B. Lieberman, Ph.D........... Columbia University College of Physicians and Surgeons 

Scott W. Lowe, Ph.D. ...............................................................Cold Spring Harbor Laboratory 

Ruth J. Muschel, M.D., Ph.D.......................... University of Pennsylvania School of Medicine 

Susan L. Naylor, Ph.D. ...........................................University of Texas Health Science Center 

Harvey L. Ozer, M.D. ... University of Medicine and Dentistry of New Jersey Medical School 

Maria G. Pallavicini, Ph.D.................. University of California, San Franciscio Cancer Center 

Angel G. Pellicer, M.D., Ph.D. ....................................... New York University Medical Center 

Peter J. Polverini, DDS, DMSC .......................... University of Minnesota School of Dentistry 

Garth Powis, D.Phil. ....... University of Arizona College of Medicine, Arizona Cancer Center 

Vito Quaranta, M.D. ...................................................................The Scripps Research Institute 

Eddie Reed, M.D. ................................................................................ West Virgina University 

Gary S. Stein, Ph.D..............................................University of Massachusetts Medical School 

Bill M. Sugden, Ph.D.........................................................University of Wisconsin at Madison 

Donald J. Tindall, Ph.D................................................................. Mayo Clinic and Foundation 

Philip N. Tsichlis, M.D, Ph.D................Thomas Jefferson University, Kimmel Cancer Center 

Louis M. Weiner, M.D........................................................................Fox Chase Cancer Center 

Bernard E. Weissman, Ph.D. ........................................................ University of North Carolina 

Scientific Review Administrator 

Michael Small, Ph.D........................................................................... National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
Subcommittee D—Clinical Studies 

Chair 

Philip B. McGlave, M.D............................................ University of Minnesota Medical School 

Past Chair 

Nathan A. Berger, M.D......................... Case Western Reserve University School of Medicine 

Members 

Kenneth C. Anderson, M.D. .........................................................Dana-Farber Cancer Institute 

Jessie L. Au, Ph.D...................................Ohio State University Comprehensive Cancer Center 

William T. Beck, Ph.D.....................................University of Illinois at Chicago Cancer Center 

J. Martin Brown, D.Phil.............................................. Stanford University School of Medicine 

David P. Carbone, M.D., Ph.D. ........................................Vanderbilt University Cancer Center 

Richard E. Champlin, M.D. ...............The University of Texas M.D. Anderson Cancer Center 

Alfred E. Chang, M.D..................................................University of Michigan Medical School 

Jose C. Costa, M.D. ...........................................................Yale University School of Medicine 

Robert B. Diasio, M.D. ........................University of Alabama Comprehensive Cancer Center 

Harriett B. Eggert, B.S.......................................... Susan G. Komen Breast Cancer Foundation 

Stephen J. Forman, M.D. ............................................... City of Hope National Medical Center 

Karen King-Wah Fu, M.D. ........................................University of California at San Francisco 

Steven J. Grant, M.D. ........................................................Virginia Commonwealth University 

John G. Gribben, M.D. .................................................................Dana-Farber Cancer Institute 

Barbara W. Henderson, Ph.D.......................................................Roswell Park Cancer Institute 

Helen Heslop, M.D. .....................................................University of Maryland Medical Center 

Elizabeth M. Jaffee, M.D................................................. The Johns Hopkins Oncology Center 

Roy B. Jones, M.D.......................................... Health Sciences Center, University of Colorado 

Gloria C. Li, Ph.D. ................................................... Memorial Sloan-Kettering Cancer Center 

Patricia M. Lorusso, D.O.. .................................................................... Wayne State University 

Dana C. Matthews, M.D. ...................................................................University of Washington 

Mark D. Minden, M.D., Ph.D................. Ontario Cancer Institute, Princess Margaret Hospital 

Robert S. Negrin, M.D................................................ Stanford University School of Medicine 

Raphael E. Pollock, M.D., Ph.D. ........The University of Texas M.D. Anderson Cancer Center 

Carol K. Redmond, Ph.D. ..............University of Pittsburgh Graduate School of Public Health 

Rupert K. Schmidt-Ullrich, M.D. ......................................Virginia Commonwealth University 

Keith A. Stewart, M.D. ...................................................................Princess Margaret Hospital 

Herman D. Suit, M.D., Ph.D.................................................... Massachusetts General Hospital 

Scientific Review Administrators 

William Merritt, Ph.D......................................................................... National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
Subcommittee E—Cancer Epidemiology, Prevention, and Control 

Chair 

Paul F. Engstrom, Ph.D., M.D. ............................Fox Chase Cancer Center, Sciences Division 

Members 

Joan E. Bailey-Wilson, Ph.D. ......................National Human Genome Research Institute, NIH 

Doris M. Benbrook, Ph.D. ............................. University of Oklahoma Health Sciences Center 

William L. Bigbee, Ph.D. .............University of Pittsburgh, Graduate School of Public Health 

Tim E. Byers, M.P.H., M.D............................. University of Colorado Health Sciences Center 

Karen M. Emmons, Ph.D..............................................................Dana-Farber Cancer Institute 

Gary E. Fraser, M.B., C.H.B...................... Loma Linda University School of Health Research 

Kyungmann Kim, Ph.D.............................................. University of Wisconsin Medical School 

Patrick M. Lynch, M.D.......................The University of Texas M.D. Anderson Cancer Center 

Jeanne S. Mandelblatt, M.D., M.P.H. .................................................Lombardi Cancer Center 

Ann E. McNeil, RN ....................................................................................University of Miami 

Charles R. Meyer, Ph.D. ..............................................University of Michigan Medical School 

Elaine A. Ostrander, Ph.D......................................... Fred Hutchinson Cancer Research Center 

Henry R. Pacheco, M.D. ...............................................................National Council of La Raza 

Barbara C. Pence, Ph.D. ...................................Texas Tech University Health Sciences Center 

Michael B. Sporn, M.D....................................................................Dartmouth Medical School 

Terry M. Therneau, Ph.D.............................................................. Mayo Clinic and Foundation 

Paolo G. Toniolo, M.D. ........................................... New York University School of Medicine 

Michael J. Welch, Ph.D. .......................................Washington University School of Medicine 

Scientific Review Administrator 

Mary Fletcher, Ph.D............................................................................ National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
Subcommittee F—Manpower and Training 

Chair 

James S. Economou, M.D., Ph.D.......... University of California, Los Angeles Medical Center 

Past Chair 

Nancy L. Oleinick, Ph.D....................... Case Western Reserve University School of Medicine 

Members 

Judy A. Bean, Ph.D............................................................ Children’s Hospital Medical Center 

Powel H. Brown, M.D., Ph.D. .......................................................Baylor College of Medicine 

Philip J. Browning, M.D..........................................Vanderbilt University School of Medicine 

Malaya Chatterjee, Ph.D.............................................University of Cincinnati Medical Center 

Edward A. Copelan, M.D. ....... Ohio State University College of Medicine and Public Health 

Denis F. Deen, Ph.D. .................................................University of California at San Francisco 

Soldano Ferrone, M.D., Ph.D. .................................................... Roswell Park Cancer Institute 

James W. Freeman, Ph.D........................................University of Texas Health Science Center 

Michael R. Freeman, Ph.D................. Harvard Medical School, Enders Research Laboratories 

David A. Gewirtz, Ph.D.....................................................Virginia Commonwealth University 

Seymour Grufferman, M.D., Dr.P.H. ...................................................University of Pittsburgh 

Marc F. Hansen, Ph.D................................... University of Connecticut Health Science Center 

Jeffrey T. Holt, M.D. ...................................... University of Colorado Health Sciences Center 

P. Jack Hoopes, Ph.D., D.V.M.........................................................Dartmouth Medical School 

Larry R. Kaiser, M.D. ..................................... University of Pennsylvania School of Medicine 

Jeffrey P. Krischer, Ph.D. .............................................................. University of South Florida 

Diana E. Lake, M.D. ................................................. Memorial Sloan-Kettering Cancer Center 

David M. Mahvi, M.D. .....................................................University of Wisconsin at Madison 

Timothy W. McKeithan, M.D., Ph.D. ......................... University of Nebraska Medical Center 

Maureen E. Murphy, Ph.D..................................................................Fox Chase Cancer Center 

Mary Ann Osley, Ph.D.................................University of New Mexico Health Science Center 

Gary R. Pasternack, M.D., Ph.D................ The Johns Hopkins University School of Medicine 

Ann Roman, Ph.D. ....................................................... Indiana University School of Medicine 

Kathleen Rundell, Ph.D. ............................................ Northwestern University Medical Center 

John E. Shively, Ph.D. ................................................... City of Hope National Medical Center 

Douglas Yee, M.D. ...................................................... University of Minnesota Cancer Center 

Alice Yu, M.D., Ph.D. ..............................University of California, San Diego Medical Center 

Scientific Review Administrators 

Mary Bell, Ph.D. ................................................................................. National Cancer Institute 

Robert E. Bird, Ph.D........................................................................... National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
Subcommittee G—Education 

Chair 

Steven M. Grunberg, M.D. .................................................................... University of Vermont 

Past Chair 

Ajit K. Sachdeva, M.D., FRCS, FACS ..................................... American College of Surgeons 

Members 

Andrea M. Barsevick, R.N..................................................................Fox Chase Cancer Center 

Robert M. Chamberlin, Ph.D. .............The University of Texas M.D. Anderson Cancer Center 

Karen Hassey Dow, Ph.D. ............................................................University of Central Florida 

Jose M. Esteban, M.D., Ph.D..............................................Providence Hospital Cancer Center 

Jeffrey J. Guidry, Ph.D. .........................................................................Texas A&M University 

Lynn C. Hartmann, M.D............................................................... Mayo Clinic and Foundation 

Curtis J. Mettlin, Ph.D. ...............................................................Roswell Park Cancer Institute 

Patricia Dolan Mullen, D.R.P.H. .........University of Texas Health Science Center at Houston 

Ana M. Navarro, Ph.D. .................University of California at San Diego, School of Medicine 

Billy U. Philips, Jr., M.P.H., Ph.D. .............University of Texas Medical Branch at Galveston 

Phyllis L. Pirie, Ph.D. ................................... University of Minnesota School of Public Health 

William H. Redd, Ph.D............... Mount Sinai School of Medicine, Ruttenberg Cancer Center 

Vernon K. Sondak, M.D. ....University of Michigan Comprehensive Cancer/Geriatrics Center 

Cameron K. Tebbi, M.D. .................................................................Tampa Children’s Hospital 

John T. Vetto, M.D. ......................................................Oregon Health and Science University 

Scott A. Waldman, M.D., Ph.D. ................................................... Thomas Jefferson University 

Jeffrey N. Weitzel, M.D................................................. City of Hope National Medical Center 

Katharine A. Whartenby, Ph.D................. The Johns Hopkins University School of Medicine 

Scientific Review Administrator 

Harvey Stein, Ph.D. ............................................................................ National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
60

Subcommittee H—Clinical Trials 

Chair 

Leslie J. Kohman, M.D................................................................SUNY Health Science Center 

Past Chair 

Herbert K. Lyerly, M.D. ......................................................... Duke University Medical Center 

Members 

James R. Anderson, M.D., Ph.D..................................University of Nebraska Medical School 

Constance Baird, R.N. ............................................ Healthcare Association of New York State 

Brent A. Blumenstein, Ph.D. ........................................... Duke University School of Medicine 

John C. Byrd, M.D..................... Ohio State University School of Medicine and Public Health 

Walter M. Cronin, M.P.H. ................... University of Pittsburgh, NSABP Biostatistical Center 

William S. Dalton, M.D., Ph.D....................................................... University of South Florida 

Martin J. Edelman, M.D. ......................... University of Maryland Greenebaum Cancer Center 

Laurie E. Gaspar, M.D........................................................................... University of Colorado 

Mary K. Gospodarowicz, M.D. .......................................................Princess Margaret Hospital 

Stuart A. Grossman, M.D. ...................................................... Johns Hopkins Oncology Center 

Daniel F. Hayes, M.D. ................................................. Georgetown University Medical Center 

Steven C. Horii, M.D. ............................................ University of Pennsylvania Medical Center 

Charles E. Kahn, Jr., M.D...........................................................Medical College of Wisconsin 

Ann Marilyn Leitch, M.D. ......................................University of Texas Health Science Center 

Neal J. Meropol, M.D. ........................................................................Fox Chase Cancer Center 

Judith A. Miller, Ph.D.....................................................................................Emory University 

George L. Mutter, M.D............................................................Brigham and Women’s Hospital 

Craig R. Nichols, M.D. .......................................................Oregon Health Sciences University 

Carolyn D. Runowicz, M.D. ...............................................St. Luke Roosevelt Hospital Center 

Daniel J. Sargent, Ph.D................................................................. Mayo Clinic and Foundation 

Marilyn L. Slovak, Ph.D................................................ City of Hope National Medical Center 

James A. Stewart, M.D. ..... University of Wisconsin, Madison Comprehensive Cancer Center 

Marilyn Stromborg, Ph.D. ................................Northern Illinois University School of Nursing 

Nicholas J. Vogelzang, M.D....................................................................University of Chicago 

Steven Weitman, M.D., Ph.D. ..................................................................... Ilex Oncology, Inc. 

Andrew M. Yeager, M.D. .................................... University of Pittsburgh School of Medicine 

Scientific Review Administrator 

Deborah R. Jaffe, Ph.D. ...................................................................... National Cancer Institute 

Appendix B: List of Chartered Committees, FY2002
Appendix C: NCI Initial Review Group Consultants, FY2002 

1. Consultants Serving as Temporary Members on IRG Subcommittees in FY2002 

A Adjei, Alex A., M.D., Ph.D. ....................Mayo Clinic, Rochester 

Ahles, Tim A., Ph.D.................................Dartmouth College 

Aisner, Seena C., M.D. ............................University of Medicine/Dentistry of New Jersey 

Alarid, Elaine T., Ph.D.............................University of Wisconsin at Madison 

Altman, Norman Harry, D.V.M...............University of Miami 

Ambros, Victor R., Ph.D..........................Dartmouth College 

Amos, Christopher I., Ph.D......................University of Texas, MD Anderson Cancer Center 

Anderson, Carolyn J., Ph.D. ....................Washington University, School of Medicine 

Anderson, Wayne F., Ph.D. .....................Northwestern University 

Andersson, Borje S., M.D., Ph.D.............Sandra Technology, Inc. 

Andrykowski, Michael A., Ph.D..............University of Kentucky 

Anver, Miriam R., Ph.D...........................SAIC Frederick-NCI Frederick Cancer Research 

Arthur, R. Martin, Ph.D. ..........................Washington University 

Ascoli, Mario, Ph.D. ................................University of Iowa, College of Medicine 

Atcher, Robert W., Ph.D..........................Los Alamos National Laboratory 

Auerbach, Robert, Ph.D...........................University of Wisconsin at Madison 

Augenlicht, Leonard H., Ph.D. ................Montefiore Medical Center (Bronx, NY) 

Austin, Donald F., M.D. ..........................Oregon Health & Science University 

B Bailey, Howard H., M.D..........................University of Wisconsin, Madison 

Baker, David C., Ph.D. ............................Texas A&M University Health Science Center 

Baldwin, Defloris M., Ph.D. ....................Office of Women’s Health, State of Georgia 

Balmain, Allan, Ph.D...............................University of California at San Francisco 

Barmada, Mahumd M., Ph.D...................University of Pittsburgh at Pittsburgh 

Bar-Sagi, Dafna, Ph.D. ............................State University New York at Stony Brook 

Bast, Robert C., M.D. ..............................University of Texas, MD Anderson Cancer Center 

Bauer-Wu, Susan M., D.Sc., R.N. ...........Dana-Farber Cancer Institute 

Baum, Stanley, M.D.................................University of Pennsylvania 

Becich, Michael J., M.D., Ph.D. ..............University of Pittsburgh at Pittsburgh 

Belk, Bonnie F., M.A., M.P.A. ................Private Practice 

Bellen, Hugo J., Ph.D..............................Baylor College of Medicine 

Benbrook, Doris M., Ph.D. ......................University of Oklahoma, Health Sciences Center 

Benson, Al B., M.D. ................................Northwestern University 

Berger, James M., Ph.D. ..........................University of California at Berkeley 

Berger, Mitchel S., M.D...........................University of California at San Francisco 

Bigbee, William L., Ph.D.........................University of Pittsburgh 

Biondi, Andrea, M.D. ..............................Universita Milano-Bicocca Clinica Pediatrica 

Birt, Diane F., Ph.D. ................................Iowa State University of Science & Technology 

Bittner, Michael L., Ph.D.........................National Human Genome Research Institute 

Blumenstein, Brent A., Ph.D. ..................American College of Surgeons 

Bogler, Oliver, Ph.D. ...............................Case Western Reserve University-Henry Ford 

Hospital 

Brattain, Michael G., Ph.D.......................Roswell Park Cancer Institute 

Breitz, Hazel B., M.D. .............................Neorx Corporation 
Brooks, Antone L., Ph.D..........................Washington State University 

Brown, Powel, M.D., Ph.D. .....................Baylor College of Medicine 

Brugge, Joan S., Ph.D. .............................Federation of American Societies for Experimental 

Biology 

Buckner, Jan C., M.D...............................Mayo Clinic, Rochester 

Buettner, Gary R., Ph.D...........................University of Iowa 

Buka, Stephen L., Ph.D............................Harvard University, School of Public Health 

Burgess, Kevin, Ph.D...............................Texas A&M University Health Science Center 

Burke, Harry B., M.D., Ph.D. ..................George Washington University 

Byrd, John C., M.D..................................Ohio State University 

C Cagan, Ross L., Ph.D...............................Washington University 

Carey, Thomas E., Ph.D...........................University of Michigan at Ann Arbor 

Cassady, James R., M.D. .........................Lahey Hitchcock Medical Center 

Chamberlin, Helen M., Ph.D. ..................Ohio State University 

Champlin, Richard E., M.D. ....................University of Texas, MD Anderson Cancer Center 

Chen, David J., M.D., Ph.D. ....................University of California-Lawrence Berkeley 

Laboratory 

Chen, George T.Y., Ph.D.........................University of Chicago 

Chin, Tom D.Y., M.D.,............................University of Kansas Medical Center 

Christie, Debra W., Ph.D. ........................University of Mississippi Medical Center 

Chute, Christopher G., M.D., Ph.D..........Mayo Clinic, Rochester 

Clark, Gary M., Ph.D...............................Baylor College of Medicine 

Clarke, Robert R., Ph.D. .........................Georgetown University 

Cody, Vivian, Ph.D..................................Hauptman-Woodward Medical Research Institute 

Coffino, Philip, M.D., Ph.D.....................Clontech Laboratories, Inc. 

Cohen, Alfred M., M.D............................University of Kentucky 

Cohen, Peter A., M.D...............................Cleveland Clinic Foundation 

Copelan, Edward A., M.D. ......................Ohio State University 

Corry, Peter M., Ph.D. .............................William Beaumont Hospital 

Cowell, John K., Ph.D. ............................Roswell Park Cancer Institute 

Craft, Alan W., M.D. ...............................Royal Victoria Infirmary Department of Child 

Health 

Croce, Carlo M., M.D. .............................Thomas Jefferson University 

Cunningham, Richard P., Ph.D................State University of New York at Albany 

Currie, John L., M.D................................Dartmouth Medical School 

D Das Gupta, Tapas K., Ph.D......................University of Illinois at Chicago 

Davis, Roger J., Ph.D...............................University of Massachusetts Medical School at 

Worcester 

Davisson, V. Jo, Ph.D. .............................Purdue University at West Lafayette 

De Clerck, Yves A., M.D.........................American Association for Cancer Research 

Degregori, James V., Ph.D.......................University of Colorado Health Sciences Center 

Demark-Wahnefried, Wendy, Ph.D.........Duke University 

Demple, Bruce F., Ph.D...........................Harvard University, School of Public Health 

Dennis, James W., Ph.D...........................Samuel Lunenfield Research Institute 

Dewey, William C., Ph.D. .......................Virginia Commonwealth University 

Dewhirst, Mark W., Ph.D. .......................Duke University 

Dickey, Burton F., M.D. ..........................Baylor College of Medicine 

Digate, Russell J., Ph.D. ..........................University of Maryland, College Park Campus 

Appendix C-1: Consultants Serving as Temporary Members 

on IRG Subcommittees
Djuric, Zora, Ph.D....................................Wayne State University, Kimmel Cancer Institute 

Donehower, Lawrence, Ph.D...................Baylor College of Medicine 

Dupont, Bo, M.D. ....................................Sloan-Kettering Institute for Cancer Research 

E Edgar, Bruce A., Ph.D. ............................Fred Hutchinson Cancer Center 

Eggert, Harriet B., B.S.............................Susan G. Komen Breast Cancer Foundation 

Eiseman, Julie L., Ph.D............................University of Pittsburgh at Pittsburgh 

Elliott, Thomas E., M.D., Ph.D.,..............Duluth Clinic 

Ellman, Jonathan A., Ph.D.......................University of California at Berkeley 

Erdman, John W., Ph.D. ..........................University of Illinois 

Erickson, Kent L., Ph.D...........................University of California at Davis 

Erickson, Leonard C., Ph.D. ....................Indiana University Cancer Center 

F Fahs, Marianne C., Ph.D..........................New School University 

Feldman, Roy S., D.D.S., D.M.Sc. ..........University of Pennsylvania 

Felton, James S., Ph.D. ............................University of California-Lawrence Livermore 

National Laboratory 

Ferenczy, Alex, M.D................................McGill University 

Ferrone, Soldano, M.D., Ph.D. ................Roswell Park Cancer Institute 

Finer-Moore, Janet S., Ph.D.....................University of California at San Francisco 

Forman, Stephen J., M.D. ........................City of Hope National Medical Center 

Foster, Thomas H., Ph.D.........................University of Rochester 

Freeman, James W., Ph.D........................University of Texas Health Sciences Center at San 

Antonio 

Friedlander, Barry R., M.D., Ph.D...........University of Medicine/Dentistry of New Jersery, 

Rutgers 

Fu, Karen King-Wah, M.D. .....................University of California at San Francisco 

G Gallagher, Richard E., Ph.D....................Wayne State University 

Galloway, Denise A., Ph.D......................Fred Hutchinson Cancer Research Center 

Ganzel, Toni M., M.D.............................University of Louisville 

Geacintov, Nicholas E., Ph.D. ................New York University 

Geist-Martin, Patricia, Ph.D.....................San Diego State University 

Gilliland, D. Gary, M.D., Ph.D................Brigham and Women’s Hospital 

Glazer, Peter M., M.D., Ph.D...................Yale University 

Goldberg, Judith D., M.D ........................Bristol-Myers Squibb 

Goldsmith, Mark A., M.D., Ph.D.............J. David Gladstone Institutes 

Gomer, Charles J., Ph.D...........................Children’s Hospital, Los Angeles 

Gospodarowicz, Mary K., M.D. ..............Princess Margaret Hospital 

Graham, Michael M., M.D., Ph.D. ..........University of Iowa 

Grant, Steven J., M.D...............................Virginia Commonwealth University 

Gray, Robert J., Ph.D...............................Frontier Science & Tech Research Foundation, Inc. 

Grdina, David J., Ph.D............................University of Chicago 

Gribben, John G., M.D............................Dana-Farber Cancer Institute 

Gribskov, Michael R., Ph.D.....................General Atomics 

Grossman, Stuart A., M.D. ......................Johns Hopkins University 

Grubbs, Clinton J., Ph.D. .........................Life Sciences Technologies, Inc. 

Grufferman, Seymour, M.D., Ph.D..........University of Pittsburgh at Pittsburgh 

Grundfest, Warren S., M.D......................University of California at Los Angeles 

Guidry, Jeffrey J., Ph.D. ..........................Texas A&M University System 

Appendix C-1: Consultants Serving as Temporary Members 

on IRG Subcommittees
Gustafson, David H., Ph.D.......................Metastar Technologies, Inc. 

H Halazonetis, Thanos D., Ph.D..................Wistar Institute 

Hansen, Marc F., Ph.D.............................University of Connecticut School of 

Medicine/Dentistry 

Harris, Randall E., M.D., Ph.D. ...............Ohio State University 

Hart, Gerald W., Ph.D..............................University of Alabama at Birmingham 

Hayes, Daniel F., M.D., ...........................University of Michigan at Ann Arbor 
Hays, John B., Ph.D.................................Oregon State University 

Hellstrom, Ingegerd E., M.D., Ph.D. .......Pacific Northwest Research Institute 

Herlyn, Meenhard I., D.Sc., D.V.M.........Wistar Institute 

Herman, James G., M.D...........................Johns Hopkins University Medical School 

Hess, Allan D., Ph.D................................Johns Hopkins University 

Heston, Warren D., Ph.D. ........................Cleveland Clinic Foundation 

Hilsenbeck, Susan G., Ph.D.....................Baylor College of Medicine 

Ho, Gloria Y., Ph.D. ................................Yeshiva University 

Ho, Shuk-Mei, Ph.D.................................Wayne State University 

Hogge, Donna E., M.D., Ph.D. ................British Columbia Cancer Research Center 

Holland, Eric C., M.D., Ph.D...................Sloan-Kettering Institute for Cancer Research 

Hollingsworth, Michael A., Ph.D. ...........University of Nebraska Medical Center 

Holt, Jeffrey T., M.D. ..............................University of Colorado Health Sciences Center 

Holt, Peter R., M.D. .................................St. Luke’s-Roosevelt Institute for Health Sciences 

Hom, David J., B.S. .................................Baylor College of Medicine 

Honn, Kenneth V., Ph.D. .........................Biomide Corporation 

Hoon, Dave S., Ph.D................................John Wayne Cancer Institute 

Horii, Steven C., B.A...............................University of Pennsylvania 

Horwitz, Edwin M., M.D., Ph.D..............International Society for Cellular Therapy 

Houghton, Janet A., Ph.D. .......................St. Jude Children’s Research Hospital 

Hughes, Chanita A., Ph.D........................University of Pennsylvania 

Huston, James S., Ph.D............................Intraimmune Therapies 

I Iavarone, Antonio, M.D...........................Columbia University Health Sciences 

Iruela-Arispe, Luisa, Ph.D. ......................University of California at Los Angeles 

J James, Charles D., Ph.D...........................Mayo Clinic, Rochester 

Janmey, Paul A., Ph.D. ............................University of Pennsylvania 

Jensen, Ronald H., Ph.D. .........................University of California at San Francisco 

Jewell, William R., M.D. .........................University of Kansas Medical Center 

Johnson, Linda B., B.S.............................National Coalition for Cancer Survivorship 

Jones, Roy B., M.D., Ph.D.......................University of Colorado Health Sciences Center 

Jorgensen, Timothy J., Ph.D. ...................Johns Hopkins University 

June, Carl H., M.D., Ph.D........................University of Pennsylvania 

Justement, Louis B., Ph.D........................University of Alabama at Birmingham 

K Kahn, Charles E., M.D., Ph.D..................Medical College of Wisconsin 

Kaplan, Alan M., Ph.D.............................University of Kentucky 

Karnitz, Larry M., Ph.D...........................Mayo Clinic, Rochester 

Keating, Armand, M.D. ...........................Princess Margaret Hospital 

Kelly, Regis B., Ph.D...............................University of California at San Francisco 

Kennedy, Ronald C., Ph.D.......................University of Oklahoma Health Sciences Center 

Kennel, Stephen John, Ph.D.. ..................Oak Ridge Associated Universities 

Kerbel, Robert S., Ph.D. ..........................Sunnybrook & Women’s College Health Sciences 

Center 

Keyes, Sean M., B.A................................Fox Chase Cancer Center 

Kim, Kyungmann, Ph.D...........................University of Wisconsin at Madison 

King, Bonnie L., Ph.D. ............................Yale University 

Kirchen, Dennis J., Ed.D. ........................Dominican University 

Appendix C-1: Consultants Serving as Temporary Members 

on IRG Subcommittees
Knight, Kendall L., Ph.D. ........................University of Massachusetts Medical School at 

Worcester 

Koch, Cameron J., Ph.D...........................University of Pennsylvania 

Kohman, Leslie J., M.D...........................State University of New York Health Science 

Center 

Kolasa, Kathryn M., Ph.D., .....................East Carolina University 

Koos, Robert D., Ph.D. ...........................University of Maryland at Baltimore 

Koral, Kenneth F., Ph.D...........................University of Michigan at Ann Arbor 

Korngold, Robert, Ph.D. .........................Thomas Jefferson University 

Kow, Yoke W., Ph.D. ..............................Emory University 

Kreuter, Matthew W., Ph.D. ....................St. Louis University 

Krischer, Jeffrey P., Ph.D. .......................H. Lee Moffitt Cancer Center & Research Institute 

Krohn, Kenneth A., Ph.D.........................University of Washington 

Krontiris, Theodore G., M.D., Ph.D. .......Beckman Research Institute 

Kundel, Harold L., M.D...........................University of Pennsylvania 

Kung, Hsing-Jien, Ph.D. ..........................University of California, Davis Cancer Center 

L Lahue, Robert S., Ph.D. ...........................University of Nebraska Medical Center 

Lange, Beverly J., M.D............................Children’s Hospital of Philadelphia 

Larson, Richard A., M.D. ........................University of Chicago 

Leavitt, Dennis D., Ph.D..........................University of Utah 

Lee, Eva Y., Ph.D. ...................................University of California at Irvine 

Leslie, Kevin B., M.D., Ph.D...................Immgenics Pharmaceuticals, Inc. 

Li, Gloria C., Ph.D...................................Sloan-Kettering Institute for Cancer Research 

Lieberman, Howard B., Ph.D...................Columbia University Health Sciences 

Lieberman, Michael, M.D., Ph.D.............Baylor College of Medicine 

Lillegard, Debra G., M.A.........................Methodist Hospital Cancer Center 

Limburg, Paul J., M.D., ..........................Mayo Clinic and Foundation 

List, Marcy A., Ph.D................................University of Chicago 

Livingston, Philip O., M.D. .....................Sloan-Kettering Institute for Cancer Research 

Ljung, Britt-Marie E., M.D......................University of California at San Francisco 

Lyerly, Herbert K., M.D. .........................Duke University Medical Center 

Lynch, David H., Ph.D.............................Immunex 

Lynch, Richard G., M.D., Ph.D. ..............University of Iowa 

M Mandelblatt, Jeanne S., M.D., Ph.D.........Georgetown University/Lombardi Cancer Center 

Mann, Jill R., M.D. ..................................Birmingham Children’s Hospital, Oncology 

Department 

Manni, Andrea, M.D................................Pennsylvania State University, Hershey Medical 

Center 

Marinkovich, M. Peter, M.D....................Stanford University 

Marmorstein, Ronen, Ph.D. .....................Wistar Institute 

Marrack, Philippa C., Ph.D......................National Jewish Medical & Research Center 

Mason, Joel B., M.D. ...............................Tufts University, Boston 

Matzuk, Martin, M.D., Ph.D....................Baylor College of Medicine 

Mayer, Joni A., Ph.D. ..............................San Diego State University 

McBride, William H., Ph.D. ....................University of California at Los Angeles 

McGlave, Philip B., M.D.........................University of Minnesota Medical School 

McMillan, Susan C., Ph.D., .....................University of South Florida 

McNeil, Ann E., R.N. ..............................University of Miami 

Appendix C-1: Consultants Serving as Temporary Members 

on IRG Subcommittees
Melendez, Juan A., Ph.D. ........................Albany Medical College of Union University 

Menoret, Antoine, Ph.D...........................University of Connecticut, School of 

Medicine/Dentistry 

Mettlin, Curtis J., Ph.D. ...........................Roswell Park Cancer Institute Corporation 

Meyn, Raymond E., Ph.D. .......................Introgen Therapeutics, Inc. 

Mier, James W., M.D...............................Beth Israel Deaconess Medical Center 

Mierke, Dale F., M.D., Ph.D....................Brown University 
Mignatti, Paolo, M.D. ..............................New York University 

Miles, Steven A., M.D. ............................University of California at Los Angeles 

Miller, Jeffrey S., M.D.............................University of Minnesota at Twin Cities 

Miller, Judith A., Ph.D.............................Emory University 

Miller, Robert H., Ph.D............................University of Minnesota at Twin Cities 

Minden, Mark D., M.D., Ph.D.................Princess Margaret Hospital 

Morgan, William F., Ph.D. ......................University of Maryland 

Morris, Selma J., M.Ed. ...........................Grady Health System 

Mortimer, Joanne E., M.D. ......................Washington University 

Moses, Harold L., M.D., Ph.D.................Vanderbilt University 

Mosmann, Tim R., Ph.D. .........................University of Rochester 

Moss, Steven F., M.D. .............................St. Luke’s-Roosevelt Institute for Health Sciences 

Mullen, Patricia Dolan, Ph.D...................University of Texas Health Sciences Center at 

Houston 

Murre, Cornelis, Ph.D..............................University of California at San Diego 

N Nagle, Raymond B., M.D., Ph.D. ............University of Arizona 

Nasca, Philip C., Ph.D. ............................University of Massachusetts at Amherst 

Nash, Justin M., Ph.D. .............................Miriam Hospital 

Navarro, Ana M., Ph.D. ...........................University of California at San Diego 

Naylor, Susan L., Ph.D. ...........................University of Texas Health Science Center 

Neale, Geoffrey A., Ph.D.........................St. Jude Children’s Research Hospital 

Nedrud, John G., Ph.D.............................Case Western Reserve University 

Neuberg, Donna S., Sc.D.........................Dana-Farber Cancer Institute 

Neuhauser, Duncan B., Ph.D. ..................Case Western Reserve University 

Neuwald, Andrew F., M.D., Ph.D. ..........Cold Spring Harbor Laboratory 

Nichols, Craig R., M.D. ...........................Oregon Health & Science University 

Nickoloff, Brian J., M.D., Ph.D...............Loyola University of Chicago 

Nimer, Stephen D., M.D. .........................Sloan-Kettering Institute for Cancer Research 

Norman, Anthony W., Ph.D.....................University of California at Riverside 

Norris, James S., Ph.D. ............................Medical University of South Carolina 

O Oleinick, Nancy L., Ph.D.........................Case Western Reserve University 

Olive, Peggy L., Ph.D. .............................British Columbia Cancer Research Centre 

Olson, Sara H., M.D., Ph.D. ....................Sloan-Kettering Institute for Cancer Research 

O’Reilly, Richard J., M.D........................Sloan-Kettering Institute for Cancer Research 

Orentas, Rimas J., Ph.D. ..........................Medical College of Wisconsin 

Ota, David M., M.D.................................University of Missouri, Ellis Fischel Cancer Center 

Ozer, Harvey L., M.D. .............................University of Medicine/Dentistry NJ Newark 

P Pacheco, Henry R., M.D. .........................National Council of La Raza 

Padilla, Luis A., M.D...............................University of New Mexico Health Sciences Center 

Pallavicini, Maria G., Ph.D......................University of California at San Francisco 

Parker, Charles J., M.D............................University of Utah 

Parrott, Roxanne L., Ph.D........................University of Georgia 

Parsons, J. Thomas, M.D., Ph.D. .............University of Virginia at Charlottesville 

Pasqualini, Renata R., Ph.D.....................University of Texas 

Patte, Catherine, M.D...............................Institut Gustave Roussy Service d’Oncologie 

Pediatrique 

Pence, Barbara C., Ph.D...........................Texas Tech University Health Sciences Center 

Appendix C-1: Consultants Serving as Temporary Members 

on IRG Subcommittees
Peterson, Douglas E., Ph.D......................University of Connecticut, School of 

Medicine/Dentistry 

Piedrahita, Jorge A., Ph.D........................North Carolina State University at Raleigh 

Piland, Neill F., Ph.D...............................Medical Group Management Association Center for 

Research 

Piwnica-Worms, David R., M.D., Ph.D...Brigham and Women’s Hospital 

Pizzo, Salvatore V., M.D., Ph.D. .............Duke University 

Plate, Janet M., Ph.D................................Rush-Presbyterian-St. Lukes Medical Center 

Pledger, W. J., Ph.D.................................University of South Florida 

Pogue, Brian W., Ph.D.............................Dartmouth College 

Pollack, Alan, M.D., Ph.D. ......................Fox Chase Cancer Center 

Polverini, Peter J., D.D.S., D.M.Sc..........University of Michigan at Ann Arbor 

Powell, Isaac J., M.D., .............................Wayne State University, Karmanos Cancer Center 

Powell, Simon N., M.D., Ph.D. ...............Massachusetts General Hospital 

Powell, Steven M., M.D...........................University of Virginia at Charlottesville 

Powis, Garth, Ph.D...................................University of Arkansas Medical Sciences at Little 

Rock 

Prout, Marianne N., M.D., ......................Boston University, School of Medicine 

Pumiglia, Kevin M., Ph.D........................Albany Medical College of Union University 

Q Quaranta, Vito, M.D. ...............................Scripps Research Institute 

Quesenberry, Peter J., M.D......................Roger Williams Hospital 

R Rademaker, Alfred W., Ph.D...................Northwestern University 

Raffel, Corey, M.D., Ph.D. ......................Mayo Clinic, Rochester 

Rao, Chintalapally V., Ph.D.....................American Health Foundation 

Recht, Lawrence D., M.D., Ph.D.............University of Massachusetts Medical School at 

Worcester 

Redd, William H., Ph.D...........................Mount Sinai School of Medicine of NYU 

Reddy, Satyanarayana G., M.D. ..............Women and Infants Hospital, Rhode Island 

Redmond, Carol K., SCD ........................University of Pittsburgh 

Reid, Brian R., Ph.D. ...............................University of Washington 

Reiss, Michael, M.D. ...............................University of Medicine/Dentistry of New Jersey 

Resnicow, Ken A., Ph.D. .........................Emory University 

Rexer, Mary Katherine, MA ....................University of Michigan at Ann Arbor 

Reynolds, Al, Ph.D. .................................Vanderbilt University 

Rhodes, Kris E., MS ................................University of Kentucky 

Rhodus, Nelson L., DMD, MPH..............University of Minnesota at Twin Cities 

Robbins, Michael E. C., Ph.D..................Wake Forest University Health Sciences 

Robertson, Erle S., Ph.D. .........................University of Michigan at Ann Arbor 

Robinson, Leslie A., Ph.D. ......................University of Memphis 

Roman, Ann, Ph.D...................................Indiana University-Purdue University at 

Indianapolis 

Rosmarin, Alan G., M.D..........................Miriam Hospital 

Ross, Douglas D., M.D., Ph.D.................University of Maryland, Baltimore Professional 

School 

Rosse, Wendell F., M.D...........................Duke University 

Rothenberg, Mace L., M.D. .....................Vanderbilt University 

Rothman, Alexander J., Ph.D...................University of Minnesota at Twin Cities 

Rothstein, Rodney J., Ph.D. .....................Columbia University at New York, Morningside 

Appendix C-1: Consultants Serving as Temporary Members 

on IRG Subcommittees
Rothstein, Thomas L., M.D., Ph.D. .........Boston University 

Rowitch, David H., M.D., Ph.D...............Dana-Farber Cancer Institute 

Rubin, Jonathan M., M.D., Ph.D. ............University of Michigan at Ann Arbor 

Rudders, Richard A., M.D. ......................Boston University 

Rutter, Carolyn M., Ph.D.........................Center for Health Studies 

Ryan, James C., M.D. ..............................Northern California Institute of Research and 

Education 
S Salazar-Mather, Thais P., Ph.D................Brown University 

Salvesen, Guy S., Ph.D. ...........................Burnham Institute 

Samuel, Charles E., Ph.D.........................University of California 

Sarkar, Fazlul H., Ph.D. ...........................Karmanos Cancer Institute 

Sayre, James W., Ph.D.............................University of California at Los Angeles 

Schaid, Daniel J., Ph.D. ...........................Mayo Clinic, Rochester 

Schnipper, Lowell E., M.D. .....................Beth Israel Deaconess Medical Center 

Schnuth, Rae Lee, Ph.D. ..........................Michigan State University 

Schultheiss, Timothy E., Ph.D.................City of Hope, National Medical Center 

Serody, Jonathan S., M.D., Ph.D. ............University of North Carolina at Chapel Hill 

Shakes, Diane C., Ph.D............................College of William and Mary 

Shibata, Darryl K., M.D., Ph.D................University of Southern California 

Shields, Anthony F., M.D., Ph.D.............Wayne State University 

Shultz, Leonard D., Ph.D.........................Jackson Laboratory 

Shuman, Marc A., M.D............................University of California 

Singletary, Keith W., Ph.D. .....................University of Illinois 

Skibo, Edward B., Ph.D...........................Arizona State University 

Smith, Eva D., Ph.D................................University of Illinois at Chicago 

Smoot, Duane T., M.D.............................Howard University 

Sondak, Vernon K., M.D. ........................University of Michigan 

Song, Chang W., Ph.D............................University of Minnesota Medical School 

Sowers, Lawrence C., Ph.D. ....................Loma Linda University 

Speicher, David W., Ph.D........................Wistar Institute 

Sporn, Michael B., M.D...........................Dartmouth College 

Stearns, Mark E., Ph.D.............................MCP Hahnemann University 

Stein, Gary S., Ph.D.................................University of Massachusetts Medical School at 

Worcester 

Stewart, Keith A., M.D. ...........................University of Toronto 

Stobaugh, John F., Ph.D...........................University of Kansas at Lawrence 

Stoeckert, Christian J., Ph.D. ...................University of Pennsylvania 

Stoner, Gary D., Ph.D. ............................Ohio State University 

Storey, C. Porter, M.D. ............................American Academy/Hospice & Palliative Medicine 

Strieter, Robert M., M.D..........................University of California at Los Angeles 

Struck, Robert F., Ph.D...........................Southern Research Institute 

Stuart, Gavin C.E., M.D...........................University of Calgary 

Sugden, Bill M., Ph.D..............................University of Wisconsin at Madison 

Summerhayes, Ian C., Ph.D.....................Lahey Clinic 

T Talmadge, James E., Ph.D. ......................University of Nebraska Medical Center 

Taylor, Roger, M.D..................................Cookridge Hospital 

Teitell, Michael A., M.D., Ph.D...............University of California at Los Angeles 

Terry, Michael A., M.B.A........................University of Rochester 

Tew, Kenneth D., Ph.D............................Fox Chase Cancer Center 

Thompson, Lawrence H., Ph.D................University of California-Lawrence Livermore 

National Laboatory 

Tindall, Donald J., Ph.D...........................Mayo Clinic, Rochester 

Triozzi, Pierre L., M.D.............................University of Alabama at Birmingham 

Trock, Bruce J., Ph.D...............................Johns Hopkins University 

Truitt, Robert L., Ph.D.............................Medical College of Wisconsin 

Appendix C-1: Consultants Serving as Temporary Members 

on IRG Subcommittees
Tsichlis, Philip N., M.D., Ph.D................New England Medical Center Hospitals 

U Urba, Walter J., M.D., Ph.D.....................Providence Portland Medical Center 

V Van Etten, Richard A., M.D., Ph.D. ........Center for Blood Research 

Vannier, Michael W., M.D. .....................University of Iowa 

Velcich, Anna, Ph.D. ...............................Montefiore Medical Center (Bronx, NY) 

Vetto, John T., M.D. ................................Oregon Health Sciences University 

Villalona, Miguel A., M.D.......................Ohio State University 

Vose, Julie M., M.D.................................University of Nebraska Medical Center 

W Waldman, Scott A., M.D., Ph.D. .............Thomas Jefferson University 

Wang, Kenneth K., M.D. .........................Mayo Clinic, Rochester 

Wang, Xiao-Fan, Ph.D.............................Duke University 

Ward, John H., M.D.................................University of Utah 

Wargovich, Michael J., Ph.D..................University of South Carolina at Columbia 

Watson, Dennis K., Ph.D.........................Medical University of South Carolina 

Weick, Martin P., MS ..............................Baylor College of Medicine 

Weigel, Nancy, Ph.D. ..............................Baylor College of Medicine 

Weinberg, Robert A., M.D., Ph.D. ..........Whitehead Institute for Biomedical Research 

Weiner, Louis M., M.D............................Keystone Symposia 

Weissleder, Ralph, M.D., Ph.D................Massachusetts General Hospital 

Weissman, Bernard E., Ph.D. ..................University of North Carolina at Chapel Hill 

Wettstein, Peter J., Ph.D. .........................Mayo Clinic, Rochester 

Whartenby, Katharine A., Ph.D...............Johns Hopkins University, School of Medicine 

Wheeler, Thomas M., M.D. .....................Baylor College of Medicine 

Whiteside, Theresa L., Ph.D. ...................University of Pittsburgh at Pittsburgh 

Wilding, George A., M.D. .......................University of Wisconsin at Madison 

Williard, Paul G., Ph.D. ...........................Neutron Technology 

Wilson, Brian C., Ph.D. ...........................University of Toronto 

Wilson, Glenn L., Ph.D............................University of South Alabama 

Winett, Richard A., Ph.D.........................Virginia Polytechnic Institute and State University 

Wishnok, John S., Ph.D. ..........................Massachusetts Institute of Technology 

Witherspoon, Yvonne, B.A......................Dana-Farber Cancer Institute 

Woloschak, Gayle E., Ph.D. ....................Northwestern University 

Wong, John W., Ph.D. .............................William Beaumont Hospital Research Institute 

Y Yalowich, Jack C., Ph.D. .........................University of Pittsburgh at Pittsburgh 

Yancey, Antronette K., M.D., .................University of California at Los Angeles 

Yannelli, John R., Ph.D. .........................University of Kentucky Medical Center 

Yeatman, Timothy J., M.D. .....................H. Lee Moffitt Cancer Center & Research Institute 

Yeger, Herman, Ph.D...............................University of Toronto 

Younes, Mamoun, M.D. ..........................Baylor College of Medicine 

Yu, Dihua, M.D., Ph.D. ...........................Texas Tech University Health Sciences Center 

Z Zalutsky, Michael R., Ph.D......................Duke University 

Zee, Phyllis C., M.D., Ph.D. ....................Northwestern University 

Zwicker, Robert D., Ph.D. .......................Virginia Commonwealth University 

Total Number of Reviewers: 413 

Appendix C-1: Consultants Serving as Temporary Members 

on IRG Subcommittees
2. Consultants Serving as Ad Hoc Committee Members on IRG Site Visit Teams in 

FY2002 

A Abrams, Judith, Ph.D...............................Wayne State University 

Aggarwal, Bharat B., Ph.D. .....................University of Texas, MD Anderson Cancer Center 

Agrawal, Babita, Ph.D. ............................University of Alberta 

Akporiaye, Emmanuel T., Ph.D...............Warren Grant Magnuson Clinical Center, NIH 

Ali-Osman, Francis C., D.Sc. ..................University of Texas, MD Anderson Cancer Center 

Altman, Norman Harry, D.V.M...............University of Miami 

Ambrosone, Christine B., Ph.D. ..............Mount Sinai School of Medicine 

Andersen, Janet W., Sc.D. .......................Harvard University 

Anderson, Garnet L., Ph.D.......................Fred Hutchinson Cancer Research Center 

Andrykowski, Michael A., Ph.D..............University of Kentucky 

Anscher, Mitchell S., M.D., Ph.D............Duke University 

Antman, Karen H., M.D...........................Columbia University, New York, Morningside 

Aristondo, Linda, J.D...............................Columbia University 

Arthur, R. Martin, Ph.D. ..........................Washington University 

Artzt, Karen J., Ph.D................................University of Texas at Austin 

Asch, Bonnie B., Ph.D.............................Roswell Park Cancer Institute 

Atcher, Robert W., Ph.D..........................Los Alamos National Laboratory 

Auerbach, Robert, Ph.D...........................University of Wisconsin at Madison 

Augenlicht, Leonard H., Ph.D. ................Montefiore Medical Center (Bronx, NY) 

Avadhani, Narayan G., Ph.D. ..................University of Pennsylvania 

Avraham, Hava K., Ph.D. ........................Beth Israel Deaconess Medical Center 

B Baker, Vicki V., M.D., Ph.D....................University of Michigan Medical Center 

Balaban, Barbara J. ..................................West Islip Breast Cancer Coalition 

Balducci, Lodovico, M.D.........................University of South Florida 

Bankaitis, Vytas A., Ph.D. .......................University of North Carolina at Chapel Hill 

Bar-Sagi, Dafna, Ph.D. ............................State University of New York at Stony Brook 

Basch, Ross S., M.D., Ph.D. ....................New York University 

Bast, Robert C., M.D. ..............................University of Texas, MD Anderson Cancer Center 

Bastia, Deepak, Ph.D. ..............................Medical University of South Carolina 

Basu, Ashis K., Ph.D. ..............................University of Connecticut 

Baylin, Stephen B., M.D..........................Keystone Symposia 

Bearman, Gregory H., Ph.D.....................California Institute of Technology 

Becich, Michael J., M.D., Ph.D. ..............University of Pittsburgh at Pittsburgh 

Beckwith, Barbara J., M.A.......................Columbus Community Clinical Oncology Program 

Belinsky, Steven A., Ph.D. ......................Lovelace Biomedical and Environmental Research 

Belk, Bonnie F., M.A., M.P.A. ................Private Practice 

Bellen, Hugo J., D.V.M., Ph.D. ...............Baylor College of Medicine 

Benbrook, Doris M., Ph.D. ......................University of Oklahoma Health Sciences Center 

Benson, Al B., M.D. ................................Northwestern University 

Berens, Michael E., Ph.D.........................St. Joseph’s Hospital and Medical Center 

Berezney, Ronald, Ph.D...........................Keystone Symposia 

Berger, Mitchel S., M.D...........................University of California at San Francisco 

Bergeron, Christophe, M.D......................Responsable du Department D’Oncologie Pediatrie 

Bernos, Eve E., B.A.................................University of Michigan Medical Center 

Berwick, Marianne, Ph.D.........................Sloan-Kettering Institute for Cancer Research 
Biondi, Andrea, M.D. ..............................Universita Milano-Bicocca Clinica Pediatrica 

Blair, Carol D., Ph.D................................Colorado State University 

Blaney, Susan, M.D. ................................Baylor College of Medicine 

Blasberg, Ronald G., M.D. ......................Sloan-Kettering Institute for Cancer Research 

Blond, Sylvie Y., Ph.D.............................University of Illinois at Chicago 

Blum, Ronald H., M.D.............................New York University 

Bogler, Oliver, Ph.D. ...............................Case Western Reserve University 

Boyajian, Richard Nishan ........................Dana Farber Cancer Institute 

Boyd, Jeff A., Ph.D..................................Sloan-Kettering Institute for Cancer Research 

Brandsma, Janet L., Ph.D.........................Yale University School of Medicine 

Brash, Alan R., Ph.D................................Vanderbilt University 

Brautigan, David L., Ph.D. ......................University of Virginia at Charlottesville 

Bronson, Roderick T., D.V.M..................Tufts University School of Veterinary Medicine 

Brown, William J., Ph.D..........................Cornell University, Ithaca 

Bryant, Joseph L., D.V.M........................University of Maryland at College Park Campus 

Bryant, Peter J., Ph.D...............................University of California at Irvine 

Buatti, John M., M.D. ..............................University of Iowa 

Buchsbaum, Donald J., Ph.D. ..................University of Alabama at Birmingham 

Buckner, Jan C., M.D...............................Mayo Clinic, Rochester 

Budinger, Thomas F., M.D., Ph.D...........University of California, Berkeley 

Buka, Steven, Ph.D. .................................Harvard University School of Public Health 

Burke, Daniel J., Ph.D. ............................University of Virginia at Charlottesville 

Burke, Steven D., Ph.D............................University of Wisconsin at Madison 

Burt, Randall W., M.D.............................University of Utah Health Sciences Center 

Byers, Stephen W., Ph.D. ........................Georgetown University 

C Cabot, Myles C., Ph.D. ............................John Wayne Cancer Institute 

Caligiuri, Michael A., M.D., Ph.D...........Ohio State University 

Cannon, Martin J., Ph.D...........................Scripps Research Institute 

Cantor, Alan B., M.D., Ph.D....................Children’s Hospital (Boston) 

Capen, Charles C., DVM, Ph.D...............Ohio State University 

Caron, Hubert, M.D., Ph.D. .....................Emma Kinderziekenhuis AMC, Department of 

Human Genetics 

Carr, Olga S., B.A....................................Columbia University 

Carroll, Dana, Ph.D..................................University of Utah School of Medicine 

Carroll, William L., M.D. ........................Mount Sinai School of Medicine 

Catapano, Carlo V., M.D., Ph.D. .............Medical University of South Carolina 

Champion, Victoria L., D.N.S., FAAN ...Indiana University-Purdue University at 

Indianapolis 

Chang, David D., M.D., Ph.D..................University of California at Los Angeles 

Chao, Nelson J., M.D...............................Duke University 

Chatterjee, Subroto, Ph.D. .......................Johns Hopkins University 

Chau, Vincent, Ph.D. ...............................Pennsylvania State University, Hershey Medical 

Center 

Chaudhuri, Gautam, M.D., Ph.D. ............University of California at Los Angeles 

Chen, Chin-Tu, Ph.D. ..............................University of Chicago 

Chen, David J., M.D., Ph.D. ....................University of California-Lawrence Berkeley 

Laboratory 

Chenevert, Thomas L., Ph.D....................University of Michigan at Ann Arbor 

Cheng, Liang, M.D., Ph.D. ......................Indiana University School of Medicine 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
Chiocca, E. Antonio, M.D., Ph.D. ...........Massachusetts General Hospital 

Chodosh, Lewis A., M.D., Ph.D. .............University of Pennsylvania 

Choy, Hak, M.D.......................................Vanderbilt University 

Christie, Debra W., Ph.D. ........................University of Mississippi Medical Center 
Christman, Michael F., Ph.D. ..................Boston University 

Chung, Fung-Lung, Ph.D.........................American Health Foundation 

Chung, Leland W., Ph.D..........................Emory University School of Medicine 

Chute, Christopher G., M.D., Ph.D..........Mayo Clinic, Rochester 

Claffey, Kevin P., Ph.D. ..........................University of Connecticut School of 

Medicine/Dentistry 

Clevenger, Charles V., M.D., Ph.D. ........University of Pennsylvania School of Medicine 

Cochran, Brent H., Ph.D. .........................Tufts University, Boston 

Cohen, Edward P., M.D...........................University of Illinois at Chicago 

Colditz, Graham A., M.D.........................Brigham and Women’s Hospital 

Cole, Michael D., Ph.D............................Georgetown University 

Colvin, Oliver M., M.D. ..........................Duke University 

Compton, Duane A., Ph.D. ......................Dartmouth College 

Constantine, Corinne, M.B.A. .................New York University 

Cook, Penny, M.P.A., R.N.......................The Rockefeller University 

Cordeiro-Stone, Marila, Ph.D. .................University of North Carolina at Chapel Hill 

Cowan, Kenneth H., M.D., Ph.D. ............University of Nebraska Medical Center 

Cowell, John K., Ph.D. ............................Roswell Park Cancer Institute 

Craft, Alan W., M.D. ...............................Royal Victoria Infirmary 

Croce, Carlo M., M.D. .............................Thomas Jefferson University 

Crouse, Gray F., Ph.D..............................Emory University 

Curtis, Jeffrey L., M.D.............................University of Michigan at Ann Arbor 

Czachowski, Ralph E., M.A.....................Dartmouth College 

D Damha, Masad Jose’, Ph.D......................McGill University 

Darling, Michael W., M.H.A. ..................Indiana University Cancer Center 

Davie, James R., Ph.D. ............................Manitoba Institute of Cell Biology 

Davisson, V. Jo, Ph.D. .............................Purdue University, West Lafayette 

Dayal, Hari H., Ph.D................................University of Texas Medical Branch at Galveston 

De Kraker, Jan, M.D................................Emma Kinderziekenhuis 

Deeg, H. Joachim, M.D., Ph.D. ...............Fred Hutchinson Cancer Research Center 

Degregori, James V., Ph.D.......................University of Colorado Health Sciences Center 

Deisseroth, Albert B., M.D., Ph.D...........Sidney Kimmel Cancer Center 

Dejesus, Onofre T., Ph.D.........................University of Wisconsin 

Delaney, Fred C., M.S. ............................University of Texas Medical Branch 

Delucchi, Kevin L., Ph.D.........................University of California at San Francisco 

Demayo, Francesco, Ph.D........................Baylor College of Medicine 

Desaix, Peter, Ph.D. .................................University of North Carolina at Chapel Hill 

Devine, Steven M., M.D. .........................Washington University 

Dickey, Burton F., M.D. ..........................Baylor College of Medicine 

Divgi, Chaitanya R., M.D. .......................Sloan-Kettering Institute for Cancer Research 

Djeu, Julie Y., Ph.D. ................................University of South Florida 

Dlugosz, Andrzej A., M.D.......................University of Michigan at Ann Arbor 

Dow, Karen H., Ph.D...............................University of Central Florida 

Drabkin, Harry A., M.D...........................University of Colorado Health Sciences Center 

Dubinett, Steven M.., M.D.......................University of California, Los Angeles School of 

Medicine 

Dunlap, R. Bruce, Ph.D. ..........................University of South Carolina at Columbia 

Dupont, Bo, M.D. ....................................Sloan-Kettering Institute for Cancer Research 

Durant, Robert H., Ph.D...........................Wake Forest University Health Sciences 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
Durden, Donald L., M.D., Ph.D...............University of Indiana 

Dynan, William S., Ph.D. ........................Medical College of Georgia 

E Earp, H. Shelton, M.D., Ph.D. .................University of North Carolina at Chapel Hill 

Ebbini, Emad S., Ph.D. ............................University of Minnesota at Twin Cities 

Eck, Stephen L., M.D., Ph.D. ..................Pfizer, Inc. 

Eden, Osborn Bryan, M.D. ......................Christie Hospital Young Oncology Unit 

Eggert, Harriet B., B.S.............................Susan G. Komen Breast Cancer Foundation 

Eisenberg, Burton, M.D...........................Fox Chase Cancer Center 

Ely, Kathryn R., Ph.D. .............................Burnham Institute 

Emami, Bahman N., M.D. .......................Mallinckrodt Institute of Radiology 

Erickson, Leonard C., Ph.D. ....................Indiana University Cancer Center 

Ethier, Stephen P., Ph.D...........................University of Michigan at Ann Arbor 

Evans, Sydney M., V.M.D.......................University of Pennsylvania 

Evelhoch, Jeffrey L., Ph.D.......................Wayne State University 

F Farkas, Daniel L., Ph.D............................University of Pittsburgh at Pittsburgh 

Feldman, Eva L., M.D., Ph.D. .................University of Michigan at Ann Arbor 

Ferenczy, Alex, M.D................................McGill University 

Ferrone, Soldano, M.D., Ph.D. ................Roswell Park Cancer Institute 

Fike, John R., Ph.D. .................................University of California at San Francisco 

Finn, Olivera J., Ph.D...............................Keystone Symposia 

Fischer, James J., M.D., Ph.D..................Icthyox, Inc. 

Fisher, Paul B., Ph.D................................Columbia University Health Sciences 

Floyd, Carey E., Ph.D. .............................Duke University 

Fowlkes, J. Brian, Ph.D. ..........................National Institute of Allergy and Infectious 

Diseases 

Frank-Kamenetskii, Maxim D., Ph.D. .....Boston University 

Franko, Joann C., M.H.A.........................Case Western Reserve University 

Freundlich, Barbara S., B.A.....................Lymphoma Research Foundation 

Fuks, Zvi Y., M.D....................................Memorial Sloan-Kettering Cancer Center 

Fuller, Gregory N., M.D., Ph.D. ..............University of Texas, MD Anderson Cancer Center 

Furnari, Frank B., Ph.D............................University of California at San Diego 

G Galloway, Denise A., Ph.D......................Fred Hutchinson Cancer Research Center 

Galvin, James M., D.Sc. ..........................Thomas Jefferson University Hospital 

Gambhir, Sanjiv S., M.D., Ph.D. .............University of California at Los Angeles 

Ganapathi, Ram N., Ph.D.........................Cleveland Clinic Foundation 

Garfield, Robert E., Ph.D.........................University of Texas Medical Branch at Galveston 

Garte, Seymour J., Ph.D...........................Heck Biotek 

Gehan, Edmund A., Ph.D.........................Georgetown University 

Gelovani Tjuvajev, Juri G., Ph.D.............Sloan-Kettering Institute for Cancer Research 

Gerlach, Robert W., M.P.A......................Cleveland Clinic Foundation 

Gill, Parkash S., M.D...............................University of Southern California 

Gillespie, Brenda W., Ph.D......................University of Michigan 

Gillespie, G. Yancey, Ph.D......................University of Alabama at Birmingham 

Gilliland, D. Gary, M.D., Ph.D................Brigham and Women’s Hospital 

Gimotty, Phyllis A., Ph.D. .......................University of Pennsylvania 

Ginder, Gordon D., M.D., Ph.D...............Virginia Commonwealth University 

Glazer, Robert I., Ph.D.............................Georgetown University 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
Glickson, Jerry D., Ph.D. .........................University of Pennsylvania 

Goebl, Mark G., Ph.D. .............................Indiana University-Purdue University at 

Indianapolis 

Goldsmith, Stanley J., M.D......................Weill Medical College of Cornell University 

Golub, Todd R., M.D...............................Dana-Farber Cancer Institute 
Gomer, Charles J., Ph.D...........................Children’s Hospital, Los Angeles 

Gooley, Ted A., Ph.D...............................Fred Hutchinson Cancer Research Center 

Gorbsky, Gary J., Ph.D. ...........................University of Oklahoma Health Sciences Center 

Gordin, Barbara, B.A...............................Baylor College of Medicine 

Gore, John C., Ph.D. ................................Vanderbilt University 

Gore, Steven D., M.D., Ph.D. ..................Johns Hopkins University 

Gosky, David M., M.B.A.........................Case Western Reserve University 

Graham, Michael M.., M.D., Ph.D. .........University of Iowa 

Grandis, Jennifer R., M.D........................University of Pittsburgh at Pittsburgh 

Gravekamp, Claudia, Ph.D. .....................Institute for Drug Development, Cancer Therapy 

and Research 

 Center 

Gray, Robert J., Ph.D...............................Frontier Science and Technology Research 

Foundation, Inc. 

Grdina, David J., Ph.D.............................University of Chicago 

Greenberger, Joel S., M.D. ......................University of Pittsburgh at Pittsburgh 

Gricoski, John J., C.P.A...........................Fox Chase Cancer Center 

Groopman, John D., Ph.D........................Johns Hopkins University 

Grossman, Stuart A., M.D. ......................Johns Hopkins University 

Grundfest, Warren S., M.D......................University of California at Los Angeles 

H Hackney, David D., Ph.D.........................Carnegie-Mellon University 

Hahn, Stephen M., M.D...........................University of Pennsylvania 

Halazonetis, Thanos D., D.D.S., Ph.D.....Wistar Institute 

Hamilton, Thomas A., Ph.D.....................Cleveland Clinic Foundation 

Hanash, Samir M., M.D., Ph.D................University of Michigan at Ann Arbor 

Hann, Danette M., Ph.D...........................American Cancer Society Behavioral Research 

Center 

Hann, Stephen R., Ph.D. ..........................Vanderbilt University 

Hannon, Gregory J., Ph.D........................Cold Spring Harbor Laboratory 

Harrington, David P., Ph.D......................Dana-Farber Cancer Institute 

Harrington, Maureen A., Ph.D.................Indiana University School of Medicine 

Harrison, Anita L., M.A...........................Eastern Virginia Medical School 

Havill-Ryan, Diana, C.P.A. .....................University of Chicago Pritzker School of Medicine 

Heerema, Nyla A., Ph.D. .........................Parker Hughes Institute 

Heisler, Jules, Ph.D..................................University of Pittsburgh 

Henderson, Barbara W., Ph.D..................Roswell Park Cancer Institute 

Hendrix, Mary J., Ph.D. ...........................Gordon Research Conferences 

Herlyn, Meenhard I., D.Sc., D.V.M.........Wistar Institute 

Herndier, Brian G., M.D., Ph.D...............University of California at San Francisco 

Heslop, Helen E., M.D.............................St. Jude Children’s Research Hospital 

Heston, Warren D., Ph.D. ........................Cleveland Clinic Foundation 

Hinders, Mark K., Ph.D. ..........................College of William and Mary 

Hinds, Philip W., Ph.D.............................Harvard University (Medical School) 

Hnatowich, Donald J., Ph.D.....................University of Massachusetts Medical School at 

Worcester 

Ho, Peter T.C., M.D., Ph.D......................Glaxo Smith Kline 

Ho, Shuk-Mei, Ph.D.................................Wayne State University 

Holland, Eric C., M.D., Ph.D...................Sloan-Kettering Institute for Cancer Research 

Holt, Jeffrey T., M.D. ..............................University of Colorado Health Sciences Center 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
Hoon, Dave S., Ph.D................................John Wayne Cancer Institute 

Hopkins, Nancy H., Ph.D.........................Massachusetts Institute of Technology 

Houghton, Janet A., Ph.D. .......................St. Jude Children’s Research Hospital 

Howe, Philip H., Ph.D. ............................Cleveland Clinic Foundation 

Howett, Mary K., Ph.D. ...........................Pennsylvania State University Hershey Medical 

Center 

Hromas, Robert A., M.D..........................Indiana University-Purdue University at 

Indianapolis 

Hsu, Edward W., Ph.D.............................Duke University 

Hurwitz, Arthur A., Ph.D.........................Upstate Medical University 

I Iavarone, Antonio, M.D...........................Columbia University Health Sciences 

Ihle, James N., Ph.D.................................St. Jude Children’s Research Hospital 

Isaacs, Stuart N., M.D..............................University of Pennsylvania 

Israel, Mark A., M.D................................Dartmouth College 

Ittmann, Michael M., M.D., Ph.D............New York University School of Medicine 

J Jaenisch, Rudolf, M.D. ............................Whitehead Institute for Biomedical Research 

James, Charles D., Ph.D...........................Mayo Clinic, Rochester 

Jenkins, Robert B., M.D., Ph.D. ..............Mayo Clinic, Rochester 

Jensen, Roy A., M.D................................Vanderbilt University Medical Center 

Jinks-Robertson, Sue, Ph.D. ....................Emory University 

Johnston, Dennis A., Ph.D.......................Wayne State University 

Jonak, Zdenka L., Ph.D............................Glaxo Smith Kline Pharmaceuticals 

Jorgensen, Timothy J., Ph.D. ...................Johns Hopkins University 

Juliano, Rudolph L., Ph.D........................Keystone Symposia 

June, Carl H., M.D., Ph.D........................University of Pennsylvania 

K Kacinski, Barry M., M.D., Ph.D. .............Yale University School of Medicine 

Kangarloo, Hooshang, M.D.....................University of California at Los Angeles 

Kan-Mitchell, June K., Ph.D....................Wayne State University 

Karnes, William E., M.D. ........................Mayo Clinic, Rochester 

Karnitz, Larry M., Ph.D...........................Mayo Clinic, Rochester 

Keene, Jack D., Ph.D. ..............................Duke University 

Kellogg, Glen E., Ph.D. ...........................Virginia Commonwealth University 

Kelly, Regis B., Ph.D...............................University of California at San Francisco 

Kennel, Stephen John, Ph.D. ...................Oak Ridge Associated Universities 

Key, Charles R., M.D...............................University of New Mexico at Albuquerque 

Keyes, Sean M., B.A................................Fox Chase Cancer Center 

Kidd, Vincent J., Ph.D. ............................St. Jude Children’s Research Hospital 

Killackey, Maureen A., M.D. ..................Bassett Cancer Center 

Kleinman, Nanette, D.V.M......................Case Western Reserve University 

Klein-Szanto, Andres J., M.D..................Fox Chase Cancer Center 

Kontoyiannis, Dimitrios P., M.D.............University of Texas, MD Anderson Cancer Center 

Kopecky, Kenneth J., Ph.D......................Fred Hutchinson Cancer Research Center 

Krohn, Kenneth A., Ph.D.........................University of Washington 

Krontiris, Theodore G., M.D., Ph.D. .......Beckman Research Institute 

Kubagawa, Hiromi, M.D. ........................University of Alabama at Birmingham 

Kucera, Gregory L., Ph.D. .......................Kucera Pharmaceutical Company 

Kucuk, Omer J., M.D...............................Wayne State University 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
Kukreja, Subhash C., M.D.......................University of Illinois at Chicago 

Kung, Hsing Jien, Ph.D............................University of California, Davis Cancer Center 

L Lahue, Robert S., Ph.D. ...........................University of Nebraska Medical Center 

Lambert, Peggy A., M.S. .........................West Virginia University 

Largaespada, David A., Ph.D...................University of Minnesota at Twin Cities 
Larson, Richard A., M.D. ........................University of Chicago 

Laterra, John J., M.D., Ph.D. ...................Kennedy Krieger Research Institute, Inc. 

Le, Chap T., Ph.D. ...................................University of Minnesota at Twin Cities 

Leary, Steven L., D.V.M..........................Washington University School of Medicine 

Lebien, Tucker W., Ph.D. ........................University of Minnesota Cancer Center 

Lee, Tun-Hou, D.Sc.................................Harvard University School of Public Health 

Leis, Jonathan P., Ph.D. ...........................Northwestern University 

Leof, Edward B., Ph.D.............................Mayo Clinic, Rochester 

Levy, Robert B., Ph.D..............................University of Miami 

Li, Jonathan J., Ph.D. ...............................University of Kansas Medical Center 

Liebermann, Dan A., Ph.D.......................Temple University 

Link, Brian K., M.D.................................University of Iowa 

Link, Charles J., M.D...............................Iowa State University 

Link, Judith L., RN ..................................Alaska Regional Hospital 

Linville, Linda H., Ph.D...........................University of Kentucky 

Liu, Fei-Fei, M.D.....................................University of Toronto 

Lo, David D., M.D., Ph.D........................Digital Gene Technologies, Inc. 

Lotlikar, Prabhakar D., Ph.D. ..................Temple University 

Lowe, Scott W., Ph.D. .............................Cold Spring Harbor Laboratory 

Lu, Jian-Yu X., Ph.D. ..............................University of Toledo 

Lu, Ying, Ph.D.........................................University of California at San Francisco 

Lubaroff, David M., Ph.D........................University of Iowa 

Lukacs, Nicholas W., Ph.D......................University of Michigan at Ann Arbor 

Luskin, Marla B., Ph.D. ...........................Emory University 

Lynch, David H., Ph.D.............................Immunex 

Lynch, James F., M.B.A. .........................Fox Chase Cancer Center 

Lynch, Patrick M.., M.D..........................University of Alabama at Birmingham 

Lynch, Richard G., M.D., Ph.D. ..............University of Iowa 

M Maciag, Thomas, Ph.D.............................Maine Medical Center 

Madsen, Ernest L., Ph.D. .........................University of Wisconsin at Madison 

Mahvi, David M., M.D., Ph.D. ................University of Wisconsin Hospitals and Clinics 

Malandrucco, Roby, B.A. ........................Patient Advocate 

Malkas, Linda H., Ph.D. ..........................Indiana University Indianapolis 

Maloney, David G., M.D., Ph.D. .............Fred Hutchinson Cancer Research Center 

Manetta, Alberto, M.D.............................University of California at Irvine 

Mann, Jill R., M.D. ..................................Birmingham Children’s Hospital 

Marriott, Susan, Ph.D...............................Baylor College of Medicine 

Matrisian, Lynn M., M.D., Ph.D..............Vanderbilt University 

McCauley, Laurie K., D.D.S., Ph.D. .......University of Michigan at Ann Arbor 

McCormick, J. Justin, Ph.D. ....................Michigan State University 

McGarry, Michael P., Ph.D. ....................Roswell Park Cancer Institute 

McGlave, Philip B., M.D.........................University of Minnesota Medical School 

McGough, Robert J., M.D., Ph.D. ...........Duke University 

McIntyre, Thomas M., M.D., Ph.D..........University of Utah 

McKay, Paul P. ........................................Patient Advocate 

McNeil, Ann E., R.N. ..............................University of Miami 

McNiece, Ian K., Ph.D.............................Osiris Therapeutics, Inc. 

Medina, Daniel, Ph.D...............................Baylor College of Medicine 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
Melera, Peter W., Ph.D. ...........................University of Maryland, Baltimore Professional 

School 

Mellon, Isabel W., Ph.D...........................University of Kentucky 

Meropol, Neal J., M.D. ............................Fox Chase Cancer Center 

Meyn, M. S., M.D., Ph.D.........................Hospital for Sick Children (Toronto) 

Meyn, Raymond E., Ph.D. .......................Introgen Therapeutics, Inc. 

Mikkelsen, Tom, M.D..............................Case Western Reserve University 

Miller, Jeffrey S., M.D.............................University of Minnesota at Twin Cities 

Miller, Judith A., Ph.D.............................Emory University 

Miller, Robert H., Ph.D............................University of Minnesota at Twin Cities 

Miller, Scott J., Ph.D................................California Institute of Technology 

Mills, Gordon B., M.D., Ph.D..................University of Texas, MD Anderson Cancer Center 

Mills, Susan S., B.S. ................................Vanderbilt University 

Minden, Mark D., M.D., Ph.D.................Princess Margaret Hospital 

Mok, Samuel C., Ph.D. ............................Brigham and Women’s Hospital 

Molnar-Kimber, Katherine L., Ph.D........University of Pennsylvania 

Monteiro, Alvaro N., Ph.D.......................Strang Cancer Prevention Center 

Moore, Patrick S., M.D., Ph.D.................Columbia University Health Sciences 

Morgan, Timothy M., Ph.D. ....................Wake Forest University 

Mori, Motomi, Ph.D.................................Oregon Health and Science University 

Morrow, Charles S., M.D., Ph.D. ............Wake Forest University Health Sciences 

Morse, Michael A., M.D..........................Duke University 

Moses, Harold L., M.D., Ph.D.................Vanderbilt University 

Mosmann, Tim R., Ph.D. .........................University of Rochester 

Motamedi, Massoud, Ph.D.......................University of Texas Medical Branch at Galveston 

Mukherji, Bijay, M.D...............................University of Connecticut, School of 

Medicine/Dentistry 

Mukhtar, Hasan, Ph.D..............................University of Wisconsin, Madison 

Mullins, Meredith, M.B.A. ......................H. Lee Moffitt Cancer Center 

Murdock, Sandra, Dr.P.H. .......................Emory University 

Myers, Mark G., Ph.D..............................Veterans Medical Research Foundation, San Diego 

N Nademanee, Auayporn, M.D. ..................City of Hope National Medical Center 

Najfeld, Vesna, Ph.D. ..............................Mount Sinai School of Medicine 

Nalcioglu, Orhan, Ph.D............................University of California 

Nasca, Philip C., Ph.D. ............................University of Massachusetts at Amherst 

Naylor, Susan L., Ph.D. ...........................University of Texas Health Science Center 

Neel, Benjamin G., M.D., Ph.D...............Beth Israel Deaconess Medical Center 

Nelson, Mark A., Ph.D.............................University of Arizona 

Ness, Scott A., Ph.D.................................University of New Mexico at Albuquerque 

Neuberg, Donna S., Sc.D.........................Dana Farber Cancer Institute 

Newcomb, Elizabeth W., Ph.D. ...............New York University 

Niblack, Joyce, J.D. .................................Myeloproliferative Disorder Foundation 

Nicklas, R. Bruce, Ph.D...........................Duke University 

Nicosia, Santo V., M.D............................University of South Florida 

Nolta, Jan A., Ph.D. .................................Washington University 

Normolle, Daniel P., Ph.D. ......................University of Michigan 

Norris, James S., Ph.D. ............................Medical University of South Carolina 

Nowak, Norma J., Ph.D. ..........................Roswell Park Cancer Institute 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
O Ochs, Michael F., Ph.D............................Institute for Cancer Research 

Ojima, Iwao, Ph.D. ..................................State University of New York at Stony Brook 

Omel, James L., M.D...............................Private Practice 
Osteen, Kevin G., Ph.D............................Vanderbilt University 

Ostrand-Rosenberg, Suzanne O., Ph.D....University of Maryland, Baltimore Professional 

School 

Ota, David M., M.D.................................University of Missouri, Ellis Fischel Cancer Center 

P Pagano, Joseph S., M.D., Ph.D. ...............University of North Carolina at Chapel Hill 

Page, Rodney, D.V.M..............................Cornell University at Ithaca 

Paliwal, Bhudatt R., Ph.D. .......................University of Wisconsin at Madison 

Pallavicini, Maria G., Ph.D......................University of California at San Francisco 

Panasci, Lawrence C., M.D. ....................Sir Mortimer B. Davis/Jewish General Hospital 

Paquette, Leo A., Ph.D.............................Ohio State University 

Parada, Luis F., Ph.D. ..............................National Neurofibromatosis Foundation 

Park, Dorothy J., M.D..............................Cedars-Sinai Medical Center 

Parker, Charles J., M.D............................University of Utah 

Paskett, Electra D., Ph.D..........................Ohio State University 

Pasqualini, Renata R., Ph.D.....................University of Texas 

Patchell, Roy A., M.D., Ph.D. .................University of Kentucky 

Patte, Catherine, M.D...............................Institut Gustave Roussy Service d’Oncologie 

Pediatrique 

Patterson, Michael S., Ph.D. ....................Hamilton Regional Cancer Center 

Patterson, Thomas F., M.D. .....................University of Texas Health Sciences Center at San 

Antonio 

Pearcey, Robert G., M.D..........................University of Alberta 

Pedersen, Peter L., Ph.D. .........................Johns Hopkins University 

Pelling, Jill C., Ph.D.................................University of Kansas Medical Center 

Perkins, Kenneth A., Ph.D.......................Society for Research on Nicotine/Tobacco 

Persons, Diane L., M.D............................University of Kansas Medical Center 

Peter, Marcus E., Ph.D.............................University of Chicago 

Pfeifer, Gerd P., Ph.D. .............................Beckman Research Institute 

Piedrahita, Jorge A., Ph.D........................North Carolina State University at Raleigh 

Pierce, John P., Ph.D................................University of California at San Diego 

Pieters, Robrecht, M.D., Ph.D. ................Sophia Children’s Hospital 

Pinkerton, Charles Ross, M.D..................Royal Marsden Hospital 

Plate, Janet M., Ph.D................................Rush-Presbyterian-St. Lukes Medical Center 

Platsoucas, Chris D., Ph.D.......................Temple University 

Pleasure, David E., M.D. .........................Children’s Hospital of Philadelphia 

Pledger, W. J., Ph.D.................................University of South Florida 

Podack, Eckhard R., M.D., Ph.D. ............University of Miami at Coral Gables 

Pollack, Alan, M.D., Ph.D. ......................Fox Chase Cancer Center 

Pope, Melissa J., M.D., Ph.D...................Population Council 

Powell, Simon N., M.D., Ph.D. ...............Massachusetts General Hospital 

Powell, Steven M., M.D...........................University of Virginia at Charlottesville 

Prasad, Kedar N., Ph.D. ...........................University of Colorado Health Sciences Center 

Primus, F. James, Ph.D. ...........................Vanderbilt University 

Prokhorov, Alexander V., M.D., Ph.D.....University of Texas, MD Anderson Cancer Center 

Pruitt, Steven C., Ph.D.............................Roswell Park Cancer Institute 

Q Qin, Jun, Ph.D..........................................Baylor College of Medicine 

Quesenberry, Peter J., M.D......................Roger Williams Hospital 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
79 

R Raghavan, Derek, M.D., Ph.D. ................University of Southern California, Norris Cancer 

Center 

Rakhmilevich, Alexander L., M.D., Ph.D. University of Wisconsin at Madison 

Ramotar, Dindial, Ph.D............................Hospital Maisnonneuve-Rosemont 

Ransohoff, Richard M., M.D. ..................Cleveland Clinic Foundation 

Raper, Steven E., M.D. ............................University of Pennsylvania 

Rapraeger, Alan C., Ph.D.........................University of Wisconsin at Madison 

Raz, Avraham, Ph.D. ...............................Wayne State University 

Redd, William H., Ph.D...........................Mount Sinai School of Medicine 

Reddi, A. Hari, Ph.D................................University of California at Davis 

Redmond, Carol K., Sc.D. .......................University of Pittsburgh 

Reed, Carolyn E., M.D.............................Medical University of South Carolina 

Reed, Eddie, M.D.....................................West Virginia University 

Rehemtulla, Alnawaz, Ph.D.....................University of Michigan at Ann Arbor 

Rinker-Schaeffer, Carrie W., Ph.D. .........University of Chicago 

Robbins, Michael E. C., Ph.D..................Wake Forest University Health Sciences 

Roberts, Charles T., Ph.D. .......................Oregon Health and Science University 

Robertson, Erle S., Ph.D. .........................University of Michigan at Ann Arbor 

Robertson, Kent A., M.D., Ph.D..............Indiana University-Purdue University at 

Indianapolis 

Robinson, June K., M.D...........................Loyola University Medical Center 

Robinson, Leslie A., Ph.D. ......................University of Memphis 

Rodeck, Ulrich, M.D., Ph.D.....................Thomas Jefferson University 

Roe, Bruce A., Ph.D.................................University of Oklahoma at Norman 

Rogers, Buck E., Ph.D. ............................University of Alabama at Birmingham 

Ronai, Ze’Ev A., Ph.D.............................Mount Sinai School of Medicine 

Rosenbaum, Louise M., Ph.D. .................Dartmouth College 

Rosmarin, Alan G., M.D..........................Miriam Hospital 

Rossant, Janet, Ph.D.................................Keystone Symposia 

Rosse, Wendell F., M.D...........................Duke University 

Roti-Roti, Joseph L., Ph.D.......................Washington University, School of Medicine 

Rowitch, David H., M.D., Ph.D...............Dana-Farber Cancer Institute 

Rowley, David R., Ph.D...........................American Urological Association 

Rubin, Eva, M.D. .....................................University of Alabama School of Medicine 

Rubin, Jonathan M., M.D., Ph.D. ............University of Michigan at Ann Arbor 

Runowicz, Carolyn D., M.D. ...................Albert Einstein College of Medicine 

Ruohola-Baker, T. H., Ph.D.....................University of Washington 

Ruth, Thomas J., Ph.D. ............................University of British Columbia 

Ryan, James C., M.D. ..............................Northern California Institute Research and 

Education 

S Sadofsky, Moshe J., M.D., Ph.D..............Yeshiva University 

Safa, Ahmad R., Ph.D..............................University of Chicago 

Salgaller, Michael L., Ph.D......................Northwest Biotherapeutics, Inc. 

Saltz, Frances M., B.S.W.........................Cancer Hope Network 

Sample, Clare E., Ph.D. ...........................St. Jude Children’s Research Hospital 

Sampson, John H., M.D., Ph.D................Duke University 

Samuel, Charles E., Ph.D.........................University of California 

Sarkar, Fazlul H., Ph.D. ...........................Karmanos Cancer Institute 

Sartor, Oliver, M.D. .................................Louisiana State University 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
Sathyamoorthy, Neeraja, Ph.D.................National Cancer Institute 

Schmid, Sandra L., Ph.D..........................Scripps Research Institute 

Schmiegelow, Kjeld, M.D. ......................The University Hospital Rigshospitalet, Pediatric 

Clinic II 

Schnipper, Lowell E., M.D. .....................Beth Israel Deaconess Medical Center 

Schoenberger, Stephen P., Ph.D. .............La Jolla Institute for Allergy/Immunology 

Schuler, Linda A., M.D., Ph.D.................University of Wisconsin 
Schultheiss, Timothy E., Ph.D.................City of Hope National Medical Center 

Seigel, Carole, M.S. .................................Massachusetts General Hospital 

Senter, Peter D., Ph.D. .............................Seattle Genetics, Inc. 

Shaw, Chris C., Ph.D. ..............................University of Texas, MD Anderson Cancer Center 

Shiekhattar, Ramin, Ph.D.........................Wistar Institute 

Shields, Anthony F., M.D., Ph.D.............Wayne State University 

Shreve, Paul D., M.D...............................University of Michigan at Ann Arbor 

Shyr, Yu, Ph.D.........................................Vanderbilt University Medical School 

Simon, Julian A., Ph.D.............................Fred Hutchinson Cancer Research Center 

Singh, Harinder, Ph.D..............................University of Chicago 

Sinha, Dipen N., Ph.D..............................Los Alamos National Laboratory 

Slaga, Thomas J., Ph.D. ...........................University of Texas, MD Anderson Cancer Center 

Sluder, Greenfield, Ph.D..........................Worcester Foundation for Biomedical Research 

Smith, Shirley A.......................................American Melanoma Foundation 

Snapka, Robert M., Ph.D. ........................Ohio State University 

Soehnlen, Barbara J., M.P.A....................Arizona Cancer Center 

Solberg, Timothy D., Ph.D. .....................University of California at Los Angeles 

Song, Chang W., Ph.D.............................University of Minnesota Medical School 

Soprano, Kenneth J., Ph.D.......................Temple University 

Sotomayor, Eduardo M., M.D. ................University of South Florida 

Souza, Rhonda F., M.D............................University of Texas SW Medical Center, Dallas 

Sowers, Lawrence C., Ph.D. ....................Loma Linda University 

Spallone, Robert E., B.A..........................Fox Chase Cancer Center 

Speicher, David W., Ph.D........................Wistar Institute 

Springer, Charles S., Ph.D. ......................Brookhaven Science Association-Brookhaven 

Laboratory 

Srivastava, Deo Kumar, Ph.D..................St. Jude Children’s Research Hospital 

Stampfli, Martin R., Ph.D. .......................McMaster University 

Stein, Cy A., M.D., Ph.D. ........................Columbia University College of Physicians and 

Surgery 

Stein, Gary S., Ph.D.................................University of Massachusetts Medical School, 

Worcester 

Steindler, Dennis A., Ph.D.......................University of Florida 

Stewart, A. Keith, M.D. ...........................University of Toronto 

Stewart, F. Marc, M.D. ............................Fred Hutchinson Cancer Research Center 

Storrie, Brian, Ph.D..................................Virginia Polytechnic Institute and State University 

Stratakis, Constantine A., M.D. ...............National Institute of Child Health and Human 

Development 

Subramanian, Manny R., Ph.D. ...............Best Industries, Inc. 

Sullivan, Kevin F., Ph.D. .........................Scripps Research Institute 

Summerhayes, Ian C., Ph.D.....................Lahey Clinic 

T Tang, Eric M., Ph.D.................................New York University, School of Medicine 

Tansey, William P., Ph.D.........................Cold Spring Harbor Laboratory 

Taparowsky, Elizabeth J., Ph.D...............Purdue University, West Lafayette 

Taylor, Roger, M.D..................................Cookridge Hospital 

Teitell, Michael A., M.D., Ph.D...............University of California at Los Angeles 

Terry, Michael A., M.B.A........................University of Rochester 

Tew, Kenneth D., Ph.D............................Fox Chase Cancer Center 

Thakur, Mathew L., Ph.D. .......................Thomas Jefferson University 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
Thompson, E. A., Ph.D............................University of Texas Medical Branch at Galveston 

Threadgill, David W., Ph.D. ....................University of North Carolina at Chapel Hill 

Tisch, Roland M., Ph.D. ..........................Stanford University 

Tlsty, Thea D., Ph.D. ...............................University of California at San Francisco 

Toker, Alex, Ph.D. ...................................Beth Israel Deaconess Medical Center 

Toledano, Alicia Y., Ph.D........................Brown University 

Torok-Storb, Beverly J., Ph.D. ................Fred Hutchinson Cancer Research Center 

Travis, Elizabeth L., Ph.D........................University of Texas, MD Anderson Cancer Center 

Treisman, Jessica E., M.D. ......................New York University School of Medicine 

Triozzi, Pierre L., M.D.............................University of Alabama at Birmingham 

Trock, Bruce J., Ph.D...............................Johns Hopkins University 

Truitt, Robert L., Ph.D.............................Medical College of Wisconsin 

Turner, Larry W., B.S. .............................Emory University 

U Urba, Walter J., M.D., Ph.D.....................Providence Portland Medical Center 

V Van Oers, Nicolai S.C., Ph.D...................University of Texas SW Medical Center, Dallas 

Vanasse, K. Gary, M.D............................University of Washington 

Vannier, Michael W., M.D. .....................University of Iowa 

Varni, James W., Ph.D.............................Children’s Hospital Research Center 

Vile, Richard G., Ph.D.............................Mayo Clinic, Rochester 

Von Herrath, Matthias G., M.D. ..............La Jolla Institute for Allergy/Immunology 

Von Hoff, Daniel D., M.D. ......................University of Arizona 

W Wada, Randal K., M.D.............................University of Hawaii at Manoa 

Wade, Amy B., M.B.A. ...........................University of Michigan 

Walters, Gayle, M.A. ...............................University of Maryland, Baltimore County Campus 

Wang, Hong-Gang, Ph.D.........................H. Lee Moffitt Cancer Center and Research Institute 

Wang, Lihong, Ph.D. ...............................Texas Engineering Experiment Station 

Wang, Lu-Hai, Ph.D. ...............................Mount Sinai School of Medicine 

Watson, Dennis K., Ph.D.........................Medical University of South Carolina 

Wear, Keith A., Ph.D...............................Food and Drug Administration 

Weber, Lee A., Ph.D................................University of Nevada at Reno 

Weick, Martin P., M.S. ............................Baylor College of Medicine 

Weiner, George J., M.D...........................University of Iowa 

Weiner, Susan L., Ph.D............................The Children’s Cause, Inc. 

Weinert, Ted A., Ph.D. ............................University of Arizona 

Weisman, Lois S., Ph.D...........................University of Iowa 

Weissman, Bernard E., Ph.D. ..................University of North Carolina at Chapel Hill 

Wells, Alan, M.D., Ph.D..........................University of Alabama at Birmingham 

Wheeler, Richard H., M.D.......................Mayo Clinic, Arizona 

Wicha, Max S., M.D. ...............................University of Michigan at Ann Arbor 

Wilburn, Louella S., M.Ed.......................People Living Through Cancer 

Wilding, George A., M.D. .......................University of Wisconsin at Madison 

Wilkins, Linda S., B.A.............................Duke University Medical Center 

Willman, Cheryl L., M.D.........................University of New Mexico at Albuquerque 

Wilson, Brian C., Ph.D. ...........................University of Toronto 

Wilson, Glenn L., Ph.D............................University of South Alabama 

Wilson, Leslie, Ph.D. ...............................University of California at Santa Barbara 

Wilson-Sanders, Susan E., D.V.M...........University of Arizona 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
Wingard, John R., M.D............................University of Florida 

Witherspoon, Yvonne, B.A......................Dana-Farber Cancer Institute 

Witschi, Hanspeter R., M.D., Ph.D..........University of California at Davis 

Wojcik, Edward J., Ph.D..........................Virginia Polytechnic Institute and State University 
Wolf, Dieter A., M.D...............................Harvard University School of Public Health 

Wolgemuth, Debra J., Ph.D. ....................Columbia University, New York, Morningside 

Wollett, Rosalie, B.A...............................Johns Hopkins Oncology Center 

Woloschak, Gayle E., Ph.D. ....................Northwestern University 

Wong, John W., Ph.D. .............................William Beaumont Hospital Research Institute 

Woo, Savio L., Ph.D. ...............................Mount Sinai School of Medicine 

Woods, William G., M.D.........................Palmetto Richland Memorial Hospital 

Wynshaw-Boris, Anthony J., M.D., Ph.D. University of California at San Diego 

X Xiong, Yue, Ph.D.....................................University of North Carolina at Chapel Hill 

Y Yandell, David W., SCD..........................University of Vermont and State Agricultural 

College 

Yang, Chung S., Ph.D..............................Rutgers, The State University of New Jersey 

Yannelli, John R., Ph.D. ..........................University of Kentucky Medical Center 

Yeatman, Timothy J., M.D. .....................H. Lee Moffitt Cancer Center and Research Institute 

Yeger, Herman, Ph.D...............................University of Toronto 

Yen, Andrew, Ph.D..................................Cornell University at Ithaca 

Young, Donn C., Ph.D.............................Ohio State University 

Yu, Cedric X., D.Sc. ................................University of Maryland, Baltimore Professional 

School 

Yu, Dihua, M.D., Ph.D. ...........................Texas Tech University Health Sciences Center 

Yu, Hongtao, Ph.D...................................University of Texas SW Medical Center at Dallas 

Yuan, Zhi-Min, M.D., Ph.D.....................Harvard University, School of Public Health 

Z Zahrbock, Cary A.C., M.S.W. .................National Coalition/Cancer Survivorship 

Zalutsky, Michael R., Ph.D......................Duke University 

Zhou, Daohong, M.D...............................Medical University of South Carolina 

Zhou, Renping, Ph.D. ..............................Rutgers, The State University of New Jersey 

Zimbrick, John D., Ph.D. .........................Purdue University at West Lafayette 

Zipfel, Warren R., Ph.D...........................Cornell University at Ithaca 

Total Number of Reviewers: 603 

Appendix C-2: Consultants Serving as Ad Hoc Committee Members 
3. Consultants Serving on Special Emphasis Panels (SEPs) in FY2002 

A Abdel-Nabi, Hani H., Ph.D......................State University of New York at Buffalo 

Abraham, George N., M.D.......................University of Rochester 

Abrams, David B., Ph.D. .........................Miriam Hospital 

Abrams, John M., Ph.D............................University of Texas SW Medical Center at Dallas 

Abrams, Judith, Ph.D...............................Wayne State University 

Ackerman, Joseph J.H., Ph.D. .................Washington University 

Agarwal, Ram P., Ph.D............................University of Miami 

Aggarwal, Bharat B., Ph.D. .....................University of Texas, MD Anderson Cancer Center 

Agrawal, Krishna C., Ph.D. .....................Tulane University of Louisiana 

Ahern, David K., Ph.D.............................Abacus Management Technologies, LLC 

Ahmed, Khalil, Ph.D................................University of Minnesota at Twin Cities 

Aickin, Mikel G., Ph.D. ...........................Kaiser Foundation Research Institute 

Aisner, Joseph, M.D.................................University of Medicine and Dentistry of New Jersey 

Aisner, Seena C., M.D. ............................University of Medicine and Dentistry of New Jersey 

Albelda, Steven M., M.D.........................University of Pennsylvania 

Alben, Katherine T., Ph.D. ......................State University of New York at Albany 

Albertson, Donna G., Ph.D. .....................University of California at San Francisco 

Albrecht, Terrance L., Ph.D.....................H. Lee Moffitt Cancer Center and Research Institute 

Allbritton, Nancy L., M.D., Ph.D. ...........University of California at Irvine 

Ambinder, Richard F., M.D., Ph.D..........Johns Hopkins University 

Ambrosone, Christine B., Ph.D. ..............Mount Sinai School of Medicine 

Amit, Yali, Ph.D. .....................................University of Chicago 

Amols, Howard I., Ph.D...........................Sloan-Kettering Institute for Cancer Research 

Anderson, Adam W., Ph.D. .....................Yale University 

Anderson, Cheryl B., Ph.D. .....................University of Texas, MD Anderson Cancer Center 

Anderson, Garnet L., Ph.D.......................Fred Hutchinson Cancer Research Center 

Anderson, James R., M.D., Ph.D.............Foundation for The Children’s Oncology Group 

Andrews, Philip C., Ph.D.........................University of Michigan at Ann Arbor 

Androphy, Elliott, M.D............................University of Massachusetts Medical School 

Arab, Lenore, Ph.D. .................................University of North Carolina 

Arbuck, Susan, M.D.................................Bristol-Myers Squibb 

Arden, Karen C., Ph.D.............................University of California at San Diego 

Arenaz, Pablo, Ph.D.................................University of Texas at El Paso 

Arneson, Dora W., Ph.D. .........................Midwest Research Institute 

Arrick, Bradley A., M.D., Ph.D...............Dartmouth College 

Asher, Sanford A., Ph.D. .........................University of Pittsburgh 

Ashikaga, Takamaru, Ph.D. .....................University of Vermont and State Agricultural 

College 

Aspinwall, Lisa G., Ph.D. ........................University of Maryland, College Park Campus 

Aston-Jones, Gary, Ph.D..........................VA Medical Center 

Athas, William F., Ph.D...........................University of New Mexico 

Au, Jessie L., Ph.D...................................Ohio State University 

Auble, David T., Ph.D. ............................University of Virginia at Charlottesville 

Auborn, Karen J., Ph.D............................North Shore-Long Island Jewish Research Institute 

Auerbach, Robert, Ph.D...........................University of Wisconsin at Madison 

Augenlicht, Leonard H., Ph.D. ................Montefiore Medical Center (Bronx, NY) 
Auld, Garry W., Ph.D. .............................Colorado State University 

Ayer, Donald E., Ph.D. ............................University of Utah 

Aylward, Stephen R., Ph.D......................University of North Carolina at Chapel Hill 

B Back, Anthony L., M.D. ..........................University of Washington 

Badano, Aldo, Ph.D. ................................Food and Drug Administration 

Bair, William J., Ph.D..............................Health Protection Research, Inc. 

Baird, Constance, MS ..............................Healthcare Association of New York State 

Baker, Vicki V., M.D., Ph.D....................University of Michigan Medical Center 

Ballard-Reisch, Deborah, Ph.D................University of Nevada at Reno 

Band, Vimla, Ph.D...................................New England Medical Center Hospitals 

Banks, William L., Ph.D..........................Virginia Commonwealth University 

Baquet, Claudia R., M.D., Ph.D...............University of Maryland 

Barany, Francis, M.D., Ph.D....................Cornell University Medical College 

Barbosa, Miguel S., Ph.D.........................Chugai Biopharmaceuticals 

Barker, Jane E., Ph.D...............................Jackson Laboratory 

Barker, Peter E., Ph.D..............................National Institute of Standards and Technology 

Barnes, Stephen, Ph.D. ............................University of Alabama at Birmingham 

Bar-Sagi, Dafna, Ph.D. ............................State University of New York at Stony Brook 

Barsevick, Andrea M., A.O.C.N., D.N.Sc., D.Sc. Fox Chase Cancer Center 

Bartel, David P., Ph.D..............................Whitehead Institute for Biomedical Research 

Bartolucci, Alfred A., Ph.D. ....................University of Alabama School of Public Health 

Basak, Subhash C., Ph.D. ........................University of Minnesota at Twin Cities 

Bases, Robert E., M.D. ............................Montefiore Medical Center (Bronx, NY) 

Bates, Paula J., Ph.D. ...............................University of Louisville 

Beach, Kirk W., M.D., Ph.D....................University of Washington 

Beach, Wayne A., Ph.D. ..........................San Diego State University 

Bean, Judy A., Ph.D.................................Children’s Hospital Medical Center 

Becich, Michael J., M.D., Ph.D. ..............University of Pittsburgh at Pittsburgh 

Bedi, Atul, M.D. ......................................Johns Hopkins University 

Begg, Colin B., Ph.D. ..............................Sloan-Kettering Institute for Cancer Research 

Bell, Thomas W., Ph.D. ...........................University of Nevada at Reno 

Belshe, Robert B., M.D............................St. Louis University 

Benaron, David A., M.D..........................Spectros Corporation 

Benbrook, Doris M., Ph.D. ......................University of Oklahoma Health Sciences Center 

Bennett, John M., M.D.............................University of Rochester, School of Medicine 

Benson, Mitchell C., M.D........................Columbia Presbyterian Medical Center 

Bepler, Gerold, M.D., Ph.D. ....................H. Lee Moffitt Cancer Center and Research Institute 

Berenson, James R., M.D.........................Cedars-Sinai Medical Center 

Berg, Christine D., M.D...........................Georgetown University 

Berkowicz, David A., M.D., Ph.D...........Harvard Medical School 

Bernhard, Eric J., Ph.D. ...........................University of Pennsylvania 

Bernstein, Jonine L., Ph.D. ......................Mount Sinai, School of Medicine 

Berrios, Miguel, Ph.D. .............................State University of New York at Stony Brook 

Bertagnolli, Monica M., M.D. .................Brigham and Women’s Hospital 

Beth, Albert H., Ph.D...............................Vanderbilt University 

Bethea, Lisa Sparks, Ph.D........................George Mason University 

Bhalla, Kapil N., M.D..............................H. Lee Moffitt Cancer Center and Research Institute 

Bigbee, William L., Ph.D.........................University of Pittsburgh 

Blackband, Stephen J., Ph.D....................University of Florida 

Appendix C-3: Consultants Serving on SEPs
Blair, William, B.A..................................US TOO International 
Blancato, Jan, Ph.D..................................Georgetown University Hospital 

Blaney, Susan, M.D. ................................Baylor College of Medicine 

Bloom, Joan R., Ph.D...............................University of California at Berkeley 

Blum, Ronald H., M.D.............................New York University 

Blumenstein, Brent A., Ph.D. ..................American College of Surgeons 

Bock, Beth C., Ph.D.................................Miriam Hospital 

Bogdanov, Alexei A., Ph.D. ....................Massachusetts General Hospital 

Bondy, Melissa L., Ph.D..........................University of Texas, MD Anderson Cancer Center 

Bonner, James A., M.D., Ph.D.................National Institutes of Health 

Boone, John M., Ph.D..............................University of California at Davis 

Boothman, David A., Ph.D. .....................University of Wisconsin at Madison 

Boreham, Douglas R., Ph.D.....................McMaster University 

Bornhop, Darryl J., Ph.D. ........................Texas Tech University Health Sciences Center 

Borrello, Melinda A., Ph.D......................Vaccinex, Inc. 

Bos, Timothy J., Ph.D..............................Eastern Virginia Medical School 

Bosl, George J., M.D., Ph.D. ...................University of Medicine and Dentistry of New Jersey 

Bosland, Maarten C., Ph.D. .....................New York University Medical Center 

Boss, Jeremy M., M.D., Ph.D. .................Emory University 

Bostick, Roberd M., M.D., Ph.D. ............University of South Carolina at Columbia 

Boyd, Neal R., Ph.D.................................George Washington University 

Boyd, Norman F., M.D. ...........................Ontario Cancer Institute 

Bradfield, Christopher A., Ph.D...............Northwestern University 

Bram, Richard J., M.D., Ph.D..................Mayo Clinic, Rochester 

Brattain, Michael G., Ph.D.......................Roswell Park Cancer Institute 

Braylan, Raul C., M.D. ............................University of Florida Medical School 

Brenan, Colin J.H., Ph.D..........................Biotech Research Laboratories (Btrl) 

Brenner, Dean E., M.D. ...........................University of Michigan at Ann Arbor 

Brewer, Molly A., M.D............................University of Arizona 

Bright, Harold J., Ph.D.............................Office of Naval Research 

Brink, Susan G., Dr.P.H., ........................Healthmark Multimedia, LLC 

Broaddus, William C., M.D., Ph.D..........Virginia Commonwealth University 

Brown, Clyde P., Ph.D.............................Florida Agricultural and Mechanical University 

Brown, Diane R., Ph.D. ...........................Wayne State University 

Brown, J. Martin, M.D., Ph.D..................Stanford University 

Brown, Joe, Ph.D. ....................................SRA International, Inc. 

Brugge, Joan S., Ph.D. .............................Federation of American Societies for Experimental 

Biology 

Bruner, Janet M., M.D., ...........................University of Texas, MD Anderson Cancer Center 

Bryant, John L., M.D., Ph.D. ...................University of Pittsburgh at Pittsburgh 

Buatti, John M., M.D. ..............................University of Iowa 

Buchsbaum, Donald J., Ph.D. ..................University of Alabama at Birmingham 

Budinger, Thomas F., M.D., Ph.D...........University of California at Berkeley 

Buncher, Charles R., Sc.D. ......................University of Cincinnati 

Bunin, Greta R., Ph.D. .............................Children’s Hospital of Philadelphia 

Burdette, Everette C., Ph.D......................Burdette Medical Systems, Inc. 

Burdette, Jonathan H., M.D. ....................Wake Forest University 

Burgess, Arthur E., Ph.D. ........................Brigham and Women’s Hospital 

Burhans, William C., Ph.D. .....................Roswell Park Cancer Institute 

Burhansstipanov, Linda, Ph.D. ................Native American Cancer Research 

Appendix C-3: Consultants 

Serving on SEPs
Burk, Robert D., M.D. .............................University of Massachusetts Medical School at 

Worcester 

Burke, Daniel J., Ph.D. ............................University of Virginia at Charlottesville 

Burke, Harry B., M.D., Ph.D. ..................George Washington University 

Burlingame, Alma L., Ph.D. ....................University of California at San Francisco 

Burns, David M., M.D. ............................University of California at San Diego 

C Cabot, Myles C., Ph.D. ............................John Wayne Cancer Institute 

Cagan, Ross L., Ph.D...............................Washington University 

Cairns, Paul, Ph.D....................................Fox Chase Cancer Center 

Cairo, Mitchell S., M.D. ..........................Children’s Hospital of Orange County 

Caldwell, Charles W., M.D., Ph.D...........University of Missouri at Columbia 

Caligiuri, Michael A., M.D., Ph.D...........Ohio State University 

Camp, Nicola J., Ph.D..............................University of Utah 

Campbell, Catherine E., Ph.D..................Finch University of Health Sciences 

Campbell, Marci K., Ph.D. ......................University of North Carolina at Chapel Hill 

Cannon-Albright, Lisa A., Ph.D. .............LDS Hospital 

Carbone, David P., M.D., Ph.D. ..............Vanderbilt-Ingram Cancer Center 

Carducci, Michael A., M.D......................Johns Hopkins University 

Carey, Lisa A., M.D.................................University of North Carolina at Chapel Hill 

Carroll, Gregory, Ph.D.............................Bayer Institute for Health Care Communication 

Carroll, William L., M.D. ........................Mount Sinai School of Medicine 

Carson, Johnny L., Ph.D. .........................University of North Carolina at Chapel Hill 

Cegala, Donald J., Ph.D...........................Ohio State University 

Celis, Esteban, M.D., Ph.D. .....................Mayo Clinic, Rochester 

Chadburn, Amy, Ph.D..............................Cornell University, School of Medicine 

Champlin, Richard E., M.D. ....................University of Texas, MD Anderson Cancer Center 

Chang, Stephen M., Ph.D.........................Chiron Technologie, Center for Gene Therapy 

Chao, Nelson J., M.D...............................Duke University 

Chapman, Simon, Ph.D............................University of Sydney 

Chen, Ching-Nien, Ph.D. .........................National Institutes of Health 

Chen, Wei William, Ph.D. .......................University of Florida 

Chen, Yao-Tseng, M.D., Ph.D.................Weill Medical College of Cornell University 

Chenevert, Thomas L., Ph.D....................University of Michigan at Ann Arbor 

Cheng, Keith C., M.D., Ph.D...................Pennsylvania State University, Hershey Medical 

Center 

Cheng, Liang, M.D., Ph.D. ......................Indiana University, School of Medicine 

Cher, Michael L., M.D.............................Wayne State University 

Chlebowski, Rowan T., M.D., Ph.D. .......Harbor-UCLA Research and Education Institute 

Chmiel, Joan S., Ph.D. .............................Northwestern University 

Cho, Raymond J., Sc.B. ...........................Ingenuity Systems, Inc. 

Christie, Debbie W., M.B.A. ...................University of Mississippi Medical Center 

Chung, Leland W., Ph.D..........................Emory University, School of Medicine 

Clark, Douglas P., M.D., Ph.D. ...............Johns Hopkins University 

Clark, Edward A., M.D., Ph.D.................Keystone Symposia 

Clarke, Geoffrey D., Ph.D. ......................University of Texas Health Science Center at San 

Antonio 

Clarke, John, Ph.D. ..................................University of California at Berkeley 

Clarke, Lauren D., M.S............................Cornerstone Systems Northwest 

Clarke-Tasker, Veronica A., Ph.D. ..........Howard University 

Appendix C-3: Consultants 

Serving on SEPs
Clawson, Gary A., M.D., Ph.D. ...............Pennsylvania State University, Hershey Medical 

Center 

Cline, Rebecca J., Ph.D............................University of Florida 

Cobau, Charles D., M.D...........................Toledo Clinic, Inc. 

Coetzee, Gerhard A., Ph.D.......................University of Southern California 
Cokkinides, Vilma, Ph.D. ........................American Cancer Society 

Cole, Bernard F., Ph.D.............................Dartmouth College 

Colton, Theodore, D.Sc., Sc.D.................ABT Associates, Inc. 

Conaway, Mark R., Ph.D.........................Duke University 

Constantinou, Andreas I., M.D., Ph.D.....University of Illinois at Chicago 

Cook, Richard G., M.D., Ph.D.................Baylor College of Medicine 

Cordon-Cardo, Carlos, M.D., Ph.D. ........Sloan-Kettering Institute for Cancer Research 

Correa, Pelayo, M.D. ...............................Prospect Associates, Ltd. 

Correia, John A., Ph.D.............................Massachusetts General Hospital 

Cory, Michael, Ph.D. ...............................Glaxo Wellcome, Inc. 

Costa, Jose C., M.D. ................................Yale University 

Costantino, Joseph P., Ph.D.....................University of Pittsburgh at Pittsburgh 

Cote, Richard J., M.D. .............................University of Southern California 

Counter, Christopher M., Ph.D. ...............Duke University 

Cowan, Kenneth H., M.D., Ph.D. ............University of Nebraska Medical Center 

Cowburn, David A., Ph.D........................New York Structural Biology Center 

Cowell, John K., Ph.D. ............................Roswell Park Cancer Institute 

Cox, Adrienne D., Ph.D...........................University of North Carolina at Chapel Hill 

Crane, Lori A., Ph.D. ...............................AMC Cancer Research Center 

Cravatt, Benjamin F., Ph.D......................Scripps Research Institute 

Cromack, Keith R., Ph.D. ........................Abbott Laboratories 

Croop, James M., Ph.D. ...........................Dana-Farber Cancer Institute 

Crosby, Margaree S., EDD ......................Clemson University 

Cross, Anne P., Ph.D. ..............................Bristol-Myers Squibb Pharmaceutical Research 

Institute 

Crowell, Pamela L., Ph.D. .......................Indiana University-Purdue University at 

Indianapolis 

Crum, Christopher P., M.D......................Brigham and Women’s Hospital 

Cummings, Richard D., Ph.D. .................University of Oklahoma Health Sciences Center 

Curbow, Barbara Ann, Ph.D....................Johns Hopkins University, School of Public Health 

Curran, Walter J., M.D.............................American College of Radiology 

Czerniak, Bogdan A., M.D., Ph.D. ..........University of Texas, MD Anderson Cancer Center 

D Dalla-Favera, Riccardo, M.D...................Columbia University 

Dalton, William S., M.D., Ph.D...............H. Lee Moffitt Cancer Center and Research Institute 

Daniels, Michael J., Sc.D.........................University of Florida 

Daskalakis, Constantine, Sc.D.................Thomas Jefferson University 

Datar, Ram H., Ph.D. ...............................University of Southern California 

Davidson, Bradley S., Ph.D. ....................Utah State University 

Davidson, Nancy E., M.D........................Johns Hopkins University 

Davies, Stella, M.D., Ph.D.......................Children’s Hospital Medical Center, Cincinnati 

Dawson, Jeffrey R., Sc.D.........................Duke University 

Day, Billy, Ph.D.......................................Prolx Pharmaceuticals, LP 

De Leon, Daisy D., Ph.D. ........................Loma Linda University 

De Moor, Carl, Ph.D................................University of Texas, MD Anderson Cancer Center 

Deen, Dennis F., Ph.D. ............................University of California at San Francisco 

Defleur, Margaret H., Ph.D......................Boston University 

Dejesus, Onofre T., Ph.D.........................University of Wisconsin 

Delipkau, Sally A., B.S. ..........................Harvard Hughes Medical Institute 

Demark-Wahnefried, Wendy, Ph.D.........Duke University 

Appendix C-3: Consultants 

Serving on SEPs
Demas, James N., Ph.D............................University of Virginia at Charlottesville 

Deng, Hong-Wen W., Ph.D. ....................Creighton University 

Depue, Judith D., M.P.H..........................Miriam Hospital/Brown University 

Descour, Michael R., Ph.D. .....................University of Arizona 

Devere White, Ralph W., M.D. ...............University of California at Davis 

Dewey, William C., Ph.D. .......................Virginia Commonwealth University 

Dewhirst, Mark W., D.V.M., Ph.D..........Duke University 

Di Saia, Philip, M.D.................................American College of Obstetrics and Gynecology 

Dicker, Adam, M.D., Ph.D. .....................Thomas Jefferson University 

Dickersin, Kay P., Ph.D...........................University of Maryland,Baltimore Professional 

School 

Dietrich, Allen J., M.D.............................Dartmouth College 

Dignan, Mark B., Ph.D. ...........................University of Kentucky 

Dinney, Colin P., M.D. ............................University of Texas, MD Anderson Cancer Center 

Disis, Mary L., M.D.,...............................University of Washington 

Dolnick, Bruce J., Ph.D. ..........................Roswell Park Cancer Institute 

Doroshow, James H., M.D.......................City of Hope National Medical Center 

Dow, Karen H., Ph.D...............................University of Central Florida 

Driscoll, Mark S., Ph.D............................SUNY - College of Environmental Science and 

Forestry 

Dubinett, Steven M.., M.D.......................University of California at Los Angeles School of 

Medicine 

Dueker, Steve, Ph.D.................................University of California at Davis 

Dunn, William J., Ph.D............................University of Illinois at Chicago 

Durden, Donald L., M.D., Ph.D...............University of Indiana 

Dwyer, Samuel J., Ph.D...........................University of Virginia 

Dyster, Lyn M., Ph.D...............................Gencyte, LLC 

E Earp, H. Shelton, M.D. ............................University of North Carolina at Chapel Hill 

Eck, Stephen L., M.D., Ph.D. ..................Pfizer, Inc. 

Eckelman, William C., Ph.D....................Clinical Center, NIH 

Eckhart, Walter, Ph.D. .............................Salk Institute for Biological Studies 

Edgar, Bruce A., Ph.D. ............................Fred Hutchinson Cancer Center 

Edgar, Tim M., Ph.D................................Westat 

Edgerton, Mary E., M.D., Ph.D. ..............Vanderbilt University 

Eggert, Harriet B., B.S.............................Susan G. Komen Breast Cancer Foundation 

Egli, Martin, Ph.D....................................Vanderbilt University 

Ehrlich, Garth D., Ph.D............................Allegheny-Singer Research Institute 

Eisenberg, Merrill R., Ph.D. ....................University of Arizona 

Elashoff, Robert M., Ph.D. ......................University of California, Los Angeles School of 

Medicine 

Elder, Elaine, Sc.D...................................University of Pittsburgh 

Elting, Linda S., Dr.P.H...........................University of Texas, MD Anderson Cancer Center 

Engleman, Edgar G., M.D., Ph.D. ...........Stanford University 

Engler, Jeffrey A., D.D.S., Ph.D..............U.S. Public Health Service Public Advisory Groups 

Erdman, John W., Ph.D. ..........................University of Illinois 

Esteban, Jose M., M.D., Ph.D..................Providence Hospital Cancer Center 

Esterowitz, Leon, Ph.D. ...........................Naval Research Laboratory 

Ettensohn, Charles A., Ph.D. ...................Carnegie-Mellon University 

Appendix C-3: Consultants 

Serving on SEPs
F Fahey, Frederic H., D.Sc..........................Wake Forest University 

Falciglia, Grace A., Ph.D.........................University of Cincinnati 

Faris, Gregory W., Ph.D. .........................SRI International 

Fasullo, Michael T., Ph.D. .......................Albany Medical College 

Fenoglio-Preiser, Cecilia M., M.D...........University of Cincinnati 

Fenster, Aaron, Ph.D................................J.P. Robarts Research Institute 
Fenton, Robert G., M.D., Ph.D. ...............University of Maryland, Baltimore Professional 

School 

Fernandes, Daniel J., Ph.D.......................Medical University of South Carolina 

Ferrari, Mauro, Ph.D................................Ohio State University 

Ferrone, Soldano, M.D., Ph.D. ................Roswell Park Cancer Institute 

Finer-Moore, Janet S., Ph.D.....................University of California at San Francisco 

Finley, John W., Ph.D..............................USDA Human Nutrition Research Center 

Fischman, Alan J., M.D., Ph.D. ...............Massachusetts General Hospital 

Fishbein, Michael C., M.D.......................University of California at Los Angeles 

Fisher, Richard I., M.D., Ph.D.................University of Rochester 

Floyd, Carey E., Ph.D. .............................Duke University 

Flynn, Brian S., Ph.D...............................University of Vermont 

Foerster, Susan B., M.P.H., R.D..............California Health Services 

Fontham, Elizabeth T.H., Ph.D................Louisiana State University Medical Center 

Ford, Leigh A., Ph.D................................New Mexico State University at Las Cruces 

Forster, Jean L., Ph.D...............................University of Minnesota at Twin Cities 

Foster, Brenda, M.D., Ph.D. ....................Wayne State University 

Fox, Brion J., J.D. ....................................University of Wisconsin at Madison 

Frackelton, Raymond A., Ph.D................Roger Williams Hospital 

Frankel, Arthur E., M.D...........................Wake Forest University Health Sciences 

Frankfurt, Oskar S., Ph.D.........................Apostain, Inc. 

Franklin, Wilbur A., M.D. .......................University of Colorado Health Sciences Center 

Franko, Joann C., M.H.A.........................Case Western Reserve University 

Fresco, Jacques R., Ph.D..........................Princeton University 

Frey, Eric C., Ph.D...................................Johns Hopkins University 

Friedman, Susan J., M.D..........................Facing Our Risk 

Fu, Karen King-Wah, M.D. .....................University of California at San Francisco 

Fu, Xiang-Dong, Ph.D. ............................University of California at San Diego 

Fukumura, Dai, M.D., Ph.D.....................Massachusetts General Hospital 

Futscher, Bernard W., Ph.D.....................University of Arizona 

G Gabriel, Abram, M.D., M.P.H. ................Rutgers, The State University of New Jersey 

Gabrielson, Edward W., M.D. .................Johns Hopkins University 

Gabrilove, Janice L., M.D........................Mount Sinai School of Medicine 

Gale, James M., Ph.D...............................University of New Mexico at Albuquerque 

Gallagher, Richard E., Ph.D.....................Wayne State University 

Galloway, Robert L., Ph.D.......................Vanderbilt University 

Gambhir, Sanjiv S., M.D., Ph.D. .............University of California at Los Angeles 

Gammon, Marilie D., Ph.D......................University of North Carolina at Chapel Hill 

Ganapathi, Ram N., Ph.D.........................Cleveland Clinic Foundation 

Gao, Allen C., M.D., Ph.D.......................Roswell Park Cancer Institute 

Garcia-Blanco, Mariano A., M.D., Ph.D. Duke University 

Garewal, Harinder S., M.D., Ph.D...........University of Arizona 

Garner, Harold R., Ph.D...........................University of Texas SW Medical Center at Dallas 

Gaspar, Laurie E., M.D............................University of Colorado Health Sciences Center 

Gatewood, Lael C., Ph.D. ........................University of Minnesota 

Gazdar, Adi F., M.D. ...............................University of Texas SW Medical Center at Dallas 

Gendler, Sandra J., Ph.D..........................Mayo Clinic, Rochester 

George, Donna L., Ph.D...........................University of Pennsylvania 

Gerlach, Karen K., Ph.D. .........................Robert Wood Johnson Foundation 

Appendix C-3: Consultants 

Serving on SEPs
Gerlach, Robert W., M.P.A......................Cleveland Clinic Foundation 

Gerrard, Meg, Ph.D..................................University of California at San Diego 

Gershman, Susan T., Ph.D.......................Massachusetts Cancer Registry 

Gershon, Michael D., M.D., Ph.D. ..........Columbia University 

Gewirtz, David A., Ph.D..........................Medical College of Virginia 

Giaccia, Amato J., Ph.D...........................Stanford University 

Gibson, Raymond E., Ph.D......................Merck Research Laboratories 

Gilbert, Peter B., Ph.D. ............................Fred Hutchinson Cancer Research Center 

Gillespie, G. Yancey, Ph.D......................University of Alabama at Birmingham 

Gillis, Kevin D., Ph.D..............................University of Missouri 

Gilmore, Thomas D., Ph.D. .....................Boston University 

Gimotty, Phyllis A., Ph.D. .......................University of Pennsylvania 

Giordano, Antonio, M.D., Ph.D...............Sbarro Institute for Cancer Research 

Giordano, Thomas J., M.D.......................University of Michigan 

Gite, Sadanand, Ph.D...............................Ambergen, Inc. 

Glantz, Stanton A., Ph.D..........................University of California at San Francisco 

Gleich, Lyon L., M.D...............................University of Cincinnati 

Gluck, Stephen L., M.D...........................Washington University 

Glynn, Thomas J., Ph.D...........................Cancer Science and Trends 

Godley, Paul A., M.D., Ph.D. ..................University of North Carolina at Chapel Hill 

Gold, Barry I., M.D., Ph.D.......................University of Nebraska Medical Center 

Gold, David V., Ph.D...............................Garden State Cancer Center 

Gold, Leslie I., Ph.D. ...............................New York University Medical Center 

Golden, Andy, Ph.D.................................National Institutes of Health 

Goldsmith, Elizabeth J., Ph.D..................University of Texas SW Medical Center at Dallas 

Goldson, Alfred L., M.D..........................Howard University Hospital 

Golovlev, Val V., Ph.D............................Sci-Tec, Inc. 

Gomer, Charles J., Ph.D...........................Children’s Hospital, Los Angeles 

Goodman, Gary E., M.D., Ph.D...............Fred Hutchinson Cancer Research Center 

Goodman, Murray, Ph.D..........................University of California at San Diego 

Gordon, Gary B., M.D., Ph.D. .................G.D. Searle and Company 

Gordon, Nahida H., Ph.D.........................Case Western Reserve University 

Gottlieb, Nell H., Ph.D.............................University of Texas at Austin 

Graham, Michael M., M.D., Ph.D. ..........University of Iowa 

Grana, Xavier, Ph.D.................................Temple University 

Grant, Steven J., M.D...............................Virginia Commonwealth University 

Gray, Robert J., Ph.D...............................Frontier Science and Technology Research 

Foundation, Inc. 

Grdina, David J., Ph.D.............................University of Chicago 

Greco, William R., Ph.D..........................Roswell Park Cancer Institute 

Green, Daniel M., M.D. ...........................Roswell Park Cancer Institute 

Green, Mark R., M.D., Ph.D....................Medical University of South Carolina 

Green, Sidney, Ph.D.................................Howard University 

Greene, Geoffrey W., Ph.D......................University of Rhode Island 

Greenes, Robert A., M.D., Ph.D. .............Brigham and Women’s Hospital 

Greenleaf, James F., Ph.D........................Mayo Clinic Rochester 

Griffith, Jeffrey K., Ph.D. ........................University of New Mexico at Albuquerque 

Grigsby, Perry W., M.D...........................Washington University 

Grizzle, William E., M.D., Ph.D..............University of Alabama at Birmingham 

Appendix C-3: Consultants 

Serving on SEPs
Groden, Joanna L., Ph.D..........................University of Cincinnati 

Groshen, Susan G., Ph.D. ........................USC/Norris Comprehensive Cancer Center 
Gruber, Stephen B., M.D., Ph.D. .............University of Michigan at Ann Arbor 

Grunberg, Steven M., M.D. .....................University of Vermont 

Grundfest, Warren S., M.D......................University of California at Los Angeles 

Guise, Theresa A., M.D., Ph.D. ...............University of Virginia, Charlottesville 

Gullberg, Grant T., Ph.D..........................University of California-Lawrence Berkeley 

Laboratory 

Gum, James R., Ph.D...............................Northern California Institute Research and 

Education 

Gupta, Alok, Ph.D....................................Siemens Corporate Research, Inc. 

Gurney, James G., Ph.D...........................University of Minnesota at Twin Cities 

Gutierrez, Peter L., Ph.D..........................University of Maryland Cancer Center 

Gygi, Steven P., Ph.D. .............................Harvard University (Medical School) 

H Hagen, Frederick S., Ph.D. ......................Icogen 

Hait, William N., M.D., Ph.D. .................University of Medicine and Dentistry of New Jersey 

Halabi, Susan, Ph.D. ................................National Center for Research Resources, NIH 

Halazonetis, Thanos D., D.D.S., Ph.D.....Wistar Institute 

Hallahan, Dennis E., M.D., Ph.D.............Precision Guided Therapy 

Halpern, Aaron L., Ph.D. .........................University of New Mexico at Albuquerque 

Hamburger, Anne W., Ph.D.....................University of Maryland, Baltimore Professional 

School 

Hamilton, Thomas C., Ph.D.....................Fox Chase Cancer Center 

Hammons, George J., Ph.D......................Philander Smith College 

Hanash, Samir M., M.D., Ph.D................University of Michigan at Ann Arbor 

Hanis, Craig L., Ph.D...............................University of Texas Health Sciences Center at 

Houston 

Hanna, Michelle M., Ph.D. ......................Designer Genes, Inc. 

Hansen, Marc F., Ph.D.............................University of Connecticut School of 

Medicine/Dentistry 

Harari, Paul M., M.D. ..............................University of Wisconsin at Madison 

Harlow, Edward E., Ph.D.........................Massachusetts General Hospital 

Harris, Jules Eli, M.D. .............................Rush Medical College of Rush University 

Harris, Randall E., M.D., Ph.D. ...............Ohio State University 

Hartline, Jo Ann, M.P.H., M.S.W............Select Statistical Center 

Hartmann, Lynn C., M.D., Ph.D..............Mayo Clinic, Rochester 

Haskins, Penelope S., Ph.D......................Radiation Technologies, Inc. 

Hauck, Walter W., Ph.D. .........................Thomas Jefferson University 

Haus, Erhard, Ph.D. .................................University of Minnesota 

Hawkins, William E., Ph.D......................Gulf Coast Research Laboratory 

Heffelfinger, Sue C., M.D., Ph.D.............University of Cincinnati 

Hefta, Stanley A., Ph.D............................Beckman Research Institute 

Heimburger, Douglas C., M.D.................University of Alabama at Birmingham 

Hellerqvist, Carl G., Ph.D........................Vanderbilt University 

Hemstreet, George P., M.D., Ph.D...........H and B Medical Technology 

Hendrick, R. Edward, Ph.D. ....................Northwestern University 

Hendrix, Mary J., Ph.D. ...........................Gordon Research Conferences 

Herberman, Ronald B., M.D., Ph.D.........University of Pittsburgh at Pittsburgh 

Herlyn, Dorothee M., D.V.M., Ph.D........Wistar Institute 

Herlyn, Meenhard I., D.Sc., D.V.M.........Wistar Institute 

Herman, James G., M.D...........................Johns Hopkins University Medical School 

Appendix C-3: Consultants 

Serving on SEPs
Heslop, Helen E., M.D.............................St. Jude Children’s Research Hospital 

Hess, Kenneth R., Ph.D. ..........................University of Texas, MD Anderson Cancer Center 

Hettich, Robert L., Ph.D. .........................Lockheed Martin Energy Research Corporation 

Hibbard, Lyndon S., Ph.D........................Pixel Inference Corporation 

Hichwa, Richard D., Ph.D. ......................University of Iowa 

Hickman, James J., Ph.D. ........................Science Applications International Corporation 

Hielscher, Andreas H., Ph.D....................Columbia University, New York, Morningside 

Hill, David B., M.D. ................................University of California at Davis 

Hill, Donald L., Ph.D...............................University of Alabama at Birmingham 

Hilton, Joan F., M.P.H., Sc.D. .................University of California at San Francisco 

Hinds, Philip W., Ph.D.............................Harvard University (Medical School) 

Hirschhorn, Norbert, M.D........................Private Practice 

Hnatowich, Donald J., Ph.D.....................University of Massachusetts Medical School at 

Worcester 

Ho, Peter T.C., M.D., Ph.D......................Glaxo Smith Kline 

Hobart, Peter M., Ph.D.............................Vical, Inc. 

Hockenbery, David M., M.D. ..................Fred Hutchinson Cancer Research Center 

Hodge, Felicia S., Dr.P.H. .......................University of Minnesota at Twin Cities 

Hoffman, Daniel A, Ph.D. .......................George Washington University 

Hoffman, Jerald L., Ph.D.........................University of Louisville 

Hoffman, Robert M., Ph.D.......................Anticancer, Inc. 

Hoffmann, F. M., Ph.D. ...........................University of Wisconsin at Madison 

Holiday, David B., Ph.D. .........................University of Texas Health Center at Tyler 

Holmgren, Robert A., Ph.D. ....................Northwestern University 

Hoon, Dave S., Ph.D................................John Wayne Cancer Institute 

Hooper, Herbert H., Ph.D. .......................Aclara Biosciences, Inc. 

Hooper, Joan E., Ph.D..............................University of Colorado Health Sciences Center 

Horton, John, M.D. ..................................University of South Florida 

Hosick, Howard L., Ph.D.........................Washington State University 

Hoskins, William J., M.D. .......................Sloan-Kettering Institute for Cancer Research 

Hotchkiss, John M., B.A..........................Anvil Informatics, Inc. 

Howe, Holly L., Ph.D. .............................North American Association of Central Cancer 

Registries 

Howell, Gillian M., Ph.D.........................University of Texas Health Sciences Center at San 

Antonio 

Howett, Mary K., Ph.D. ...........................Pennsylvania State University, Hershey Medical 

Center 

Hoyt, Dan R., Ph.D. .................................University of Nebraska at Lincoln 

Hromas, Robert A., M.D..........................Indiana University-Purdue University at 

Indianapolis 

Huang, Tim H., Ph.D. ..............................University of Missouri at Columbia 

Hudig, Dorothy, Ph.D. .............................University of Nevada at Reno 

Hughes, Chanita A., Ph.D........................University of Pennsylvania 

Humphrey, Peter A., M.D., Ph.D.............Washington University 

Hunger, Stephen P., M.D.........................University of Florida 

Hurley, Carolyn K., Ph.D.........................Georgetown University, Lombardi Cancer Center 

Hussein, Mohamad, M.D.........................Cleveland Clinic Foundation 

Husten, Corinne G., M.D.........................Centers for Disease Control and Prevention 

Hyland, Andrew, Ph.D.............................Roswell Park Cancer Institute 

Appendix C-3: Consultants 

Serving on SEPs
Hyman, Linda E., Ph.D............................Tulane University of Louisiana 

I Iden, Charles R., Ph.D. ............................State University of New York at Stony Brook 

Iglehart, James Dirk, M.D........................Duke University 

Ikle, David N., Ph.D.................................City of Hope 

Ingle, James N., M.D. ..............................Mayo Clinic and Foundation 

Insana, Michael F., Ph.D..........................University of California at Davis 

Inungu, Joseph N., M.D., Ph.D................Central Michigan University 

Isaacson, Michael S., Ph.D. .....................Cornell University 

Ittmann, Michael M., M.D., Ph.D............New York University, School of Medicine 
J Jacobberger, James W., Ph.D...................Case Western Reserve University 

Jacobson, Elaine L., Ph.D. .......................Niadyne, Inc. 

Jacques, Steven L., Ph.D..........................Oregon Health and Science University 

Jain, Ajay N., Ph.D. .................................University of California at San Francisco 

James, Charles D., Ph.D...........................Mayo Clinic, Rochester 

Jatoi, Aminah, M.D..................................Mayo Clinic, Rochester 

Jay, Daniel G., Ph.D.................................Tufts University at Boston 

Jaye, David L., M.D.................................Emory University 

Jeffery, Elizabeth H., Ph.D. .....................University of Illinois 

Jeftinija, Srdija, D.V.M., Ph.D.................Iowa State University of Science and Technology 

Jelinek, Diane F., Ph.D. ...........................Mayo Clinic, Rochester 

Jensen, Ronald H., Ph.D. .........................University of California at San Francisco 

Jensen, Roy A., M.D................................Vanderbilt University Medical Center 

Jessup, J. Milburn, Ph.D. .........................Georgetown University 

Jewell, William R., M.D. .........................University of Kansas Medical Center 

Johnson, Bruce E., M.D...........................Dana-Farber Cancer Institute 

Johnson, G. Allen, Ph.D...........................Duke University 

Johnson, Gary L., Ph.D............................National Jewish Medical and Research Center 

Johnson, Linda B., B.S.............................National Coalition for Cancer Survivorship 

Johnson, Richard S., Ph.D. ......................Immunex Corporation 

Johnston, Dennis A., Ph.D.......................Wayne State University 

Jones, Dean P., Ph.D................................Emory University-Winship Cancer Center 

Jones, Denyse Porter, M.S. ......................Detroit Public Health Department 

Jones, Jeffrey P., Ph.D. ............................Washington State University 

Jones, Paul K., Ph.D.................................Case Western Reserve University 

Jordan, Craig V., Ph.D.............................Northwestern University 

Jordan, Richard C., D.D.S., Ph.D. ...........University of California at San Francisco 

Joseph, Peter M., Ph.D.............................University of Pennsylvania 

Jostes, Rick, Ph.D. ...................................National Academy of Sciences 

Jove, Richard, Ph.D. ................................University of South Florida 

K Kacinski, Barry M., M.D., Ph.D. .............Yale University, School of Medicine 

Kadish, Anna S., M.D..............................Yeshiva University 

Kaiserman, Murray, Ph.D. .......................Health Canada 

Kak, Neeraj, Ph.D. ...................................University Research Co, LLC 

Kalemkerian, Gregory P., M.D................University of Michigan Medical Center 

Kalonia, Devendra, Ph.D. ........................University of Connecticut 

Kalyanaraman, Balaraman, Ph.D.............Medical College of Wisconsin 

Kane, Caroline M., Ph.D..........................University of California at Berkeley 

Kaplan, Alan M., Ph.D.............................University of Kentucky 

Karczmar, Gregory S., Ph.D. ...................University of Chicago 

Karnes, William E., M.D. ........................Mayo Clinic, Rochester 

Karrison, Theodore, Ph.D. .......................University of Chicago 

Kasid, Usha N., Ph.D...............................Georgetown University 

Kaufman, Nancy J., R.N. .........................Robert Wood Johnson Foundation 

Kaul, Karen L., M.D., Ph.D.....................Evanston Hospital 

Kay, Neil E., M.D. ...................................Mayo Clinic, Rochester 

Keating, Armand, M.D. ...........................Princess Margaret Hospital 

Keating, Nancy L., M.D...........................Harvard Medical School 

Appendix C-3: Consultants 

Serving on SEPs
Kedderis, Gregory L., Ph.D. ....................CIIT Centers for Health Research 

Kelcz, Frederick, M.D., Ph.D. .................University of Wisconsin at Madison 

Kenney, Shannon C., M.D.......................University of North Carolina at Chapel Hill 

Kennison, James A., Ph.D. ......................National Institute of Child Health and Human 

Development 

Kershaw, Josephine M., Ph.D..................Florida A and M University 

Key, Charles R., M.D., Ph.D. ..................University of New Mexico at Albuquerque 

Keyes, Sean M., B.A................................Fox Chase Cancer Center 

Khorasanizadeh, Sepideh, Ph.D...............University of Virginia at Charlottesville 

Killackey, Maureen A., M.D. ..................Bassett Cancer Center 

Killen, Joel D., M.D., Ph.D......................Stanford University 

Killoran, Moira G., Ph.D. ........................George Washington University 

Kimm, Sue Y.S., M.D..............................University of Pittsburgh School of Medicine 

Kinch, Michael S., Ph.D. .........................Purdue University at West Lafayette 

King, Bonnie L., Ph.D. ............................Yale University 

Kinghorn, Alan D., Ph.D. ........................University of Illinois at Chicago 

Kinsella, Timothy J., M.D. ......................University Hospitals of Cleveland 

Kipps, Thomas J., M.D., Ph.D.................University of California at San Diego 

Kirschner, Marvin A., M.D......................University of Medicine and Dentistry of New Jersey 

Kiviat, Nancy B., M.D.............................University of Washington 

Klein, John P., Ph.D.................................Medical College of Wisconsin 

Klesges, Lisa M., Ph.D. ...........................University of Tennessee Health Science Center 

Klinge, Carolyn M., Ph.D. .......................University of Louisville 

Knipp, Gregory T., Ph.D..........................Rutgers, The State University of New Jersey 

Knopp, Michael, M.D., Ph.D...................Ohio State University 

Knowles, Barbara B., M.D., Ph.D. ..........Jackson Laboratory 

Kogon, Alexander A., Ph.D.....................Biolinx, LLC 

Kolasa, Kathryn M., Ph.D........................East Carolina University 

Kong, Tony Ah-Ng, Ph.D........................Rutgers University, College of Pharmacy 

Kontos, Christopher D., M.D...................Duke University 

Koral, Kenneth F., Ph.D...........................University of Michigan at Ann Arbor 

Korngold, Robert, Ph.D. ..........................Thomas Jefferson University 

Kosinski, Andrzej S., Ph.D. .....................Emory University 

Kramer, Randall H., Ph.D........................University of California at San Francisco 

Krasnykh, Victor N., Ph.D.......................Vectorlogics, Inc. 

Krauss, Raul, Ph.D...................................Alphagene, Inc. 

Krischer, Jeffrey P., Ph.D. .......................H. Lee Moffitt Cancer Center and Research Institute 

Kristal, Alan R., Ph.D. .............................Fred Hutchinson Cancer Research Center 

Kristeller, Jean L., Ph.D...........................Indiana State University 

Kroeger, Richard A., Ph.D.......................Naval Research Laboratory 

Krulevitch, Peter, Ph.D. ...........................University of California-Lawrence Livermore 

National Lab 

Kruse, Carol A., Ph.D. .............................University of Colorado Health Sciences Center 

Kuebler, Philip, M.D., Ph.D.....................Columbus Oncology Associates 

Kukowska-Latallo, Jolanta F., Ph.D. .......Michigan State University 

Kulkarni, Amit, Ph.D...............................Molecular Simulations, Inc. 

Kumar, Subodh, Ph.D. .............................Buffalo State College 

Kun, Larry E., M.D..................................St. Jude Children’s Research Hospital 

Kung, Hank F., Ph.D................................University of Pennsylvania 

Appendix C-3: Consultants 

Serving on SEPs
Kung, Hsing-Jien, Ph.D. ..........................University of California, Davis Cancer Center 
Kuppusamy, Periannan, Ph.D. .................Ohio State University 

Kuspa, Adam, Ph.D. ................................Baylor College of Medicine 

L Lackland, Daniel T., Ph.D. ......................Medical University of South Carolina 

Lacroix, Andrea Z., Ph.D.........................Group Health Cooperative of Puget Sound 

Lambert, Peggy A., M.S. .........................West Virginia University 

Lamm, Donald L., M.D., Ph.D. ...............Mayo Clinic 

Landsittel, Douglas P., Ph.D....................University of Pittsburgh 

Larson, Ronald G., Ph.D..........................University of Michigan at Ann Arbor 

Larson, Steven M., M.D., Ph.D. ..............Memorial Sloan-Kettering Cancer Center 

Lashford, Linda, Ph.D..............................Cancer Research UK 

Lawrence, Hugh J., M.D..........................Northern California Institute Research and 

Education 

Layne, Elizabeth L., D.D.S., M.S.D. .......Alliance/Lung Cancer Advocacy, Support & 

Education 

Lazovich, Deann, Ph.D. ...........................University of Minnesota at Twin Cities 

Le, Chap T., Ph.D. ...................................University of Minnesota at Twin Cities 

Leary, James F., Ph.D. .............................University of Texas Medical Branch at Galveston 

Ledden, Patrick J., M.D. ..........................Nova Medical, Inc. 

Ledlow, Gerald, Ph.D. .............................Central Michigan University 

Lee, Chung, Ph.D.....................................Northwestern University 

Lee, J. Jack, D.D.S., Ph.D........................University of Texas, MD Anderson Cancer Center 

Lee, Jeannette Y., Ph.D............................University of Alabama at Birmingham 

Lee, Norman H., Ph.D. ............................Institute for Genomic Research 

Lee, Robert J., Ph.D.................................Endocyte, Inc. 

Lee, Terry D., Ph.D..................................Beckman Research Institute 

Lefebvre, R. Craig, Ph.D. ........................Prospect Associates, Ltd. 

Lerman, Caryn E., Ph.D...........................University of Pennsylvania 

Leslie, Kevin B., M.D., Ph.D...................Immgenics Pharmaceuticals, Inc. 

Leslie, Kimberly K., M.D. .......................University of New Mexico at Albuquerque 

Lesser, Martin L., Ph.D............................New York University 

Levenson, Richard M., M.D. ...................Cambridge Research and Instrumentation 

Lever, Susan Z., Ph.D. .............................University of Missouri at Columbia 

Levin, Victor A., M.D..............................University of Texas 

Li, Hongzhe, Ph.D. ..................................University of California at Davis 

Li, King C., M.D......................................Stanford University 

Li, Sara A., Ph.D......................................University of Kansas Medical Center 

Liang, Jie, Ph.D........................................University of Illinois at Chicago 

Liang, Yun, Ph.D. ....................................Indiana University-Purdue University at 

Indianapolis 

Lichtenstein, Edward L., Ph.D.................Oregon Research Institute 

Lieberman, Howard B., Ph.D...................Columbia University Health Sciences 

Lightdale, Charles J., M.D.......................Columbia University Health Sciences 

Lillegard, Debra G., M.A.........................Methodist Hospital Cancer Center 

Limburg, Paul J., M.D. ............................Mayo Clinic and Foundation 

Lingen, Mark W., D.D.S., Ph.D...............Loyola University Medical Center 

Link, Judith, R.N......................................Alaska Regional Hospital 

Linney, Elwood A., Ph.D.........................Duke University 

Linville, Linda H., Ph.D...........................University of Kentucky 

Appendix C-3: Consultants 

Serving on SEPs
Lipkus, Isaac M., Ph.D.............................Duke University 

Lipsick, Joseph S., M.D., Ph.D................State University of New York at Stony Brook 

Liu, Fei-Fei, M.D.....................................University of Toronto 

Liu, Hong, Ph.D.......................................University of Oklahoma at Norman 

Liu, Tiepu, M.D. ......................................PPD Development 

Lobuglio, Albert F., M.D.........................University of Alabama at Birmingham 

Loda, Massimo F., M.D...........................Dana-Farber Cancer Institute 

Loew, Murray H., Ph.D. ..........................George Washington University 

London, Jack W., Ph.D. ...........................Thomas Jefferson University Kimmel Cancer 

Center 

Longnecker, Daniel S., M.D. ...................Dartmouth Medical School 

Lotze, Michael T., M.D., Ph.D. ...............University of Pittsburgh at Pittsburgh 

Lu, Jian-Yu X., Ph.D. ..............................University of Toledo 

Lu, Lee-Jane W., Ph.D.............................University of Texas Medical Branch at Galveston 

Ludwig, Logan T., Ph.D. .........................Loyola University Medical Center 

Lustig, Arthur J., Ph.D.............................Sloan-Kettering Institute for Cancer Research 

Lyerly, Herbert K., M.D. .........................Duke University Medical Center 

Lynch, James F., M.B.A. .........................Fox Chase Cancer Center 

Lynch, Richard G., M.D., Ph.D. ..............University of Iowa 

Lyn-Cook, Beverly D., Ph.D. ..................Food and Drug Administration 

M Mac Nee, Marjorie...................................Crozer Regional Cancer Center 

Mach, Robert H., Ph.D.............................Wake Forest University 

Macoska, Jill A., Ph.D. ............................University of Michigan at Ann Arbor 

Mahvi, David M., M.D., Ph.D. ................University of Wisconsin Hospitals and Clinic 

Maihle, Nita J., Ph.D................................Mayo Clinic, Rochester 

Majumdar, Arun, Ph.D.............................University of California at Berkeley 

Makrigiorgos, G. Michael, Ph.D..............Dana-Farber Cancer Institute 

Malkas, Linda H., Ph.D. ..........................Indiana University Indianapolis 

Maloney, David G., M.D., Ph.D. .............Fred Hutchinson Cancer Research Center 

Mandelbaum, Jenny, Ph.D.......................Rutgers, The State University of New Jersey 

Manduca, Armando, Ph.D. ......................Mayo Clinic, Rochester 

Manni, Andrea, M.D................................Pennsylvania State University, Hershey Medical 

Center 

Marino, Christina, M.D............................Private Practice 

Markland, Francis S., Ph.D......................Pivotal Biosciences 

Marks, Carolene, A.B. .............................Consultant 

Marks, James D., M.D., Ph.D. .................University of California at San Francisco 

Marshall, James R., Ph.D.........................Roswell Park Cancer Institute 

Marshall, Lynn M., Sc.D. ........................Oregon Health and Science University 

Marsted, Marcia Reid...............................Yale University 

Masys, Daniel R., M.D. ...........................University of California at San Diego 

Maurin, Michael B., Ph.D........................Qs Pharmaceuticals 

Mazurchuk, Richard V., Ph.D..................Roswell Park Cancer Institute 

McAllister, Pamela K., Ph.D. ..................Colon Cancer Alliance 

McBride, William H., Ph.D. ....................University of California at Los Angeles 

McCance, Dennis J., Ph.D. ......................University of Rochester 

McCarty, Kenneth S., M.D., Ph.D...........University of Pittsburgh at Pittsburgh 

McClain, Mark S., Ph.D...........................Vanderbilt University 

McClure, Jennifer B., Ph.D......................Group Health Cooperative of Puget Sound 

Appendix C-3: Consultants 

Serving on SEPs
McConkey, David J., Ph.D. .....................University of Texas, MD Anderson Cancer Center 

McCormick, David L., Ph.D....................IT Research Institute 

McCubrey, James A., Ph.D......................East Carolina University 

McDonald, Jamie M., M.S.W..................Presbytarian Hospital 

McGarrity, Gerard J., Ph.D......................Genetic Therapy, Inc. 
McKay, Paul P. ........................................Patient Advocate 

McKeown, Robert E., Ph.D. ....................University of South Carolina at Columbia 

McLarty, Jerry W., Ph.D..........................University of Texas Health Center at Tyler 

McMillan, Minnie, Ph.D..........................Sequella, Inc. 

McNeil, Ann E., R.N. ..............................University of Miami 

McPherson, John D., Ph.D.......................Washington University 

Meadows, Gary G., Ph.D.........................Washington State University 

Melese, Teri, Ph.D. ..................................Columbia University at New York, Morningside 

Mercer, Shawna L., Ph.D.........................Centers for Disease Control and Prevention 

Merriman, Ronald L., Ph.D. ....................Parke Davis Pharmaceutical Research Institute 

Mesirov, Jill P., Ph.D...............................Whitehead Institute for Biomedical Research 

Metcalf, Brian W., Ph.D. .........................Kosan Biosciences 

Mettlin, Curtis J., Ph.D. ...........................Roswell Park Cancer Institute 

Metz, Charles E., Ph.D.............................University of Chicago 

Meydani, Mohsen, D.V.M., Ph.D............International Association of Biomedical 

Gerontology 

Meyer, Tobias, Ph.D. ...............................Federation of American Societies for Experimental 

Biology 

Meyers, Craig M., Ph.D...........................Pennsylvania State University, Hershey Medical 

Center 

Meyn, Raymond E., Ph.D. .......................Introgen Therapeutics, Inc. 

Meyskens, Frank L., M.D. .......................SRI International 

Miles, Steven A., M.D. ............................University of California at Los Angeles 

Miller, Donald M., M.D., Ph.D................University of Louisville 

Miller, Jeffrey E., Ph.D............................IVS Technologies, LLC 

Miller, Norman, Ph.D. .............................University of Mississippi Medical Center 

Mills, Susan S., B.S. ................................Vanderbilt University 

Minden, Mark D., M.D., Ph.D.................Princess Margaret Hospital 

Mirand, Amy L., Ph.D. ............................Roswell Park Cancer Institute 

Mischel, Paul S., M.D..............................University of California at Los Angeles 

Mitchell, Edith P., M.D............................Thomas Jefferson University 

Mitchell, Malcolm S., M.D......................Wayne State University 

Mitra, Sankar, Ph.D. ................................University of Massachusetts Medical School at 

Worcester 

Mock, Jeremiah, Ph.D..............................University of California at San Francisco 

Molnar-Kimber, Katherine L., Ph.D........University of Pennsylvania 

Monahan, Jennifer L., Ph.D.....................University of Georgia 

Moorman, Patricia G., Ph.D.....................Yale University 

Morgan, Jennifer, M.H.A.........................Medical University of South Carolina 

Morgan, Lee R., M.D., Ph.D....................Dekk-Tec, Inc. 

Morgan, William F., Ph.D. ......................University of Maryland 

Morra, Marion E., M.A............................Morra Communications 

Morris, Selma J., M.Ed. ...........................Grady Health System 

Morrow, Gary R., Ph.D............................University of Rochester 

Mortenson, Lee E., D.P.A........................Association of Community Cancer Centers 

Moses, Harold L., M.D., Ph.D.................Vanderbilt University 

Moses, William W., Ph.D. .......................University of California-Lawrence Berkeley 

Laboratory 

Mossman, Kenneth L., Ph.D....................Arizona State University 

Appendix C-3: Consultants 

Serving on SEPs
Mourant, Judith R., Ph.D. ........................University of California-Los Alamos National 

Laboratory 

Moyer, James D., Ph.D. ...........................Pfizer, Inc. 

Muddiman, David C., Ph.D. ....................Mayo Clinic, Rochester 

Muehllehner, Gerd, Ph.D.........................UGM Medical Systems, Inc. 

Mukhtar, Hasan, Ph.D..............................University of Wisconsin at Madison 

Mullaney, Holly C. ..................................Winchester Medical Center 

Mulvihill, John J., M.D............................Medical College of Ohio at Toledo 

Mun, Seong K., Ph.D...............................Georgetown University 

Munshi, Nikhil C., M.D., Ph.D................University of Arkansas at Little Rock 

Murphy, James R., Ph.D. .........................National Jewish Medical and Research Center 

Murphy, William J., Ph.D........................University of Tennessee Health Sciences Center 

Murthy, Anand, Ph.D...............................Intel Corporation 

Muschel, Ruth J., M.D., Ph.D..................University of Pennsylvania 

Musgrove, Lewis C..................................US TOO International, Inc. 

Myers, Cynthia D., Ph.D..........................University of California at Los Angeles 

N Naeve, Clayton W., Ph.D.........................St. Jude Children’s Research Hospital 

Nairn, Rodney S., Ph.D............................University of Texas, MD Anderson Cancer Center 

Najjar, Sonia M., Ph.D.............................Medical College of Ohio at Toledo 

Nasim, Suhail, M.D., Ph.D. .....................Medical College of Virginia 

Navarro, Ana M., Ph.D. ...........................University of California at San Diego 

Nedelkov, Dobrin, Ph.D...........................Intrinsic Bioprobes Inc. 

Needham, Thomas E., Ph.D.....................University of Rhode Island 

Nelson, David, Ph.D. ...............................Medical College of Ohio at Toledo 

Nelson, Peter S., M.D. .............................Fred Hutchinson Cancer Research Center 

Nelson, Randall W., Ph.D........................Intrinsic Bioprobes, Inc. 

Nelson, Richard L., M.D..........................University of Illinois at Chicago 

Neufeld, Elizabeth F., Ph.D. ....................National Institutes of Health 

Neuhausen, Susan L., Ph.D......................University of California at Irvine 

Neuwelt, Edward A., M.D. ......................Oregon Health and Science University 

Newcomb, Elizabeth W., Ph.D. ...............New York University 

Newcomer, Marcia E., Ph.D. ...................Louisiana State University A&M College at Baton 

Rouge 

Nicholas, Barbara L., A.O.C.N., M.S.N., R.N. Baptist Hospital East 

Nichols, Craig R., M.D. ...........................Oregon Health and Science University 

Nicosia, Santo V., M.D............................University of South Florida 

Nie, Shuming, Ph.D. ................................Emory University 

Nitiss, John L., Ph.D. ...............................St. Jude Children’s Research Hospital 

Noe, Dennis A., M.D. ..............................Pfizer Inc. 

Noring, Lois E., R.N. ...............................American Cancer Society 

Norling, Gretchen ....................................University of Kentucky 

Normolle, Daniel P., Ph.D. ......................University of Michigan 

O O’Brien, Thomas G., Ph.D.......................Lankenau Institute for Medical Research 

Obuchowski, Nancy, Ph.D.......................Cleveland Clinic Foundation 

Oda, Dolphine, D.D.S..............................University of Washington 

O’Fallon, Judith R., Ph.D.........................Mayo Clinic 

Oh, Seajin, Ph.D.......................................SRI International 

O’Hair, Dan, Ph.D. ..................................University of Oklahoma, Health Sciences Center 

Appendix C-3: Consultants 

Serving on SEPs
O’Hara, John H., Ph.D.............................National Security Agency 

Okada, Craig Y., M.D., Ph.D...................University of Michigan 

Olch, Arthur J., Ph.D. ..............................Childrens Hospital at Los Angeles 

Oleske, Denise M., Ph.D..........................Rush-Presbyterian-St. Lukes Medical Center 

Olive, Peggy L., Ph.D. .............................British Columbia Cancer Research Centre 

Olopade, Olufunmilayo I., M.D...............University of Chicago 

Olsen, Larry K., Dr.P.H., M.A.T. ............New Mexico State University at Las Cruces 
O’Malley, Bert, M.D................................Baylor College of Medicine 

Omel, James Lloyd, M.D.........................Leukemia, Lymphoma, Myeloma Society 

Ondrey, Frank G., M.D., Ph.D.................University of Minnesota at Twin Cities 

Orlando, Ron, Ph.D..................................University of Georgia 

Orr-Weaver, Terry L., Ph.D.....................Whitehead Institute for Biomedical Research 

Ossowski, Liliana, Ph.D...........................Mount Sinai School of Medicine 

P Page, Rodney, DVM ...............................Cornell University at Ithaca 

Pajak, Thomas F., Ph.D. ..........................American College of Radiology 

Palefsky, Joel M., M.D. ...........................University of California at San Francisco 

Pallonen, Unto E., Ph.D...........................University of Michigan at Ann Arbor 

Pardue, Mary-Lou L., Ph.D. ....................Massachusetts Institute of Technology 

Parker, Carl S., Ph.D................................California Institute of Technology 

Parles, Karen, M.L.S................................Lung Cancer Online 

Paskett, Electra D., Ph.D..........................Ohio State University 

Pasqualini, Renata R., Ph.D.....................University of Texas 

Patchell, Roy A., M.D., Ph.D. .................University of Kentucky 

Patriotis, Christos F., Ph.D.......................Fox Chase Cancer Center 

Paul, Diane B., Ph.D. ...............................Ovarian Advisory Board of SHARE 

Pavlik, John, Ph.D....................................Columbia University 

Payne, Gregory J., Ph.D...........................Emerson College 

Peck, Garnet E., Ph.D. .............................Purdue University, School of Pharmacy 

Peehl, Donna M., Ph.D. ...........................Stanford University, School of Medicine 

Pence, Barbara C., Ph.D...........................Texas Tech University, Health Sciences Center 

Pereira, Michael A., Ph.D. .......................Medical College of Ohio at Toledo 

Pergolizzi, Robert G., Ph.D. ....................North Shore University Hospital, Cornell University 

Peri, Prasad, Ph.D. ...................................Food and Drug Administration 

Perou, Charles M., Ph.D. .........................University of North Carolina at Chapel Hill 

Perry, David K., Ph.D. .............................Medical University of South Carolina 

Pestell, Richard G., M.D., Ph.D...............Georgetown University 

Peterson, Leif E., Ph.D.............................Baylor College of Medicine 

Petrak, Gina, B.A.....................................National Breast Cancer Coalition 

Pezzuto, John M., Ph.D............................Purdue University at West Lafayette 

Phillips, Peter C., M.D.............................Children’s Hospital of Philadelphia 

Phillips, Theodore L., M.D. .....................University of California at San Francisco 

Pienta, Kenneth J., M.D...........................University of Michigan at Ann Arbor 

Pieper, Russ, Ph.D. ..................................University of California, San Francisco Cancer 

Center 

Pincus, Matthew R., M.D., Ph.D. ............State University of New York, Downstate Medical 

Center 

Pipe, James G., Ph.D................................St. Joseph’s Hospital and Medical Center 

Platz, Charles E., M.D. ............................University of Iowa 

Pleasure, David E., M.D. .........................Children’s Hospital of Philadelphia 

Podack, Eckhard R., M.D., Ph.D. ............University of Miami at Coral Gables 

Pogue, Brian W., Ph.D.............................Dartmouth College 

Pollay, Richard W., Ph.D.........................University of British Columbia 

Pollock, Brad H., Ph.D.............................Foundation for The Children’s Oncology Group 

Polverini, Peter J., D.D.S., D.M.Sc..........University of Michigan at Ann Arbor 

Pomper, Martin G., M.D., Ph.D...............Johns Hopkins University 

Poola, Indra, Ph.D....................................Howard University 

Appendix C-3: Consultants 

Serving on SEPs
Porter, Carl W., Ph.D...............................Roswell Park Cancer Institute 

Posner, Marshall R., M.D. .......................Beth Israel Deaconess Medical Center 

Pouget, Alexandre, Ph.D..........................University of Rochester 

Prados, Michael D., M.D. ........................University of California at San Francisco 

Prewitt, Theresa E., Ph.D.........................Loyola University of Chicago 

Price, Pat, D.Sc. .......................................University of Manchester 

Prokhorov, Alexander V., M.D., Ph.D.....University of Texas, MD Anderson Cancer Center 

Q Quake, Stephen R., Ph.D. ........................California Institute of Technology 

Quaranta, Vito, M.D. ...............................Scripps Research Institute 

Query, James L., Ph.D. ............................University of Houston 

Quesenberry, Peter J., M.D......................Roger Williams Hospital 

Quigley, James P, Ph.D............................Scripps Research Institute 

Quint, Marleen M.....................................Patient Navigator 

R Raab-Traub, Nancy J., Ph.D. ...................University of North Carolina at Chapel Hill 

Rabinovitch, Peter S., M.D., Ph.D...........University of Washington 

Raich, Peter C., M.D................................AMC Cancer Research Center 

Rangnekar, Vivek M., Ph.D.....................University of Kentucky 

Raschke, William C., Ph.D. .....................Genstar Therapeutics 

Ratzan, Scott C., M.D. .............................Tufts University, School of Medicine 

Raubitschek, Andrew A., M.D., Ph.D. ....City of Hope, National Medical Center 

Ray, Eileen Berlin, Ph.D..........................Cleveland State University 

Raymond, Pamela A., Ph.D. ....................University of Michigan at Ann Arbor 

Reader, Steven, Ph.D. ..............................University of South Florida 

Recce, Michael L., Ph.D. .........................New Jersey Institute of Technology 

Redd, William H., Ph.D...........................Mount Sinai School of Medicine 

Reddick, Wilburn E., Ph.D. .....................St. Jude Children’s Research Hospital 

Reed, Eddie, M.D.....................................West Virginia University 

Reeves, Anthony P., Ph.D........................Cornell University, Ithaca 

Reichert, David E., Ph.D..........................Washington University 

Reiss, Michael, M.D. ...............................University of Medicine and Dentistry of New Jersey 

Rempel, Sandra A., Ph.D.........................Case Western Reserve University 

Repace, James, M.S.C..............................Repace Associates, Inc. 

Rhodus, Nelson L., D.M.D. .....................University of Minnesota at Twin Cities 

Richards, Nigel G., Ph.D. ........................University of Florida 

Riddell, Stanley R., M.D..........................Fred Hutchinson Cancer Research Center 

Ridge, John A., M.D., Ph.D.....................Fox Chase Cancer Center 

Riley, Gerald, M.S.P.H. ...........................Department of Health and Human Services 

Rinker-Schaeffer, Carrie W., Ph.D. .........University of Chicago 

Ritchie, Marylyn D., B.S. ........................Vanderbilt University 

Roberson, Noma L., Ph.D........................Roberson Consulting International 

Roberts, John D., M.D. ............................Virginia Commonwealth University/Medical 

College VA 

Robinson, Daniel R., Ph.D.......................University of California at Davis 

Robinson, Robert A., M.D., Ph.D............University of Iowa 

Rodgers, William H., M.D., Ph.D............University of Alabama at Birmingham 

Rodriguez, Gustavo, M.D. .......................Evanston Northwestern Healthcare 

Rodriquez-Bigas, Miguel, M.D. ..............University of Texas, MD Anderson Cancer Center 

Romano, Louis J., Ph.D. ..........................Wayne State University 

Appendix C-3: Consultants 

Serving on SEPs
Romkes, Marjorie, Ph.D. .........................University of Pittsburgh at Pittsburgh 

Rosenberg, Margie, Ph.D.........................University of Wisconsin at Madison 

Rosenberg, Naomi E., Ph.D.....................Tufts University, Boston 
Rosenthal, Eric T., B.A............................University of Hawaii at Manoa 

Ross, Mark M., Ph.D. ..............................Argonex, Inc. 

Rotenberg, Susan A., Ph.D. .....................Queens College 

Roth, Kevin A., M.D., Ph.D.....................University of Alabama at Birmingham 

Rothenberg, Mace L., M.D. .....................Vanderbilt University 

Rothman, Douglas L., Ph.D.....................Yale University 

Rowe, David T., Ph.D..............................University of Pittsburgh 

Royak-Schaler, Renee, Ph.D....................American Health Foundation 

Rudders, Richard A., M.D. ......................Boston University 

Rundell, M. Kathleen, Ph.D.....................Northwestern University 

Russell, Stephen J., M.D., Ph.D...............Mayo Clinic, Rochester 

Ruth, Thomas J., Ph.D. ............................Triumf/University of British Columbia 

Rutter, Carolyn M., Ph.D.........................Center for Health Studies 

S Said, Jonathan W., M.D., Ph.D................University of California, School of Medicine 

Sakr, Wael A., M.D. ................................Wayne State University 

Salazar, Omar M., M.D............................Oakwood Hospital and Medical Center 

Samet, Jonathan M., M.D. .......................Johns Hopkins University 

Sani, Brahma P., Ph.D. ............................Southern Research Institute 

Sarkar, Fazlul H., Ph.D. ...........................Wayne State University 

Sartor, Oliver, M.D. .................................Louisiana State University 

Savary, Priscilla A., B.A..........................Colorectal Cancer Network 

Sayre, James W., Ph.D.............................University of California at Los Angeles 

Scardino, Peter T., M.D. ..........................Sloan-Kettering Institute for Cancer Research 

Schad, Peter A., Ph.D...............................Alphagene, Inc. 

Scheinberg, David A., M.D., Ph.D. .........Sloan-Kettering Institute for Cancer Research 

Schell, Michael J., Ph.D...........................University of North Carolina at Chapel Hill 

Schiff, Gilbert M., M.D. ..........................Children’s Hospital Medical Center (Cincinnati) 

Schildkraut, Joellen M., Ph.D. .................Duke University 

Schiller, Joan H., M.D. ............................University of Wisconsin at Madison 

Schmale, Michael C., Ph.D......................University of Miami at Coral Gables 

Schnall, Mitchell D., M.D., Ph.D.............University of Pennsylvania 

Schnoll, Robert A., Ph.D. ........................Fox Chase Cancer Center 

Schoeller, Dale A., Ph.D..........................University of Wisconsin at Madison 

Schoenfeld, David A., Ph.D.....................Massachusetts General Hospital 

Scholnick, Steven B., Ph.D......................Washington University 

Schwartz, Ann G., Ph.D...........................Wayne State University 

Schwartz, Gary K., M.D. .........................Sloan-Kettering Institute for Cancer Research 

Schwartz, Stuart, M.D., Ph.D...................University of Medicine and Dentistry of New Jersey 

Schymura, Maria J., Ph.D. .......................New York State Cancer Registry 

Scott, Charles B., Ph.D. ...........................American College of Radiology 

Secrist, John A., Ph.D. .............................Southern Research Institute 

Seftor, Richard E.B., Ph.D.......................University of Iowa 

Sellers, William R., M.D. ........................Dana-Farber Cancer Institute 

Senie, Ruby T., Ph.D. ..............................Columbia University Health Sciences 

Serody, Jonathan S., M.D., Ph.D. ............University of North Carolina at Chapel Hill 

Shabot, M. Michael, M.D. .......................Cedars-Sinai Medical Center 

Shamsuddin, Abulkalam M., M.D., Ph.D. University of Maryland School of Medicine 

Sharlow, Elizabeth R., Ph.D. ...................Prolx Pharmaceuticals, LP 

Sharma, Sheela, M.D. ..............................Cellular and Molecular Toxicology Program 

Appendix C-3: Consultants 

Serving on SEPs
Shen, Yu, Ph.D.........................................University of Texas, MD Anderson Cancer Center 

Sherman, David H., Ph.D.........................Chromaxome Corporation 

Shewach, Donna S., Ph.D. .......................University of Michigan at Ann Arbor 

Shibata, Darryl K., M.D., Ph.D................University of Southern California 

Shields, Anthony F., M.D., Ph.D.............Wayne State University 

Shih, Le-Ming, M.D.................................Johns Hopkins University 

Shively, John E., Ph.D. ............................Beckman Research Institute 

Shope, Robert E., M.D.............................University of Texas Medical Branch at Galveston 

Showe, Louise C., Ph.D...........................Wistar Institute 

Shreve, Paul D., M.D...............................University of Michigan at Ann Arbor 

Shroyer, Kenneth R., M.D., Ph.D. ...........University of Colorado Health Sciences Center 

Shu, Xiao O., M.D., Ph.D. .......................Vanderbilt University 

Shyr, Yu, Ph.D.........................................Vanderbilt University Medical School 

Siegal, Gene P., M.D., Ph.D. ...................University of Alabama at Birmingham 

Siegfried, Jill M., Ph.D. ...........................University of Pittsburgh at Pittsburgh 

Siegle, Robert L., M.D.............................University of Texas Health Sciences Center 

Sievert, Maryellen C., Ph.D.....................Missouri University 

Simons, Jonathan W., M.D. .....................Johns Hopkins University, School of Medicine 

Sina, Joseph F., Ph.D. ..............................National Institute on Alcohol Abuse and 

Alcoholism 

Singer, Robert H., Ph.D. ..........................Yeshiva University 

Singh, Karan P., Ph.D. .............................University of North Texas Health Science Center 

Sirover, Michael A., Ph.D........................Temple University Medical Center 

Skates, Steven J., M.D., Ph.D. .................Massachusetts General Hospital 

Skubitz, Amy P., Ph.D.............................Tissue Trust, Inc. 

Slaga, Thomas J., Ph.D. ...........................University of Texas, MD Anderson Cancer Center 

Slater, James M., M.D. ............................Loma Linda University School of Medicine 

Sloan, Jeff A., Ph.D. ................................Mayo Clinic, Rochester 

Slocum, Harry K., Ph.D...........................Roswell Park Cancer Institute 

Slymen, Donald J., Ph.D..........................San Diego State University 

Smathers, James B., Ph.D. .......................University of California at Los Angeles 

Smith, Charles D., Ph.D...........................Pennsylvania State University, Hershey Medical 

Center 

Smith, David I., Ph.D...............................Mayo Clinic, Rochester 

Smith, Gary K., Ph.D...............................Glaxowellcome, Inc. 

Snyder, Leslie B., Ph.D............................University of Connecticut at Storrs 

So, Peter T., Ph.D.....................................Massachusetts Institute of Technology 

Somkin, Carol P., Ph.D............................Kaiser Foundation Research Institute 

Song, Chang W., Ph.D.............................University of Minnesota Medical School 

Soong, Seng-Jaw T., Ph.D. ......................University of Alabama at Birmingham 

Sorrentino, Brian P., M.D. .......................St. Jude Children’s Research Hospital 

Sosman, Jeffrey A., M.D. ........................Vanderbilt University 

Speicher, David W., Ph.D........................Wistar Institute 

Spink, David C., Ph.D..............................Wadsworth Center 

Spitz, Margaret R., M.D...........................University of Texas, MD Anderson Cancer Center 

Stass, Sanford A., M.D. ...........................University of Maryland, Baltimore Professional 

School 

Sternick, Edward S., Ph.D. ......................Tufts-New England Medical Center 

Appendix C-3: Consultants 

Serving on SEPs
Stevens, Richard G., Ph.D. ......................University of Connecticut, School of 

Medicine/Dentistry 

Stewart, Carleton C., Ph.D.......................Roswell Park Cancer Institute 

Stewart, Clinton F., P.H.R.M...................St. Jude Children’s Research Hospital 

Stewart, Keith A., M.D. ...........................University of Toronto 
Stoeckert, Christian J., Ph.D. ...................University of Pennsylvania 

Stoica, Adriana, Ph.D...............................Georgetown University 

Stokoe, David H., Ph.D............................University of California at San Francisco 

Stoler, Mark H., M.D...............................University of Virginia at Charlottesville 

Stoner, Gary D., Ph.D. .............................Ohio State University 

Storey, C. Porter, M.D. ............................American Academy/Hospice and Palliative 

Medicine 

Story, Jon, Ph.D. ......................................Purdue University 

Stott, William, Ph.D.................................Dow Chemical Company 

Stotts, R. Craig, Ph.D...............................University of Tennessee Health Sciences Center 

Strauss, Gary M., M.D.............................Roger Williams Hospital 

Strickland, Paul T., Ph.D. ........................Johns Hopkins University 

Strong, Gary W., Ph.D.............................National Science Foundation 

Stubbs, James B., Ph.D. ...........................Proxima Therapeutics, Inc. 

Studzinski, George P., M.D., Ph.D. .........University of Medicine and Dentistry of New Jersey 

Stuhldreher, Wendy L., Ph.D...................Slippery Rock University 

Su, Yan A., M.D., Ph.D. ..........................Georgetown University 

Sumner, Ii, Walton, M.D. ........................Barnes-Jewish Hospital 

Sussman, Daniel J., Ph.D.........................University of Maryland, Baltimore Professional 

School 

Suszka, Sylvia, M.N.................................Group Health Cooperative 

T Talavera, Gregory A., M.D., Ph.D...........San Diego State University 

Tan, Lee K., M.D.....................................Memorial Sloan-Kettering Cancer Center 

Tan, Tse-Hua, Ph.D. ................................Baylor College of Medicine 

Tan, Wai-Yuan, Ph.D...............................University of Memphis 

Taren, Douglas L., Ph.D. .........................University of Arizona, College of Medicine 

Tatum, James L., M.D. ............................Virginia Commonwealth University 

Taylor, Jeremy M., Ph.D..........................University of Michigan at Ann Arbor 

Taylor, Kathryn L., Ph.D. ........................Georgetown University 

Telang, Nitin T., Ph.D..............................Strang Cancer Prevention Center 

Tepper, Joel E., M.D................................University of North Carolina 

Thakur, Mathew L., Ph.D. .......................Thomas Jefferson University 

Therneau, Terry M., Ph.D........................Mayo Clinic and Foundation 

Thomas, Michael J., Ph.D........................Wake Forest University 

Thomason, Nancy ....................................Patient Advocate 

Thor, Ann D., M.D...................................University of Oklahoma Health Sciences Center 

Thorley-Lawson, David A., Ph.D. ...........Tufts University at Boston 

Thrall, Brian D., Ph.D..............................Battelle Pacific Northwest Laboratories 

Tilley, Barbara C., M.D., Ph.D. ...............Case Western Reserve University 

Tindall, Donald J., Ph.D...........................Mayo Clinic, Rochester 

Tockman, Melvyn S., M.D., Ph.D. ..........University of South Florida 

Toga, Arthur W., Ph.D.............................University of California at Los Angeles 

Tolias, Peter P., Ph.D...............................Public Health Research Institute 

Torok-Storb, Beverly J., Ph.D. ................Fred Hutchinson Cancer Research Center 

Triche, Timothy J., M.D., Ph.D. ..............Children’s Hospital, Los Angeles 

Tropsha, Alexander E., Ph.D. ..................University of North Carolina at Chapel Hill 

True, Lawrence D., M.D..........................University of Washington 

Truitt, Robert L., Ph.D.............................Medical College of Wisconsin 

Tsao, Ming-Sound S., M.D......................Princess Margaret Hospital 

Appendix C-3: Consultants 

Serving on SEPs
Tsui, Benjamin M., Ph.D. ........................Johns Hopkins University 

Turchi, John J., Ph.D................................Wright State University 

Turkson, James K., Ph.D. ........................H. Lee Moffitt Cancer Center and Research Institute 

Turner, James N., Ph.D............................Wadsworth Center, New York State Department 

Turner, Larry W., B.S. .............................Emory University 

Turner, Timothy, Ph.D.............................Tuskegee University 

Tyson, Julian F., Ph.D..............................University of Massachusetts 

U Urban, Nicole D., D.Sc. ...........................Fred Hutchinson Cancer Research Center 

V Valentino, Daniel J., Ph.D. ......................University of California at Los Angeles 

Valerie, Kristoffer, Ph.D..........................Virginia Commonwealth University 

Van Breemen, Richard B., Ph.D..............University of Illinois at Chicago 

Van Der Schyf, Cornelis J., D.Sc.............Virginia Polytechnic Institute and State University 

Van Meir, Erwin G., Ph.D. ......................Emory University 

Vannier, Michael W., M.D. .....................University of Iowa 

Varella-Garcia, Marileila, Ph.D...............University of Colorado Health Sciences Center 

Vaughan, John T., M.D., Ph.D.................Fred Hutchinson Cancer Research Center 

Vaughan, Thomas L., M.D. .....................Fred Hutchinson Cancer Research Center 

Verma, Ajit K., Ph.D. ..............................University of Wisconsin at Madison 

Verschraegen, Claire F., M.D. .................University of New Mexico at Albuquerque 

Vieweg, Johannes W., M.D. ....................Duke University 

Vigushin, David, Ph.D.............................Imperial College of Science, Technology and 

Medicine 

Villarreal, Roberto, M.D., Ph.D...............National Hispanic Leader, INIT/CNCR 

Virnig, Beth A., Ph.D...............................University of Minnesota at Twin Cities 

Visuri, Steven R., Ph.D............................University of California-Lawrence Livermore 

National Lab 

Vogel, John S., Ph.D................................Biocams International, Inc. 

Vose, Julie M., M.D.................................University of Nebraska Medical Center 

Votaw, John R., Ph.D...............................Emory University 

W Waldman, Scott A., M.D., Ph.D. .............Thomas Jefferson University 

Walle, Thomas, Ph.D...............................Medical University of South Carolina 

Wands, Jack R., M.D. ..............................Rhode Island Hospital (Providence, RI) 

Wang, Binghe, Ph.D. ...............................North Carolina State University at Raleigh 

Wang, Rong, Ph.D. ..................................University of California at San Francisco 

Wang, Xiaobin, M.D................................Boston Medical Center 

Wang, Yue J., Ph.D..................................Catholic University of America 

Wang, Zhigang, Ph.D...............................University of Kentucky 

Ward, John H., M.D.................................University of Utah 

Ward, Pamela, Ph.D.................................University of California at Irvine 

Ward, Sandra E., Ph.D.............................University of Wisconsin at Madison 

Ware, Carl F., Ph.D..................................La Jolla Institute for Allergy/Immunology 

Wargovich, Michael J., Ph.D...................University of South Carolina at Columbia 

Wassertheil-Smoller, Sylvia W., Ph.D.....Yeshiva University 

Watkins, Simon C., Ph.D.........................Essex Corporation 

Watson, Ada.............................................Dana-Farber Cancer Institute 

Watterson, Daniel M., Ph.D.....................Northwestern University Medical School 

Wear, Keith A., Ph.D...............................Food and Drug Administration 

Appendix C-3: Consultants 

Serving on SEPs
Weber, Jeffrey S., M.D., Ph.D.................University of Southern California 

Weber, Michael J., Ph.D. .........................University of Illinois at Champaign 

Wei, Qingyi, M.D., Ph.D. ........................University of Texas, MD Anderson Cancer Center 

Weick, Martin P., M.S. ............................Baylor College of Medicine 
Weigum, Jeanne, M.S. .............................Association for Non-Smokers, Minnesota 

Weil, Vivian, Ph.D...................................Illinois Institute of Technology 

Weiner, George J., M.D...........................University of Iowa 

Weinkam, Robert, M.D............................Matrix Pharmaceuticals Inc. 

Weinmann, Sheila A., Ph.D.....................Kaiser Foundation Research Institute 

Weir, Hannah K., Ph.D. ...........................Centers for Disease Control and Prevention 

Weis, Marcia R., M.A.Ed. .......................Washington University 

Weiss, Geoffrey R., M.D. ........................University of Texas Health Sciences Center at San 

Antonio 

Weiss, Nancy S., Ph.D.............................Texas Department of Health 

Weissman, Bernard E., Ph.D. ..................University of North Carolina at Chapel Hill 

Weissman, Sherman M., M.D..................Yale University 

Welch, Michael J., Ph.D. .........................Washington University 

Wellstein, Anton, M.D., Ph.D..................Lombardi Cancer Center 

Welsh, John T., Ph.D. ..............................Sidney Kimmel Cancer Center 

Wenzel, Lari B., Ph.D..............................University of California at Irvine 

Werness, Bruce A., M.D..........................INOVA Fair Oaks Hospital 

West, Dee W., Ph.D.................................Northern California Cancer Center 

Westra, William H., M.D.........................The Weinberg Cancer Center 

Whitman, Malcolm R., Ph.D. ..................Harvard University (Medical School) 

Wieand, Samuel H., M.D.........................University of Pittsburgh 

Wiernik, Peter H., M.D............................Our Lady of Mercy Medical Center 

Wiese, Helen Jean C., Ph.D. ....................University of Kentucky 

Wiesenfeld, Martin, M.D.........................Cedar Rapids Oncology Project 

Wiesner, Georgia L., M.D., Ph.D. ...........University of Minnesota at Twin Cities 

Wiktor, Peter J., Ph.D. .............................Engineering Arts 

Wilczynski, Sharon P., M.D., Ph.D. ........City of Hope, National Medical Center 

Wiley, Steven H., Ph.D............................Battelle Pacific Northwest Laboratories 

Williams, Bryan R., Ph.D. .......................Cleveland Clinic Foundation 

Willman, Cheryl L., M.D.........................University of New Mexico at Albuquerque 

Wilson, Brian C., Ph.D. ...........................University of Toronto 

Wilson, David F., Ph.D............................University of Pennsylvania 

Wilson, James M., M.D., Ph.D. ...............University of Pennsylvania 

Wilson, Robert B., M.D., Ph.D................University of Pennsylvania 

Windsor, Richard A., Ph.D. .....................University of Alabama at Birmingham 

Winett, Richard A., Ph.D.........................Virginia Polytechnic Institute and State University 

Witherspoon, Yvonne, B.A......................Dana-Farber Cancer Institute 

Wong, Lee-Jun C., Ph.D. .........................Georgetown University 

Wood, Katherine A., Ph.D.......................Trevigen, Inc. 

Wood, Marie E., M.D. .............................University of Vermont and State Agricultural 

College 

Woodhouse, Carolyn D., M.P.H..............Duval County Public Health Unit 

Woods, Virgil L., M.D.............................University of California at San Diego 

Wooley, Karen L., Ph.D...........................Washington University 

Wu, Xifeng, M.D., Ph.D. .........................University of Texas Health Sciences Center at 

Houston 

X Xu, Ying, Ph.D.........................................Lockheed Martin Energy Research Corp. 

Xuan, Jason J., Ph.D. ...............................Catholic University of America 

Appendix C-3: Consultants 

Serving on SEPs
Y Yabroff, Robin, Ph.D...............................Georgetown University 

Yalowich, Jack C., Ph.D. .........................University of Pittsburgh at Pittsburgh 

Yamamoto, Monica E., Dr.P.H., R.D. .....University of Pittsburgh at Pittsburgh 

Yan, Lin, Ph.D. ........................................Creighton University 

Yaniv, Shlomo, Sc.D. ..............................Consultant 

Yannelli, John R., Ph.D. ..........................University of Kentucky Medical Center 

Yee, Douglas, M.D. .................................University of Minnesota at Twin Cities 

Young, Donn C., Ph.D.............................Ohio State University 

Z Zabriskie, T. M., Ph.D. ............................Oregon State University 

Zagzebski, James A., Ph.D. .....................University of Wisconsin at Madison 

Zarbo, Richard J., M.D. ...........................Henry Ford Hospital 

Zborowski, Maciej, Ph.D.........................Cleveland Clinic Foundation 

Zeisel, Steven H., M.D., Ph.D. ................University of North Carolina at Chapel Hill 

Zhan, Xi, Ph.D. ........................................American National Red Cross 

Zhang, Xiao-Kun, Ph.D. ..........................Burnham Institute 

Zhang, Zuo-Feng, M.D., Ph.D.................University of California at Los Angeles 

Zhao, Yingming, Ph.D.............................Mount Sinai School of Medicine 

 

Total Number of Reviewers: 1,129 

Appendix C-3: Consultants 

Serving on SEPs
Appendix D: Activities of the National Cancer Advisory Board 

Originally established as the National Advisory Cancer Council in 1937, the NCAB consists of 

18 members appointed by the President and 12 nonvoting ex officio members. The NCAB 

advises, assists, consults with, and makes recommendations to the Secretary, DHHS, and to the 

NCI Director with respect to the activities carried out by and through the Institute and on policies 

pertaining to these activities. It is authorized to recommend support for grants and cooperative 

agreements, following technical and scientific peer review. The Director of the DEA serves as 

Executive Secretary of the NCAB. In fulfilling its role as the locus for second-level review of all 

peer-reviewed applications over $50,000 in direct costs, the Board reviewed a total of 4,085 

applications in FY2002. 

The Board heard presentations and discussed and provided advice on a variety of topics and NCI 

activities in FY2002, such as: 

 NCI Cancer Progress Report 

 Improving Palliative Care for Cancer: National Cancer Policy Board Report 

 Progress Review Group Report: Leukemia, Lymphoma, and Myeoloma 

 New Clinical Research Center 

 Medical Oncology Program—Update 

 Melanoma Vaccine Trials 

 Colorectal, Prostate, and Breast Cancer Vaccine Trials 

 Clinical Proteomics 

 Clinical and Molecular Targets 

 Trans-NIH Neuro-Oncology Initiative 

 Office of Policy Analysis and Response—Update 

 Extramural Statistics and Policies—Update 

 Progress Review Group Report: Gynecologic Cancers 

 Progress Review Group Report: Lung Cancer 

 Palliative Care Follow-Up 

 Cancer Survivorship: Moving Beyond the Cure 

 Understanding the Late Effects of Cancer Treatment: A Medical Oncologist’s Perspective 

 Neuropsychological Impact of Systemic Chemotherapy 

 Stress Management: Effects on Quality of Life, Physiological Functioning and Health in 

Cancer Survivors 

 Early Detection and Screening for Breast Cancer 

 Quantifying Population Effects of Mammography 
 New Approaches to Imaging 

 Molecular Profiling of Breast Cancer 

 Portfolio Transfers to National Institute of Biomedical Imaging and Bioengineering 

 NCI Center for Bioinformatics—Update 

 Center for Cancer Research Molecular Diagnostic Reference Lab—Update 

 Implementation of NIH Human Embryonic Stem Cell Policies 

 Policy Update on Peer Review Involving Human Subjects, Data Safety Monitoring, and Data 

Sharing 

 Patient Privacy Regulations—Update 

 Progress Review Group Report: Kidney and Bladder Cancers 

 Overview of the National Cancer Surveillance System and the Latest Statistics 

 Explaining Cancer Trends 

 New Tools for Understanding Cancer Patterns 

 New Tools for Cancer Planning: The State Cancer Profile 

 Using Cancer Surveillance Data for Comprehensive Cancer Control 

 The Hormonal Epidemiology of Breast Cancer 

 Overview of Mechanisms of Hormone Action on Breast Cancer Information Service 

 Normal Breast Development and the Origins of Breast Cancer 

 Extramural Research on Hormones and Breast Cancer 

The NCAB also received regular updates from the NCI Director, the NCI Office of Legislation and 

Congressional Activities, the President’s Cancer Panel, and the National Cancer Policy Board. 

Another major role of the Board is to monitor the overall advisory and oversight activities of the 

NCI as a whole. In that regard, it annually reviews the site visit outcomes of intramural review 

and the extramural RFA and RFP concepts acted upon by the BSA. The NCAB also participates 

in the framing of the annual NCI Bypass Budget and considers the impact of actualized priorities 

as expressed by the allocation of the annual operating budget. 

The full text of recent NCAB meeting summaries is available on the NCI Web site at: 

http://deainfo.nci.nih.gov/advisory/ncabminmenu.htm. 

Appendix D: Activities of the 
Appendix E: Activities of the Board of Scientific Advisors 

The BSA provides scientific advice on a wide variety of matters concerning scientific program 

policy, progress, and future direction of NCI’s extramural research programs, and concept 

review of extramural program initiatives. 

In addition to approving a number of extramural program initiatives (see below), the BSA also 

heard presentations on the following: 

 BSA Concepts Review Report 

 Molecular Profiling of Breast Cancer 

 Spiral CT Partnership—Update 

 BSA at National Meetings (“NCI Listens” Reports) 

 NCI’s Decision-Making Process for Grant Allocation 

 Subcommittee on Training Report: Communicating Training Opportunities 

 Report on RFAs That Involve Large Initiatives 

 BSA at National Meetings: Status Reports 

 NCAB Ad Hoc Working Group on Research Project Grant Report 

 RFA Reissuance Working Group Report 

 Status Report: Clinical Trials Restructuring Initiative and Formation of the Cancer Trials 

Support Unit 

 Mammography—A Continuing Controversy 

 U.S. Preventive Services Task Force: New Recommendations on Screening for Breast Cancer 

 Quantifying the Population Effect of Mammography: Performance and Outcomes 

 Rapid Access to Intervention Development (RAID) Program Progress Report 

 NIGMS/NCI Construction of New Beamlines for Macromolecular X-Ray Crystallography 

 Marketing of NCI Training and Career Development Opportunities Program—Update 

 Serum Proteomic Patterns: A New Paradigm for Early Cancer Detection 

 Expansion of the Biomedical Imaging Program—Update 

 Public/Private Partnerships: Overcoming the Barriers to Early Clinical Trials 

 American College of Radiology Imaging Network (ACRIN)—Update and Future Plans 

RFA Concepts Approved 

Division of Cancer Treatment and Diagnosis 

 Network for Translational Research in Optical Imaging (NTROI) 

 Spiral CT Lung Cancer Screening Trial 
Division of Cancer Prevention 

 Molecular Targets for Nutrients in Prostate Cancer Prevention 

 Chemoprevention of ER-Cancers in Women at High Risk: Preclinical Studies 

 DNA Methylation, Diet and Cancer Prevention 

Division of Cancer Control and Population Sciences 

 Centers for Population Health and Cancer 

Division of Cancer Biology 

 Molecular Interactions Between Tumor Cells and Bone 

Office of the Deputy Director for Extramural Science 

 Aging/Cancer Research Program Development in NCI Cancer Centers 

Cooperative Agreements Approved 

Division of Cancer Epidemiology and Genetics 

 NCI Predoctoral Research Training Partnership Award 

The full text of recent BSA meeting summaries is available on the NCI Web site at: 

http://deainfo.nci. nih.gov/advisory/bsaminmenu.htm. 

Appendix E: NCI Grant Guidelines and 
Appendix F: NCI Grant Guidelines and Descriptions 

Below is a brief description of NIH grants, contracts, and extramural policy notices. Additional 

information about these and other administrative supplements to research grants, guidelines, 

study section rosters, and information on the Center for Scientific Review, NIH, may be obtained 

by contacting the Referral Office, Division of Research, or see the DEA Web page on Grants 

Guidelines and Descriptions at http://deainfo.nci.nih.gov/flash/awards.htm. 

C Series: Research Construction Programs 

C06 Research Facilities Construction Grants 

To provide matching Federal funds, up to 75 percent, for construction or major remodeling to create new research facilities. In addition to basic research laboratories, this may 

include, under certain circumstances, animal facilities and/or limited clinical facilities 

where they are an integral part of an overall research effort. 

F Series: Fellowship Programs 

F31 Predoctoral Individual National Research Service Award (NRSA) 

To provide predoctoral individuals with supervised research training in specified health 

and health-related areas leading toward a research degree (e.g., Ph.D.). 

F31 Predoctoral Fellowship—Minority Students 

A fellowship award that provides predoctoral minority students with supervised research 

training in specified health and health-related areas leading toward the research degree 

(e.g., Ph.D.). 

F31 Predoctoral Fellowship—Students with Disabilities 

A fellowship award that provides predoctoral students with disabilities with supervised 

research training in specified health and health-related areas leading toward the research 

degree (e.g., Ph.D.). 

F32 National Research Service Award for Individual Postdoctoral Fellows 

To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. 

F33 National Research Service Award for Senior Fellows 

To provide opportunities for experienced scientists to make major changes in the 

direction of research careers, broaden scientific backgrounds, acquire new research 

capabilities, enlarge command of an allied research field, or take time from regular 

professional responsibilities to increase capabilities to engage in health-related research. 

K Series: Career Development Programs 

K01 The Howard Temin Award 

An NCI-specific variant of the NIH Mentored Research Scientist Development Award 

that is designed to provide research scientists with an additional period of sponsored 

research experience as a way to gain expertise in a research area new to the applicant or 

in an area that would demonstrably enhance the applicant’s scientific career. 

K01 Mentored Career Development Award for Underrepresented Minorities 

Appendix F: NCI Grant Guidelines and 
To support scientists committed to research who are in need of both advanced research 

training and additional experience. 

K05 Established Investigator Award in Cancer Prevention, Control, Behavioral, and 

Population Research 

To support scientists qualified to pursue independent research that would extend the 

research program of the sponsoring institution, or to direct an essential part of this 

program. 

K07 Cancer Prevention, Control, Behavioral, and Population Sciences Career Development 

Award 

To support the postdoctoral career development of investigators who are committed to 

academic research careers in cancer prevention, control, behavioral, epidemiological, 

and/or the population sciences. It supports up to 5 years of combined didactic and 

supervised (i.e., mentored) research experiences to acquire the methodological and 

theoretical research skills needed to become an independent scientist. The very broad 

nature of the prevention, control, and population sciences makes it applicable to those 

individuals doctorally trained in the basic sciences, medicine, behavioral sciences, and 

public health. The K07 award has been expanded from a scope limited to “preventive 

oncology” to include the entire spectrum of fields that are of vital importance to cancer 

prevention and control such as nutrition, epidemiology, and behavioral sciences. 

K08 Mentored Clinical Scientists Development Award 

To provide the opportunity for promising medical scientists with demonstrated aptitude 

to develop into independent investigators, or for faculty members to pursue research in 

categorical areas applicable to the awarding unit, and to aid in filling the academic 

faculty gap in specific shortage areas within U.S. health professions institutions. 

K08 Mentored Clinical Scientists Development Award—Minorities in Clinical Oncology 

A specialized type of Mentored Clinical Scientist Developmental Awards (K08s) that 

support the development of outstanding clinical research scientists, with this type being 

reserved for qualified individuals from under-represented minority groups. Both types of 

K08 awards support periods of specialized study for clinically trained professionals who 

are committed to careers in research and who have the potential to develop into 

independent investigators. The K08 awards for Minorities in Clinical Oncology are 

distinct and important because they provide opportunities for promising medical 

scientists with demonstrated aptitudes who belong to under-represented minority groups 

to develop into independent investigators, or for faculty members who belong to underrepresented minority groups to pursue research aspects of categorical areas applicable to 

the awarding unit(s), and aid in filling the academic faculty gaps in these shortage areas 

within health professions institutions in the United States. 

K12 Institutional Clinical Oncology Research Career Development Award 

To support a newly trained clinician appointed by an institution for development of 

independent research skills and experience in a fundamental science within the 

framework of an interdisciplinary research and development program. 
K22 The NCI Transition Career Development Award for Underrepresented Minorities 

To provide support to outstanding newly trained basic or clinical investigators to develop 

their independent research skills through a two-phase program: an initial period involving 

an intramural appointment at the NIH and a final period of support at an extramural 

institution. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career. 

K22 The NCI Scholars Program 

To provide an opportunity for outstanding new investigators to begin their independent 

research careers, first within the special environment of the National Cancer Institute and 

then at an institution of their choice. Specifically, this Program provides necessary 

resources to initiate an independent research program of 3 to 4 years at the NCI followed 

by an extramural funding mechanism (K22) to support their research program for 2 years 

at the extramural institution to which they are recruited. 

K23 Mentored Patient-Oriented Research Career Development Award 

To provide support for the career development of investigators who have made a 

commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for a 3-year minimum up to 5-year period of supervised study and 

research for clinically trained professionals who have the potential to develop into 

productive clinical investigators. 

K23 Mentored Patient-Oriented Research Career Development Award for Underrepresented 

Minorities 

To support the career development of investigators who have made a commitment to 

focus their research on patient-oriented research. This mechanism provides support for a 

period of supervised study and research for clinically trained professionals who have the 

potential to develop into productive clinical investigators in patient-oriented research. 

K24 Mid-Career Investigator Award in Patient-Oriented Research 

To provide support for clinicians to allow them protected time to devote to patientoriented research and to act as mentors for beginning clinical investigators. The target 

candidates are outstanding clinical scientists engaged in patient-oriented research who are 

within 15 years of their specialty training, who can demonstrate the need for a period of 

intensive research focus as a means of enhancing their clinical research careers, and who 

are committed to mentoring the next generation of clinical investigators in patientoriented research. 

K25 Mentored Quantitative Research Career Development Award 

This award allows an independent scientist in a highly technical field of research to 

identify an appropriate mentor with extensive experience in cancer research and to 

receive the necessary training and career development required to become involved in 

multidisciplinary cancer research. 

Appendix F: NCI Grant Guidelines 
P Series: Research Program Projects and Centers 

P01 Research Program Projects 

To support multidisciplinary or multifaceted research programs that have a focused 

theme. Each component project should be directly related to and contribute to the 

common theme. 

P20 Exploratory Grants 

To support planning for new programs, expansion or modification of existing resources, 

and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to 

the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers. 

P30 Center Core Grants 

To support shared use of resources and facilities for categorical research by investigators 

from different disciplines who provide a multidisciplinary approach to a joint research 

effort, or by investigators from the same discipline who focus on a common research 

problem. The core grant is integrated with the Center’s component projects or Program 

Projects, though funded independently from them. This support, by providing more 

accessible resources, is expected to assure greater productivity than that provided through 

the separate projects and Program Projects. 

P50 Specialized Center Grants 

To support any part of the full range of research and development from very basic to 

clinical; may involve ancillary supportive activities such as protracted patient care 

necessary to the primary research or R&D effort. This spectrum of activities comprises a 

multidisciplinary attack on a specific disease or biomedical problem area. These grants 

differ from Program Project grants in that they are usually developed in response to an 

announcement of the programmatic needs of an Institute or Division, and subsequently 

receive continuous attention from its staff. Centers also may serve as regional or national 

resources for special research purposes. 

R Series: Research Projects 

R01 Research Project 

Grants are awarded to institutions to allow a Principal Investigator to pursue a scientific 

focus or objective in his or her area of interest and competence. Institutional sponsorship 

assures the NIH that the institution will provide facilities necessary to conduct the 

research and will be accountable for the grant funds. Applications are accepted for healthrelated research and development in all areas within the scope of the NIH’s mission. 

R03 Small Research Grants 

Small grants provide research support, specifically limited in time and amount, for 

activities such as pilot projects, testing of new techniques, or feasibility studies of 

innovative, high-risk research, which would provide a basis for more extended research. 

Appendix F: NCI Grant Guidelines and 
R13 Conferences 

The NIH provides funding for conferences to coordinate, exchange, and disseminate 

information related to its program interests. Generally, such awards are limited to 

participation with other organizations in supporting conferences rather than provision of 

sole support. Costs eligible for support include salaries, consultant services, equipment 

rental, travel, supplies, conference services, and publications. Prospective applicants are 

encouraged to inquire in advance concerning possible interest on the part of an awarding 

Institute/Center (IC), and to obtain more information on application procedures and costs. 

R15 The NIH Academic Research Enhancement Awards (AREA) 

To enhance the research environment of educational institutions that have not been 

traditional recipients of NIH research funds, this award provides limited funds to those 

institutions’ faculty members to develop new research projects or expand ongoing 

research activities in health sciences and to encourage students to participate in the 

research activity. As funds are anticipated to continue to be available each year, the NIH 

is now inviting applications for AREA grants through a standing, ongoing Program 

Announcement. 

R21 Exploratory/Developmental Grants 

To encourage the development of new research activities in categorical program areas. 

(Support generally is restricted in level of support and duration.) 

R24 Resource-Related Research Projects 

To support research projects that will enhance the capability of resources to serve biomedical research. 

R25E Cancer Education Grant Program (CEGP) 

A flexible, curriculum-driven program aimed at developing and sustaining innovative 

educational approaches that ultimately will have an impact on reducing cancer incidence, 

mortality, and morbidity, as well as on improving the quality of life of cancer patients. 

The CEGP accepts investigator-initiated grant applications that pursue a wide spectrum 

of objectives ranging from short courses; to the development of new curriculum in 

academic institutions; to national forums and seminar series; to hands-on workshop 

experiences for the continuing education of health care professionals, biomedical 

researchers, and the lay community; to structured short-term research experiences 

designed to motivate high school, college, medical, dental, and other health professional 

students to pursue careers in cancer research. Education grants can focus on education 

activities before, during, and after the completion of a doctoral level degree, as long as 

they address a need that is not fulfilled adequately by any other grant mechanism 

available at the NIH, and are dedicated to areas of particular concern to the National 

Cancer Program. 

R25T Cancer Education and Career Development Program 

To support development and/or implementation of a program related to a category in one 

or more of the areas of education, information, training, technical assistance, 

coordination, or evaluation. 

Appendix F: NCI Grant Guidelines 
R33 Exploratory/Developmental Grants, Phase II 

To provide a second phase for support of innovative exploratory and developmental 

research activities initiated under the R21 mechanism. Although only R21 awardees are 

generally eligible to apply for R33 support, specific program initiatives may establish 

eligibility criteria under which applications could be accepted from applicants who 

demonstrate program competency equivalent to that expected under R33. 

R37 Method to Extend Research in Time (MERIT) Award 

To provide long-term grant support to investigators whose research competence and 

productivity are distinctly superior and who are highly likely to continue to perform in an 

outstanding manner. Investigators may not apply for a MERIT Award. Program staff 

and/or members of the cognizant National Advisory Council/Board will identify 

candidates for the MERIT Award during the course of review of competing research 

grant applications prepared and submitted in accordance with regular PHS requirements. 

Small Business Innovation Research (SBIR) and Small Business Technology Transfer 

(STTR) Programs 

The NIH welcomes grant applications from small businesses in any biomedical or 

behavioral research area as described in the solicitations below. Support under the SBIR 

program is normally provided for 6 months/$100,000 for Phase I, and 2 years/$500,000 

for Phase II. However, applicants may propose longer periods of time and greater 

amounts of funds necessary for completion of the project. 

R41 STTR Grants, Phase I 

To support cooperative R&D projects between small business concerns and research 

institutions, limited in time and amount; to establish the technical merit and feasibility of 

ideas that have potential for commercialization. 

R42 STTR Grants, Phase II 

To support in-depth development of cooperative R&D projects between small business 

concerns and research institutions, limited in time and amount, whose feasibility has been 

established in Phase I and that have potential for commercial products or services. 

R43 SBIR Grants, Phase I 

To support projects, limited in time and amount, to establish the technical merit and 

feasibility of R&D ideas that may ultimately lead to commercial products or services. 

R44 SBIR Grants, Phase II 

To support in-depth development of R&D ideas whose feasibility have been established 

in Phase I that are likely to result in commercial products or services. 

R55 James A. Shannon Director’s Awards; Guidelines 

To provide a limited award to investigators to further develop, test, and refine research 

techniques; perform secondary analysis of available data sets; test the feasibility of 

innovative and creative approaches; and conduct other discrete projects that can 

demonstrate their research capabilities and lend additional weight to their already 

meritorious applications. 

Appendix F: NCI Grant Guidelines 
S Series: Research-Related Programs 

S06 Minority Biomedical Research Support (MBRS) 

To strengthen the biomedical research and research training capability of ethnic minority 

institutions, and thus establish a more favorable milieu for increasing the involvement of 

minority faculty and students in biomedical research. 

S07 Biomedical Research Support Grants (NCRR BRSG) 

As an example of this funding mechanism, the NIH issued a Request for Applications 

(RFA) in FY2003 in order to provide short-term interim support for institutional activities 

that will strengthen oversight of human subjects research at institutions that receive 

significant NIH support for clinical research. Although there is considerable flexibility in 

the types of activities that could be supported under the BRSG program, this RFA 

emphasized the importance of efforts to enhance the protection of research subjects by 

means that will be sustained by the recipient institution after the award period ends. 

Awardees are also required to collaborate with other institutions conducting human 

subjects research and are not currently funded under this program, to share educational 

resources, computer technologies, best practices, etc. Although all NIH components 

supporting clinical research (including the NCI) are providing support for this program, it 

will be administered by the National Center for Research Resources (NCRR). 

S10 Biomedical Research Support Shared Instrumentation Grants (NCRR SIG) 

The National Center for Research Resources (NCRR) initiated its competitive Shared 

Instrumentation Grant (SIG) Program in FY 1982. Shared Instrumentation Grants 

provide support for expensive state-of-the-art instruments utilized in both basic and 

clinical research. This program is designed to meet the special problems of acquisition 

and updating of expensive shared-use instruments that are not generally available through 

other NIH funding mechanisms, such as the regular research project, program project, or 

center grant programs. Applications for funds to design or to advance the design of new 

instruments are not accepted. The objective of the program is to make available to 

institutions with a high concentration of NIH-supported biomedical investigators 

expensive research instruments that can only be justified on a shared-use basis and for 

which meritorious research projects are described. 

T Series: Training Programs 

T15 Continuing Education Training Grants 

To assist professional schools and other public and nonprofit institutions in the 

establishment, expansion, or improvement of programs of continuing professional education, especially for programs of extensive continuation, extension, or refresher education 

dealing with new developments in the science and technology of the profession. 

T32 NIH National Research Service Award—Institutional Research Training Grants 

To enable institutions to make National Research Service Awards to individuals selected 

by them for predoctoral and postdoctoral research training in specified shortage areas. 

Appendix F: NCI Grant Guidelines 
U Series: Cooperative Agreements 

U01 Research Projects 

To support a discrete, specified, circumscribed project to be performed by the named 

investigators in an area representing their specific interests and competencies. 

U10 Cooperative Clinical Research—Cooperative Agreements 

To support clinical evaluation of various methods of therapy and/or prevention in specific 

disease areas. These represent cooperative programs between participating institutions 

and Principal Investigators, and are usually conducted under established protocols. 

U13 Conference—Cooperative Agreements 

In order to coordinate, exchange, and disseminate information related to its program 

interests, an NIH Institute or Center can use this type of award to provide funding and 

direction for appropriate scientific conferences. These cooperative agreements allow the 

NCI to partner with one or more outside organizations in order to support international, 

national, or regional meetings, conferences, and workshops that are of value in promoting 

the goals of the National Cancer Program. 

U19 Research Program—Cooperative Agreements 

To support a research program of multiple projects directed toward a specific major 

objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and 

often long-term approach. 

U24 Resource-Related Research Projects—Cooperative Agreements 

To support research projects contributing to improvement of the capability of resources to 

serve biomedical research. 

U54 Specialized Center—Cooperative Agreements 

To support any part of the full range of research and development from very basic to 

clinical; may involve ancillary supportive activities such as protracted patient care 

necessary to the primary research or R&D effort. The spectrum of activities comprises a 

multidisciplinary attack on a specific disease entity or biomedical problem area. These 

differ from program projects in that they are usually developed in response to an 

announcement of the programmatic needs of an Institute or Division and subsequently 

receive continual attention from its staff. Centers may also serve as regional or national 

resources for special research purposes, with assistance from staff of the funding 

component in identifying appropriate priority needs. 

U56 Exploratory Grants—Cooperative Agreements 

To support planning for new programs, expansion or modification of existing resources, 

and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to 

the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers. Substantial Federal programmatic staff involvement is intended to 

assist investigators during performance of the research activities, as defined in the terms 

and conditions of award. 

Appendix F: NCI Grant Guidelines 
Appendix G: Cancer Information Sources on the Internet 

DEA Web Sites 

The following Web sites are maintained by the DEA to provide detailed information to 

researchers and the public about NCI funding opportunities and about the advisory Boards and 

groups supported by the DEA. 

http://deainfo.nci.nih.gov/index.htm 

DEA home page. Links to the individual DEA Web pages listed below; mission of the 

Division; contact information for DEA staff. 

http://deainfo.nci.nih.gov/advisory/Boards.htm 

Links to the home pages of NCI’s advisory Boards. 

http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm 

Charter of the President’s Cancer Panel; meeting agendas; meeting minutes; annual 

reports. 

http://deainfo.nci.nih.gov/advisory/ncab.htm 

Charter of the National Cancer Advisory Board; members of subcommittees; meeting 

agendas. 

http://deainfo.nci.nih.gov/advisory/ncabminmenu.htm 

Full text of NCAB meeting summaries. 

http://deainfo.nci.nih.gov/advisory/bsa.htm 

Charter of the Board of Scientific Advisors; members of subcommittees; meeting 

agendas. 

http://deainfo.nci.nih.gov/advisory/bsaminmenu.htm 

Full text of BSA meeting summaries. 

http://deainfo.nci.nih.gov/advisory/bsa/bsa_program/bsaprgr.htm 

Program Review Group reports. 

http://deainfo.nci.nih.gov/advisory/bsc.htm 

Charter of the Board of Scientific Counselors; members of subcommittees. 

http://deainfo.nci.nih.gov/advisory/irg.htm 

Charter of the Initial Review Group; members of subcommittees. 

http://deainfo.nci.nih.gov/advisory/sep.htm 

Charter of the Special Emphasis Panel; rosters of recent meetings. 

http://deainfo.nci.nih.gov/advisory/joint.htm 

Charter of the Advisory Committee to the Director; meeting schedules, agendas, and 

minutes; members of NCI Director’s Working Groups, Program Review Working 

Groups, and Progress Working Groups. 
http://deainfo.nci.nih.gov/advisory/pog/progress/index.htm 

Function and organization of Progress Review Groups, PRG reports and meeting 

schedules; members of PRGs. 

http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm 

Charter of the NCI Director’s Consumer Liaison Group; meeting schedules, agendas, 

minutes, and meeting summaries. 

http://deainfo.nci.nih.gov/funding.htm 

Comprehensive information about funding for cancer research; lists of active PAs and 

RFAs; grant policies and guidelines; downloadable application forms. 

http://deainfo.nci.nih.gov/extra/pa/all_pa.htm 

Active PAs, with links to detailed descriptions. 

http://deainfo.nci.nih.gov/extra/rfa/index.htm 

Active RFAs, with links to detailed descriptions. 

http://deainfo.nci.nih.gov/grantspolicies/index.htm 

Links to full-text NCI and NIH policies related to grants and grant review (e.g., 

Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research

and Instructions to Reviewers for Evaluating Research Involving Human Subjects in 

Grant and Cooperative Agreement Applications). 

http://deainfo.nci.nih.gov/flash/awards.htm 

Grants Guidelines and Descriptions (descriptions of NCI funding mechanisms, with links 

to PAs, RFAs, guidelines, and supplemental materials). 

http://deais.nci.nih.gov/FLAREPublic 

NCI’s Funded Research Portfolio database contains information about research grant and 

contract awards for the current and past five fiscal years. Searchable by text words 

contained in project abstracts and by Special Interest Category (SIC) and anatomic site 

codes. 

http://deainfo.nci.nih.gov/whatsnew/news.htm 

Extramural events and updates. 

NCI Web Sites 

The National Cancer Institute maintains a number of Web sites containing information about the 

Institute and its programs. All NCI Web sites, including those designed to provide cancer-related 

information to the general public and physicians, can be reached from the NCI home page at 

http://cancer.gov/.

Appendix G: Cancer Information Sources on 
Table 1.Applications Received for Referral by 

the NCI (by Mechanism), 

 FY2002* 

 Applications by Board

 Activity Totals by 

Mechanism Code Activity Jan May Sep

Research Facilities Construction Grants C06 1 0 0 1 

Predoctoral Individual National Research Service Award F31 45 0 21 24 

Postdoctoral Individual National Research Service Award F32 306 69 109 128 

National Research Service Award for Senior Fellows F33 7 2 3 2 

Research Scientist Development Award—Research & Training K01 102 32 26 44 

Research Scientist Award K05 7 4 2 1 

Academic/Teacher Award (ATA) K07 80 26 31 23 

Clinical Investigator Award K08 150 47 57 46 

Physician Scientist Award (Program) K12 9 8 0 1 

Career Transition Award K22 54 22 16 16 

Mentored Patient-Oriented Research Development Award K23 43 8 23 12 

Midcareer Investigator Award in Patient-Oriented Research K24 6 2 3 1 

Mentored Quantitative Research Career Development Award K25 1 0 1 0 

Research Program Projects P01 129 45 39 45 

Exploratory Grants P20 38 19 16 3 

Center Core Grants P30 18 10 3 5 

Specialized Center P50 71 30 24 17 

Research Project R01 5,078 1,655 1,668 1,755 

Small Research Grants R03 230 74 79 77 

Conferences R13 155 45 61 49 

Academic Research Enhancement Awards (AREA) R15 71 24 26 21 

Exploratory/Developmental Grants R21 1017 384 238 395 

Resource-Related Research Projects R24 39 34 5 0 

Education Projects R25 74 17 33 24 

Exploratory/Developmental Grants Phase II R33 66 19 24 23 

Method to Extend Research in Time (MERIT) Award R37 19 3 4 12 

Small Business Technology Transfer (STTR) Grants—Phase I R41 76 21 27 28 

Small Business Technology Transfer (STTR) Grants—Phase II R42 23 7 10 6 

Small Business Innovation Research Grants (SBIR)—Phase I R43 928 308 298 322 

Small Business Innovation Research Grants (SBIR)—Phase II R44 237 72 78 87 

(Continued)

• Source: IMPACII. Includes NCI Primary and Secondary assigned applications and withdrawn applications. Excludes 

applications deleted for other funding considerations. Of the 9,346 applications received during the year, 2,831 were not 
recommended for further consideration by the initial review committee, and an additional 1,637 received scores in the bottom 

33 percent and were not submitted for NCAB action.
Table 1.Applications Received for Referral by 

the NCI (by Mechanism), 

 FY2002* (Continued)

 Applications by Board

 Activity Totals by 

Mechanism Code Activity Jan May Sep

James A. Shannon Director’s Award R55 6 3 3 0 

Minority Biomedical Research Support—MBRS S06 4 0 3 1 

Biomedical Research Support Grants (NCRR) S07 24 0 0 24 

Biomedical Research Support Shared Instrumentation S10 2 0 2 0 

Grants (NCRR) 

Continuing Education Training Program T15 6 1 1 4 

Institutional National Research Service Award T32 81 28 37 16 

Research Project (Cooperative Agreements) U01 83 17 27 39 

Cooperative Clinical Research (Cooperative Agreements) U10 23 20 0 3 

Conference (Cooperative Agreement) U13 3 2 1 0 

Research Program (Cooperative Agreement) U19 3 0 2 1 

Resource Related Research Project (Cooperative Agreement) U24 3 0 2 1 

Specialized Center (Cooperative Agreements) U54 8 4 0 4 

Exploratory Grants—Cooperative Agreement (NCI) U56 20 14 0 6 

Overall Totals 9,346 3,076 3,003 3,267 
Table 2.Applications Reviewed by DEA/NCI (by 

Activity), FY2002 

 Applications by Board

 Activity Totals by 

Mechanism Code Activity Jan May Sep 

Research Scientist Development Award—Research & Training K01 98 30 25 43 

Research Scientist Award K05 7 4 2 1 

Academic/Teacher Award K07 80 26 31 23 

Clinical Investigator Award K08 125 41 48 36 

Physician Scientist Award (Program) K12 9 8 0 1 

Career Transition Award K22 53 22 15 16 

Mentored Patient-Oriented Research Development Award K23 32 6 19 7 

Midcareer Investigator Award in Patient-Oriented Research K24 6 2 3 1 

Research Program Projects P01 124 41 38 45 

Exploratory Grants P20 22 14 8 0 

Center Core Grants P30 12 4 3 5 

Specialized Center P50 71 30 24 17 

Research Project R01 178 65 65 48 

Small Research Grants R03 206 53 77 76 

Conferences R13 61 16 21 24 

Exploratory/Developmental Grants R21 304 185 60 59 

Resource-Related Research Projects R24 39 34 5 0 

Education Projects R25 74 17 33 24 

Exploratory/Developmental Grants Phase II R33 58 17 19 22 

Small Business Technology Transfer (STTR) Grants—Phase I R41 13 6 2 5 

Small Business Technology Transfer (STTR) Grants—Phase II R42 5 1 1 3 

Small Business Innovation Research (SBIR) Grants—Phase I R43 162 67 36 59 

Small Business Innovation Research (SBIR) Grants—Phase II R44 30 7 6 17 

Continuing Education Training Program T15 2 1 0 1 

Institutional National Research Service Award T32 77 27 36 14 

Research Project (Cooperative Agreements) U01 72 17 25 30 

Cooperative Clinical Research (Cooperative Agreements) U10 23 20 0 3 

Research Program (Cooperative Agreement) U19 2 0 1 1 

Resource-Related Research Project (Cooperative Agreements) U24 3 0 2 1 

Specialized Center (Cooperative Agreements) U54 4 4 0 0 

Exploratory Grants—Cooperative Agreement (NCI) U56 20 14 0 6 

Overall Totals 1,972 779 605 588 
Table 3.Applications Reviewed by the NCI IRG 

Subcommittees 

 for NCAB Meetings, FY2002

 Types of Applications Number of First Year Direct Total Direct Costs 

NCI IRG Subcommittee Reviewed Applications* Costs Requested Requested

A—Cancer Centers P30, P20 16 $40,672,833 $214,695,210 

C—Basic and Preclinical Reseach P01 59 68,278,272 347,406,686 

D—Clinical Studies P01, R01, U24 28 39,230,220 208,716,843 

E—Cancer Epidemiology, Prevention, P01, R01, R13, R21, 

 and Control U01, U19 30 41,921,295 200,743,760 

F—Manpower and Training K01, K08, K22, K25, 

 R13, T15, T32 329 51,698,514 264,978,199 

G—Education K05, K07, K12, K22, 

 K23, K24, R25 201 37,753,087 193,851,536 

H—Clinical Groups U10, R01 7 61,814,456 372,266,200 

Totals: 670 $341,368,677 $1,802,658,434 

* Includes all applications reviewed; some may have been withdrawn later. 

Table 4.Summary of Investigator-Initiated P01 

Applications Reviewed for 

Each NCAB Meeting, FY2002 

Type of Application Jan 2002 May 2002 Oct 2002 Total for 

 NCAB NCAB NCAB FY2002

New 15 11 10 36 

New Amended 6 10 7 23 

Recompeting 8 12 13 33 

Recompeting Amended 8 3 7 18 

Supplement 3 2 2 7 

Totals: 40 38 39 117 

Table 5. Summary of Review Formats for 

Unsolicited Program Project 

 Applications Reviewed, FY2002 

 Number of Telephone Applicant Accelerated 

NCAB Meeting Applications IRG Review SEP Review Site Visit Conference* Interview Peer Review Committee

January 40 34 6 22 13 5 2 0 

May 38 35 3 24 14 0 2 0 
October 39 35 4 21 13 4 0 1 

Totals: 117 104 13 67 40 9 4 1 

* Includes accelerated peer reviews conducted by telephone conference.
Table 6.Summary of Unsolicited P01 Applications 

by NCI Program 

 Division, FY2002 

 Number of First Year Direct Total Requested 

Program Division Applications Cost Requested Direct Cost 

Division of Cancer Biology (DCB) 44 $50,640,416 $267,623,211 

Division of Cancer Control and Population 

Sciences (DCCPS) 9 11,995,421 56,449,515 

Division of Cancer Prevention (DCP) 6 10,636,398 52,291,138 

Division of Cancer Treatment and 

Diagnosis (DCTD) 58 77,795,883 385,379,514 

Grand Totals 117 $151,068,118 $761,743,378 
NCI/DEA Annual Report 2002 

Table 7. Requests for Applications (RFAs) 

Published by the NCI, FY2002 

 Date of 

RFA Mechanism Title Division Publication

CA-02-002 U56 Cooperative Planning Grant for Division of Cancer 

 Cancer Disparities Research Partnership Treatment and Diagnosis 10/19/01 

CA-02-011 U01 Early Clinical Trials of New Anti-Cancer Division of Cancer 

 Agents With Phase I Emphasis Treatment and Diagnosis 11/19/01 

CA-03-001 U54 Cooperative Grant for Nutritional Modulation 

 of Genetic Pathways Leading to Cancer Division of Cancer Prevention 01/22/02 

CA-03-002 U54 Network for Translational Research: Division of Cancer 

 Optical Imaging Treatment and Diagnosis 08/27/02 

CA-03-003 R01 Molecular Targets for Nutrients in 

 Prostate Cancer Prevention Division of Cancer Prevention 2/13/02 

CA-03-004 R01, R21 Chemoprevention of Tobacco-Related Cancers 

 in Former Smokers: Preclinical Studies Division of Cancer Prevention 2/12/02 

CA-03-005 R01 Chemoprevention of Estrogen Receptor (ER) 

 Negative Breast Cancer Preclinical Studies Division of Cancer Prevention 03/21/02 

CA-03-006 U01 Chemoprevention of Tobacco-Related Cancers 

 in Former Smokers: Clinical Studies Division of Cancer Prevention 03/28/02 

CA-03-007 P50 Centers of Excellence in Cancer Division of Cancer Control 

 Communications Research and Population Sciences 03/21/02 

CA-03-008 U56 Cooperative Planning Grant for Comprehensive Office of Deputy Director 

 Minority Institution/Cancer Center Partnership for Extramural Science 03/28/02 

CA-03-009 P20 Planning Grant for Minority Institution/ Office of Deputy Director 

 Cancer Center Collaboration for Extramural Science 03/28/02 

CA-03-010 U54 Comprehensive Minority Institution/ Office of Deputy Director 

 Cancer Center Partnership for Extramural Science 03/28/02 

CA-03-011 U10 Community Clinical Oncology Program Division of Cancer Prevention 04/24/02 

CA-03-012 U10 Minority-Based Community Clinical 

 Oncology Program Division of Cancer Prevention 04/24/02 

CA-03-013 R01, R21 Molecular Interactions Between Tumor 

 Cells and Bone Division of Cancer Biology 05/09/02 

CA-03-015 P50 In Vivo Cellular and Molecular Imaging Division of Cancer 

 Centers (ICMICs) Treatment and Diagnosis 08/07/02 

CA-03-016 R01, R21 Diet, DNA Methylation and Other Epigenetic 

 Events, and Cancer Prevention Division of Cancer Prevention 09/27/02 

CA-03-018 U56 Cooperative Planning Grant for Cancer Division of Cancer 

 Disparities Research Partnership Program Treatment and Diagnosis 08/28/02 
Table 8.Program Announcements (PAs) Published by 

the NCI, FY2002 

 Date of 

PA Mechanism Title Division Publication

PA-02-001 R21 Exploratory Grant for Behavioral Division of Cancer Control 

 Research in Cancer Control and Population Sciences 10/01/01 

PA-02-002 R01 Clinical Cancer Therapy Research Division of Cancer 

 Treatment and Diagnosis 10/02/01 

PA-02-005 R01, R21 Economic Studies in Cancer Prevention, Division of Cancer Control 

 Screening and Care and Population Sciences 10/04/01 

PA-02-006 R01, R21 Cancer Surveillance Using Health Division of Cancer Control 

 Claims-Based Data System and Population Sciences 10/04/01 

PA-02-075 R41, R42, Innovative Toxicology Models: Division of Cancer 

 R43, R44 SBIR/STTR Treatment and Diagnosis 03/12/02 

PA-02-086 R21 Development of High-Yield Technologies 

 for Isolating Exfoliated Cells in Body Fluids Division of Cancer Prevention 03/21/02 
Table 9.Program Announcements with Special 

Referral (PARs) Published 

 by the NCI, FY2002 

 Date of 

PAR Mechanism Title Division Publication

PAR-02-037 R03 Small Grant Program for Behavioral Division of Cancer Control 

 Research in Cancer Control and Population Sciences 12/13/01 

PAR-02-040 R21 Developmental/Pilot Projects in Cancer Office of Deputy Director 

 Complementary and Alternative Medicine (CAM) for Extramural Science 12/17/01 

PAR-02-042 R21 Colorectal Cancer Screening in Primary Division of Cancer Control 

 Care Practice and Population Sciences 12/20/01 

PAR-02-051 R01 Cancer Therapy-Related Use of Genetically 

 Engineered Mice Division of Cancer Biology 01/28/02 

PAR-02-052 R01, P01, Competing Supplements for Organotypic 

 U01 Models of Cancer Division of Cancer Biology 01/29/02 

PAR-02-068 P50 Specialized Programs of Research Excellence Office of Deputy Director 

 (SPORES) in Pancreatic Cancer for the Year 2002 for Extramural Science 02/25/02 

PAR-02-074 R21, R33, Innovative Toxicology Models for Drug 

 R21/R33 Evaluation: Exploratory/Developmental Grant Division of Cancer Treatment 

 and Phased Innovation Award and Diagnosis 03/12/02 

PAR-02-126 P50 Specialized Programs of Research Excellence Office of Deputy Director 

 (SPORES) in Human Cancer for the Year 2003 for Extramural Science 07/10/02 

PAR-02-175 R01, P01, Diet, DNA Methylation and Other Epigenetic 

 U01, P30 Events, and Cancer Prevention: Competing 

 Supplements Division of Cancer Prevention 09/27/02 

PAR-02-176 R03 Cancer Research Small Grant Program Division of Cancer Prevention 09/27/02 

PAS-02-009 R01 Cohort Studies in Cancer Epidemiology Division of Cancer Control 

 and Population Sciences 10/11/01 
Table 10.RFA Applications Reviewed by the NCI 

(by Mechanism), 

 FY2002* 

 Applications by NCAB Round Direct Costs 

 RFA Activity Requested 

Title of Initiative Number Code Totals Jan May Sep First Year Initiative†

Resource-Related Research Projects CA01-009 R24 1 0 1 0 $29,800 NA 

Centers of Excellence in Cancer 

Communications Research (CECCRS) CA01-019 P50 20 20 0 0 31,121,201 O-6 

Shared Resources for Scientists Not at NCI 

Funded Cancer Centers CA01-020 R24 33 33 0 0 6,368,598 O-3 

Career Transition Award CA01-026 K22 8 8 0 0 80,000 

Tissue and Biological Fluids Bank of 

HIV Related Malignancies CA02-001 U01 6 6 0 0 4,125,656 O-3 

Cancer Disparities Research Partnerships Plan CA02-002 U56 6 0 0 6 3,686,664 C-8 

Community Clinical Oncology Program CA02-003 U10 16 16 0 0 11,403,453 C-3 

Minority-Based Community Oncology Program CA02-004 U10 2 2 0 0 781,191 C-3 

Comprehensive Minority Institution/Cancer 

Center Partnership CA02-005 U54 4 4 0 0 2,608,834 C-8 

Planning Grant for Comprehensive Minority 

Institution/Cancer Center Partnership CA02-006 P20 14 14 0 0 1,577,179 C-8 

Cooperative Planning Grant for Comprehensive 

Minority Institution/Cancer Center Partnership CA02-007 U56 14 14 0 0 3,475,818 C-8 

Chemoprevention of Tobacco-Related Cancers in 

former Smokers: Preclinical Studies CA02-008 R01 18 18 0 0 5,805,612 O-5 

Chemoprevention of Tobacco-Related Cancers in 

former Smokers: Preclinical Studies CA02-008 R21 1 1 0 0 100,000 O-5 

Chemoprevention of Tobacco-Related Cancers in 

former Smokers: Preclinical Studies CA02-009 U01 11 11 0 0 7,769,375 O-5 

Cancer Intervention and Surveillance Monitoring 

Network (CISNET) CA02-010 U01 17 0 17 0 2,650,690 C-5 

Early Clinical Trials of New Anti-Cancer Agents 

With Phase I Emphasis CA02-011 U01 30 0 0 30 13,660,039 C-3 

Cooperative Family Registry for Colorectal 

Cancer Studies CA02-501 U01 6 0 6 0 1,192,077 C-5 

Pediatric Phase I/Pilot Consortium CA02-503 U01 1 0 1 0 2,281,946 C-3 

Letter RFA-Advanced Technology for 

Radiation Therapy CA02-505 U24 2 0 2 0 2,054,339 NA 

Disseminating Evidence Based Intervention 

Resource Products (Letter RFA) CA02-506 R01 3 0 0 3 304,139 O-6 

International Tobacco and Health Research and 

Capacity Building Program** TW02-005 R01 63 0 63 0 

Cancer Research Network Across Healthcare 

Systems CA02-507 U19 1 0 0 1 4,556,837 C-7 

Overall Totals 209 147 22 40 $105,553,456 
* Includes withdrawn applications. 

** Not included in totals. 

† Where applicable, the designation refers to a Bypass Budget “opportunity” or “challenge” initiative as noted on pp. 11 and 12.
Table 11.PA Special Emphasis Panel Applications 

Reviewed by the NCI (by 

Mechanism), FY2002* 

 Applications by NCAB Round Direct Costs

 RFA Activity Requested 

Title of Initiative Number Code Totals Jan May Sep First Year Initiative†

Mentored Patient-Oriented Research 

Development Award PA00-004 K23 3 1 1 1 $350,850 C-6 

Academic/Teacher Award PA00-070 K07 1 0 1 0 115,415 C-6 

Institutional National Research 

Service Award PA00-103 T32 1 0 1 0 189,908 C-6 

Small Grants Program for Cancer 

Epidemiology PA01-021 R03 73 24 28 21 3,583,000 NA 

Non-Mammalian Organisms as 

Models for Anti-Cancer Drug Discovery PA01-042 R01 30 15 0 15 6,764,345 O-4 

Non-Mammalian Organisms as Models 

for Anti-Cancer Drug Discovery PA01-042 R21 30 15 0 15 2,925,000 O-4 

Flexible System to Advance Innovative 

Research (FLAIR) (STTR) Grants—Phase I PA01-091 R41 8 4 0 4 2,231,178 O-4 

Flexible System to Advance Innovative 

Research (FLAIR) SBIR)—Phase I PA01-091 R43 51 27 0 24 10,684,359 O-3 

Flexible System to Advance Innovative 

Research (FLAIR) (SBIR)—Phase II PA01-091 R44 7 2 0 5 2,956,494 O-3 

Cancer Prevention Small Research 

Grants Program PAR00-025 R03 76 20 29 27 3,800,000 NA 

Caner Education Grant Program PAR00-033 R25 6 2 2 2 1,254,819 C-6 

Physician Scientist Award (Program) PAR00-063 K12 1 0 0 1 510,774 C-6 

Cancer Education and Career Development 

Program PAR00-064 R25 3 1 0 2 1,982,132 C-6 

Exploratory Grants PAR00-087 P20 1 0 1 0 1,882,449 C-3 

SPORES: Brain, Head & Neck, GI, 

Prostate, Lymphoma PAR00-087 P50 29 8 21 0 52,340,945 C-3 

Innovative Toxicology Models for Drug 

Evaluation: Exploratory/Developmental 

Grants PAR01-003 R21 6 0 6 0 596,912 NA 

Innovative Toxicology Models for Drug 

Evaluation: Exploratory/Developmental 

Grants Phase II PAR01-003 R33 3 0 3 0 741,396 NA 

Innovative Toxicology Models for Drug 

Evaluation (STTR) Grants—Phase I PAR01-004 R41 1 0 1 0 105,906 NA 

Innovative Toxicology Models for Drug 

Evaluation (SBIR)—Phase I PAR01-004 R43 10 0 10 0 1,704,246 NA 

NCI Mentored Career Development Award 

for Underrepresented Minorities PAR01-016 K01 1 0 1 0 125,550 C-6 

Development of High Yield Technologies for 

Isolating Exfoliated Cells in Body Fluids PAR01-019 R21 7 0 7 0 725,000 O-3 

Phased Application Awards in Cancer 

Prognosis and Prediction PAR01-061 R21 25 12 13 0 $2,570,709 C-5 

(Continued) 
* Includes withdrawn applications. 

† Where applicable, the designation relates to a Bypass Budget “opportunity” or “challenge” initiative as noted on pp. 11 and 12.
Table 11.PA Special Emphasis Panel Applications 

Reviewed by the NCI (by 

Mechanism), FY2002* (Continued) 

 Applications by NCAB Round Direct Costs

 RFA Activity Requested 

Title of Initiative Number Code Totals Jan May Sep First Year Initiative† 

Phased Application Awards in Cancer 

Prognosis and Prediction (SBIR)—Phase II PAR01-061 R33 4 2 2 0 $1,255,890 C-5 

Cancer Prognosis and Prediction—Phase I PAR01-062 R41 1 0 1 0 122,557 C-5 

Molecular Target Drug Discovery for Cancer PAR01-045 R21 119 119 0 0 12,140,000 O-4 

Molecular Target Drug Discovery for Cancer: 

Competing Supplements PAR01-046 P01 1 1 0 0 142,337 O-4 

Molecular Target for Drug Discovery: 

Competing Supplements PAR01-046 R01 12 12 0 0 2,085,000 O-4 

Small Business Innovation Research Grants 

(SBIR)—Phase I PAR01-062 R43 9 2 7 0 792,526 C-5 

Cancer Prognosis and Prediction 

(SBIR)—Phase II PAR01-062 R44 2 1 1 0 158,266 C-5 

Review and Analysis of Tobacco Industry 

Documents PAR01-063 R01 26 12 0 14 6,061,136 O-5 

Development of Novel Technologies for 

In Vivo Imaging PAR01-101 R21 41 19 0 22 4,233,069 O-2 

Development of Novel Technologies for 

In Vivo Imaging Phase II PAR01-101 R33 13 4 0 9 3,920,180 O-2 

Development of Novel Technologies 

for In Vivo Imaging (STTR) Grants—Phase I PAR01-102 R41 2 1 0 1 313,658 O-2 

Development of Novel Technologies for 

In Vivo Imaging (STTR) Grants—Phase II PAR01-102 R42 2 1 0 1 172,417 O-2 

Development of Novel Technologies for 

In Vivo Imaging (SBIR)—Phase I PAR01-102 R43 32 21 0 11 3,492,416 O-2 

Development of Novel Technologies for 

In Vivo Imaging (SBIR)—Phase II PAR01-102 R44 8 1 0 7 1,882,081 O-2 

Innovative Technologies for the Molecular 

Analysis of Cancer PAR01-104 R21 33 7 15 11 3,340,588 O-3 

Innovative Technologies for the Molecular 

Analysis of Cancer Phase II PAR01-104 R33 17 6 6 5 6,995,907 O-3 

Innovative Technologies for the 

Molecular Analysis of Cancer (STTR) 

Grants—Phase I PAR01-105 R41 1 1 0 0 136,740 O-3 

Innovative Technologies for the 

Molecular Analysis of Cancer (STTR) 

Grants—Phase II PAR01-105 R42 1 0 0 1 563,070 O-3 

Innovative Technologies for the 

Molecular Analysis of Cancer (SBIR)— 

Phase I PAR01-105 R43 40 14 17 9 3,998,564 O-3 

Innovative Technologies for the 

Molecular Analysis of Cancer (SBIR)— 

Phase II PAR01-105 R44 7 2 1 4 1,243,388 O-3 

Applications of Innovative Technologies 

for the Molecular Analysis of Cancer, 

Phased Innovation Award PAR01-106 R21 39 10 19 10 4,005,382 O-3 

Applications of Innovative Technologies 

for the Molecular Analysis of Cancer, 

Phase II PAR01-106 R33 16 4 7 5 $9,652,679 O-3 
Table 11.PA Special Emphasis Panel Applications 

Reviewed by the NCI (by 

Mechanism), FY2002* (Continued) 

 Applications by NCAB Round Direct Costs

 RFA Activity Requested 

Title of Initiative Number Code Totals Jan May Sep First Year Initiative† 

Applications of Innovative Technologies 

for the Molecular Analysis of Cancer 

(STTR) Grants—Phase II PAR01-107 R42 2 0 1 1 $217,257 O-3 

Applications of Innovative Technologies 

for the Molecular Analysis of Cancer 

(SBIR)—Phase I PAR01-107 R43 12 3 2 7 1,440,325 O-3 

Applications of Innovative Technologies 

for the Molecular Analysis of Cancer 

(SBIR)—Phase II PAR01-107 R44 1 1 0 0 100,000 O-3 

SPORE Planning Grant PAR01-110 P20 1 0 1 0 1,722,089 C-3 

SPORE: Brain, Breast, Uterine, Cervical PAR01-110 P50 15 0 0 15 27,227,153 C-3 

Academic/Teacher Award PAR01-135 K07 1 0 1 0 126,000 C-6 

Small Grants for Behavioral Research 

and Cancer Control PAR02-037 R03 23 0 0 23 1,175,000 NA 

Competing Supplements for Organotypic 

Models of Cancer PAR02-052 P01 4 0 0 4 200,000 C-1 

Competing Supplements for Organotypic 

Models of Cancer PAR02-052 R01 12 0 0 12 575,000 C-1 

Small Grants Program for Cancer PAR99-006, 

Epidemiology 01-021 R03 32 9 19 4 1,598,585 C-5 

Applications of Innovative Technologies 

for the Molecular Analysis of Cancer PAR99-102 R21 1 0 0 1 100,000 O-2 

Academic/Teacher Award PAR99-108 K07 3 3 0 0 353,828 C-6 

SPORE: Prostate, Breast PAR99-167 P50 5 2 2 1 8,877,937 C-3 

Overall Totals 911 389 227 295 $208,562,412
Table 12.Non-RFA PA SEP Applications Reviewed by 

the NCI 

 (by Mechanism), FY2002* 

 Applications by NCAB Round Direct Costs

 Activity Requested Requested 

Mechanism Code Totals Jan May Sep First Year Total Years

Research Program Projects P01 14 6 3 5 $19,314,168 $126,637,684 

Center Core Grants P30 2 2 0 0 1,677,466 11,308,452 

Specialized Center P50 2 0 1 1 3,657,937 29,343,164 

Research Project R01 5 5 0 0 514,891 723,038 

Small Research Grants R03 2 0 1 1 100,000 299,000 

Conferences R13 59 16 21 22 1,632,955 3,170,495 

Resource-Related Research Projects R24 5 1 4 0 310,997 2,317,558 

Exploratory/Developmental Grants—Phase II R33 2 0 1 1 657,970 1,326,190 

Small Business Innovation Research Grants (SBIR)—Phase I R43 2 0 0 2 283,414 694,689 

Small Business Innovation Research Grants (SBIR)—Phase II R44 5 0 4 1 1,671,668 6,324,791 

Research Project (Cooperative Agreements) U01 5 0 5 0 6,985,911 46,052,523 

Overall Totals 103 30 40 33 $36,807,377 $228,197,584 

*Includes withdrawn applications. 
Table 13.Average Total Cost of Research Program 

Grant Awards, by Division, FY2000, 

FY2001, FY2002 

 FY 2000 FY 2001 FY 2002 Percent Change 

 01-02 00-02 

 Number Cost Number Cost Number Cost No. Cost No. Cost

R01 Average Cost of Award Data 

NCI Overall 3,011 $295,000 3,234 $312,000 3,378 $324,000 4.5 3.8 12.2 9.8 

DCB 1,780 270,000 1,838 280,000 1,942 298,000 5.7 6.4 9.1 10.4 

DCP 65 552,000 122 423,000 126 403,000 3.3 -4.7 93.8 -27.0 

DCTD 852 266,000 915 281,000 918 288,000 0.3 2.5 7.7 8.3 

DCCPS 313 449,000 357 494,000 389 497,000 9.0 0.6 24.3 10.7 

P01 Average Cost of Award Data 

NCI Overall 179 1,599,000 178 1,692,000 173 1,836,000 -2.8 8.5 -3.4 14.8 

DCB 66 1,343,000 61 1,451,000 63 1,571,000 3.3 8.3 .5 17.0 

DCP 8 2,076,000 11 1,776,000 13 1,931,000 18.2 8.7 62.5 -7.0 

DCTD 87 1,723,000 91 1,754,000 80 1,995,000 -12.1 13.7 -8.0 15.8 

DCCPS 18 $1,693,000 15 $2,169,000 16 $2,015,000 6.7 -7.1 -11.1 19.0 

DCB..... Division of Cancer Biology 

DCP..... Division of Cancer Prevention 

DCTD.... Division of Cancer Treatment and Diagnosis 

DCCPS... Division of Cancer Control and Population Sciences 
Table 14.Summary for NCI Grant Awards (by Mechanism) 

for FY2002 

 Award Dollars in Thousands % of NCI Total Competing Success 

 Mechanism Count Dollar Avg. Cost Number Dollar Requested Awarded Rate

RPG R01—Traditional Research Grants 3,378 1,093,908 324 52.41 39.20 3,301 844 25.6 

 P01—Program Projects 173 317,632 1,836 2.68 11.38 98 37 37.8 

 R03—Small Grants 186 14,115 76 2.89 0.51 228 100 43.9 

 R15—Academic Research Enhancement Awards (AREA) 10 1.478 148 0.16 0.05 38 10 26.3 

 R21—Exploratory/Developmental Research 309 57,633 187 4.79 2.07 758 187 24.7 

 R33—Phased Innovation Grant (Phase 2) 79 39,318 498 1.23 1.41 71 22 31.0 

 R29—First Awards 110 12,471 113 1.71 0.45 

 R37—Merit Awards 65 29.445 453 1.01 1.06 13 13 100.0 

 R55—Shannon Awards 9 850 94 0.14 0.03 10 9 90.0 

 U19, U01—Cooperative Agreements 17 17,530 1,031 0.26 0.63 3 2 66.7 

 R01—Program Evaluation 45,273 0.00 1.62 

 Total for RPG POOL Group 4.336 1,629.653 4,760 67.28 58.40 4,520 1,224 27.1 

 P01, R01, R03, R21, R33, U010—Request for Applications 68 28,458 419 1.06 1.02 28 15 53.6 

 U01, U19, U42-Cooperative Agreements (RFAs) 199 148,737 747 3.09 5.33 40 25 62.5 

 Total for RFA/Cooperative Agreements 267 177,195 1,166 4.14 6.35 68 40 58.8 

 U43, U44, R43, R44-Small Business Innovative Research 349 81,324 233 5.42 2.91 785 264 33.6 

 R41, R42-SmaII Business Technology Transfer 25 5,042 202 0.39 0.18 69 19 27.5 

 Total for SBIR/STTR 374 86,366 435 5.80 3.10 854 283 33.1 

 Total for RPG 4.977 1,893,214 6,361 77.22 67.85 5,442 1,547 28.4 

Centers U54-Specialized Center (Cooperative Agreements) 12 16,847 1,404 0.19 0.60 

 Comprehensive Core Grants 36 138,316 3,842 0.56 4.96 4 4 100.0 

 P20-Exploratory Grants 29 6,714 232 0.45 0.24 58 0.0 

 P30, P40, P41, U42-Core Clinical 13 45.145 3,473 0.20 1.62 8 7 87.5 

 P20, P50-Spores 34 94,897 2,791 0.53 3,40 68 23 33.8 

 P30-Core Basic 7 17.834 2,548 0.11 0.64 1 1 100.0 

 Total for CORE 131 319,153 14,290 2.03 11.46 139 35 25.2 

Other U56-Exploratory Grants-Cooperative Agreement (NCI) 14 6,558 468 0.22 0.24 16 10 62.5 

Research U10-Clinical Cooperative Groups 137 163,826 1,196 2.13 5,87 4 3 75.0 

 R09, U09-Scientific Evaluation 1 7,408 7,408 0.02 0.27 

 S06-Minority Biomedical Research Support 3,980 0.00 0.14 

 R24, U24-Research/Resource Grant 65 32,395 498 1.01 1.16 40 19 47.5 

 T15-Training Conference Grants 2 204 102 0.03 0.01 1 0.0 

 Biomedical Research Support Grant 4,253 0.00 0.15 

 

 D43, R13-Conference Grants/International Training Grants 

 in Epidemiology 81 1,989 25 1.26 0.07 77 60 77.9 

 Biomedical Research Support Shared Instrumentation Grants 1,880 0.00 0.07 

 Total for OTHER RESEARCH 300 222,493 9,697 4.65 7.97 138 92 66.7 
Table 14.Summary for NCI Grant Awards (by Mechanism) 

for FY2002 

 (Continued) 

 Award Dollars in Thousands % of NCI Total Competing Success 

 Mechanism Count Dollar Avg. Cost Number Dollar Requested Awarded Rate

Careers R25-Cancer Education 96 26,775 279 1.49 0.96 67 28 41.8 

 K01-Temin Award K01 86 11,739 137 1.33 0.42 76 28 36.8 

 K05-Established Invest. Award in Ca Prevention & Control K05 10 1,206 121 0.16 0.04 7 5 71.4 

 K07-Preventive Oncology Award K07 75 7,023 94 1.16 0.25 71 23 32.4 

 K08-Mentored Clinical Scientist K08 134 13,188 98 208 0.47 113 33 29.2 

 K25-Mentored Quantitative Research Career Dev Award K25 1 138 138 0.02 0.00 2 0.0 

 K12, K14-Mentored Career Award K12 11 7,715 701 0.17 0.213 8 4 50.0 

 K30-Instilutional Curriculum Award K30 1,600 0.00 0.06 

 K23-Mentored Patient-Oriented Research Career Dev, A K23 44 4,673 106 0.68 017 32 14 43.8 

K24-Mid-Career Investigator in Patient-Oriented Research A K24 37 4.226 114 0.57 0.15 10 4 40.0 

 K22-Clinical Research Track K22 22 3,359 153 034 0.12 41 14 34.1 

 Total for CAREERS 420 54,867 1,662 6.52 1,97 360 125 34,7 

 Total Other Research 816 304,135 11,638 12.66 10.90 565 245 43.4 

NRSA T32, T34, T35, T36-NRSA Institution 197 58,455 297 3.06 2.09 79 44 55.7 

 F30, F31, F32, F33, F34-NRSA Fellowships 124 5.219 42 1.92 0.19 211 32 15.2 

 Total for NRSA 321 63,674 339 4.98 2.28 290 76 26.2 

Control P20, P50, R01, R21, U01, U10, U19, U24 

 related to 

 Cancer Prevention and Control, 182 191,598 1,053 2.82 6.87 59 28 47.5 

 Cancer Control Special Populations 18 16,610 923 0.28 0.60 

Construction C06-Construction 1,500 0.00 0.05 

 Total NCI Grants 6,445 2,790,484 34,604 100.00 100.00 6,495 1,931 29.7
Table 15.NCI Special Interest Category (SIC) Dollars 

for FY2002— 

 Percent Change from FY2001* 

 Special Interest 2001 2002 Percent 2001 2002 Percent 2001 2002 Percent 

 Category (SIC) Grants Grants Change Contracts Contracts Change Totals Totals Change

Acquired Immune Deficiency $30,178,570 $26,853,112 -11.02 $5,552,875 $3,762,383 -32.24 $35,731,445 $30,615,495 -14.32 

Adoptive Cell Immunotherapy 54,038,845 62,020,806 14.77 0 0 54,038,845 62,020,806 14.77 

Adv. Manufacturing Technology 22,650,296 12,573,059 -44.49 2,280,914 1,698,837 -25.52 24,931,210 14,271,896 -42.75 

Aging 111,511,570 130,562,127 17.08 4,288,016 8,548,329 99.35 115,799,586 139,110,456 20.13 

Alternative Medicine, Direct 22,487,573 29,883,761 32.89 1,309,367 3,066,382 134.19 23,796,940 32,950,143 38.46 

Alternative Medicine, Indirect 28,206,026 28,408,151 0.72 600,213 1,277,445 112.83 28,806,239 29,685,596 3.05 

Alzheimers Dementia 712,086 1,030,384 44.70 0 0 712,086 1,030,384 44.70 

Arthritis 525,144 1,120,913 113.45 0 0 525,144 1,120,913 113.45 

Asbestos 1,468,410 1,836,892 25.09 0 0 1,468,410 1,836,892 25.09 

Ataxia Telangiectasia 6,377,560 7,916,376 24.13 70,000 34,035 -51.38 6,447,560 7,950,411 23.31 

Autoimmune Diseases 6,121,649 7,067,274 15.45 27,527 23 -99.92 6,149,176 7,067,297 14.93 

Behavior Research, Direct 198,496,112 205,410,803 3.48 3,315,371 4,198,913 26.65 201,811,483 209,609,716 3.86 

Bioengineering 213,564,969 248,182,230 16.21 24,262,167 33,279,602 37.17 237,827,136 281,461,832 18.35 

Biological Response Modifiers 637,679,013 662,169,054 3.84 46,062,079 39,296,508 -14.69 683,741,092 701,465,562 2.59 

Biomaterials Research 12,077,508 19,921,311 64.95 2,754,385 4,017,504 45.86 14,831,893 23,938,815 61.40 

Birth Defects 10,289,795 8,353,572 -18.82 76,288 15,035 -80.29 10,366,083 8,368,607 -19.27 

Bone Marrow Transplantation 67,242,722 65,937,038 -1.94 0 0 67,242,722 65,937,038 -1.94 

Breast Cancer Detection 77,682,291 85,530,617 10.10 4,488,224 3,115,652 -30.58 82,170,515 88,646,269 7.88 

Breast Cancer Education 17,436,053 15,775,726 -9.52 106,755 539 -99.50 17,542,808 15,776,265 -10.07 

Breast Cancer Epidemiology 59,488,529 64,790,564 8.91 3,737,780 2,996,210 -19.84 63,226,309 67,786,774 7.21 

Breast Cancer Genetics 69,754,670 78,160,277 12.05 1,751,642 730,266 -58.31 71,506,312 78,890,543 10.33 

Breast Cancer Prevention 26,501,037 27,877,909 5.203 ,790,133 2,801,617 -26.08 30,291,170 30,679,526 1.28 

Breast Cancer Rehabilitation 12,704,463 12,268,949 -3.430 0 25,707 12,704,463 12,294,656 -3.23 

Breast Cancer Screening 30,797,950 27,483,358 -10.76 1,000,734 0 -100.00 31,798,684 27,483,358 -13.57 

Breast Cancer Treatment 125,885,138 139,311,736 10.67 6,699,684 6,481,948 -3.25 132,584,822 145,793,684 9.96 

Breast Cancer—Basic 103,258,330 124,002,636 20.09 805,504 476,244 -40.88 104,063,834 124,478,880 19.62 

Cancer Survivorship 110,834,449 121,248,170 9.40 2,547,142 2,402,478 -5.68 113,381,591 123,650,648 9.06 

Carcinogenesis, Environmental 460,386,298 489,132,687 6.24 38,806,843 30,671,225 -20.96 499,193,141 519,803,912 4.13 

Cervical Cancer Education 2,875,322 1,988,194 -30.85 0 0 2,875,322 1,988,194 -30.85 

Chemoprevention 87,852,536 108,460,873 23.46 30,497,643 29,238,960 -4.13 118,350,179 137,699,833 16.35 

Chemotheraphy 345,463,751 385,496,067 11.59 26,385,611 20,080,145 -23.90 371,849,362 405,576,212 9.07 

Child Health 39,961,876 42,029,648 5.17 1,831,611 721,264 -60.62 41,793,487 42,750,912 2.29 

Childhood Cancers 115,533,390 134,620,199 16.52 47,060 41,915 -10.93 115,580,450 134,662,114 16.51 

Clinical Trials, Diagnosis 47,170,393 58,080,246 23.13 21,228,951 33,127,604 56.05 68,399,344 91,207,850 33.35 

Clinical Trials, Prevention 53,610,220 54,760,830 2.15 13,749,438 10,723,782 -22.01 67,359,658 65,484,612 -2.78 

Clinical Trials, Therapy 343,992,499 376,474,443 9.44 7,859,885 7,440,726 -5.33 351,852,384 383,915,169 9.11 

Clinical Trials, Other 9,040,036 11,304,651 25.05 367,693 338,023 -8.07 9,407,729 11,642,674 23.76 

Combined Treatment Modalities 230,278,274 242,999,243 5.52 0 0 230,278,274 242,999,243 5.52 

Diabetes 5,152,356 7,215,043 40.03 0 160,380 5,152,356 7,375,423 43.15 

Diagnosis 409,834,044 457,525,593 11.64 32,683,199 45,212,195 38.33 442,517,243 502,737,788 13.61 

Diagnostic Imaging 191,658,854 208,649,190 8.86 19,367,150 28,408,030 46.68 211,026,004 237,057,220 12.34 

Diethylstilbestrol 168,885 799,254 373.25 919,728 1,311,257 42.57 1,088,613 2,110,511 93.87 

Dioxin $1,176,288 $1,203,176 2.29 $0 $0 $1,176,288 $1,203,176 2.29 

(Continued) 

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the 

extramural budget.
Table 15.NCI Special Interest Category (SIC) Dollars 

for FY2002— 

 Percent Change from FY2001 (Continued) 

 Special Interest 2001 2002 Percent 2001 2002 Percent 2001 2002 Percent 

 Category (SIC) Grants Grants Change Contracts Contracts Change Totals Totals Change

DNA Repair $119,512,548 $132,131,096 10.56 $119,877 $1,227,104 923.64 $119,632,425 $133,358,200 11.47 

Drug Development 323,066,785 372,377,063 15.26 48,116,585 32,510,368 -32.43 371,183,370 404,887,431 9.08 

Drug Resistance 84,045,970 91,532,583 8.91 212,005 149,743 -29.37 84,257,975 91,682,326 8.81 

Drugs-Natural Products 117,723,931 129,558,190 10.05 2,291,555 5,655,782 146.81 120,015,486 135,213,972 12.66 

Endocrinology 137,280,270 156,203,671 13.78 6,507,888 5,205,320 -20.02 143,788,158 161,408,991 12.25 

Epidemiology-Biochemical 241,573,239 241,511,924 -0.031 1,591,599 10,454,574 -9.81 253,164,838 251,966,498 -0.47 

Gene Transfer Clinical 15,608,158 19,026,602 21.90 0 0 15,608,158 19,026,602 21.90 

Helicobacter 2,043,806 2,155,965 5.49 0 0 2,043,806 2,155,965 5.49 

Hematology 371,307,415 410,583,465 10.58 3,849,396 5,519,782 43.39 375,156,811 416,103,247 10.91 

Hematopoietic Stem Cell Research 86,508,848 89,663,101 3.65 0 0 86,508,848 89,663,101 3.65 

Hormone Replacement Rx 9,312,758 12,170,912 30.69 0 0 9,312,758 12,170,912 30.69 

Hospice 1,631,747 1,554,969 -4.71 0 0 1,631,747 1,554,969 -4.71 

Iatrogenesis 55,422,201 52,363,969 -5.52 1,742,154 1,344,565 -22.82 57,164,355 53,708,534 -6.05 

Infant Mortality 874,643 415,516 -52.49 0 0 874,643 415,516 -52.49 

Information Dissemination 206,600,804 225,817,314 9.30 89,403,158 101,603,549 13.65 296,003,962 327,420,863 10.61 

Interferon 30,732,837 32,284,204 5.05 0 0 30,732,837 32,284,204 5.05 

Mammography 35,546,409 34,655,900 -2.51 532,160 25,707 -95.17 36,078,569 34,681,607 -3.87 

Metastasis 204,140,797 250,350,433 22.64 1,752,221 3,022,663 72.50 205,893,018 253,373,096 23.06 

Mind/Body Research 11,496,467 11,405,866 -0.79 0 0 11,496,467 11,405,866 -0.79 

Molecular Disease 1,036,211,253 1,158,808,792 11.83 14,765,290 11,969,047 -18.94 1,050,976,543 1,170,777,839 11.40 

Neurofibromatosis 123,168 779,543 532.91 6,288 0 -100.00 129,456 779,543 502.17 

Neurofibromatosis, Related 3,909,631 4,941,020 26.38 0 0 3,909,631 4,941,020 26.38 

Magnetic Resonance Imaging 59,418,389 66,882,447 12.56 0 727,054 59,418,389 67,609,501 13.79 

Nursing Research 7,783,431 9,702,363 24.65 0 0 7,783,431 9,702,363 24.65 

Vitamin A 20,103,753 23,883,101 18.80 249,221 2,123,408 752.02 20,352,974 26,006,509 27.78 

Vitamin C 5,042,409 6,379,668 26.52 250,184 0 -100.00 5,292,593 6,379,668 20.54 

Vitamins, Other 12,413,643 13,073,118 5.31 250,184 816,487 226.35 12,663,827 13,889,605 9.68 

Nutrition 166,036,640 179,032,658 7.83 7,003,494 11,854,416 69.26 173,040,134 190,887,074 10.31 

Nutrition Monitoring 37,655,854 38,850,410 3.17 3,391,635 0 -100.00 41,047,489 38,850,410 -5.35 

Obesity 24,412,132 28,475,968 16.65 53,377 270 -99.49 24,465,509 28,476,238 16.39 

Occupational Cancer 14,643,231 12,992,732 -11.27 1,842,111 861,012 -53.26 16,485,342 13,853,744 -15.96 

Oncogenes 494,908,236 542,665,620 9.65 5,324,228 8,973,622 68.54 500,232,464 551,639,242 10.28 

Organ Transplant Research 76,238,755 75,564,744 -0.88 822,426 0 -100.00 77,061,181 75,564,744 -1.94 

Osteoporosis 1,287,965 1,372,960 6.60 0 0 1,287,965 1,372,960 6.60 

P53 98,703,903 114,641,163 16.15 2,244,701 2,032,371 -9.46 100,948,604 116,673,534 15.58 

Pain 10,031,119 9,302,205 -7.27 0 0 10,031,119 9,302,205 -7.27 

Palliative Care 14,758,958 16,548,850 12.13 0 0 14,758,958 16,548,850 12.13 

PAP Testing 13,235,326 13,578,109 2.59 371,914 76,370 -79.47 13,607,240 13,654,479 0.35 

Pesticides 3,624,649 3,580,892 -1.21 1,248,416 704,095 -43.60 4,873,065 4,284,987 -12.07 

Population Research 10,439,957 10,335,971 -1.00 0 0 10,439,957 10,335,971 -1.00 

Prevention, Primary 252,251,073 286,005,520 13.38 36,878,661 33,630,480 -8.81 289,129,734 319,636,000 10.55 

Radiation-Electromagnetic Fields 202,904 467,375 130.34 0 0 202,904 467,375 130.34 

Radiation-Ionizing 39,545,455 41,945,036 6.07 858,412 156,917 -81.72 40,403,867 42,101,953 4.20 

Radiation-Low-Level Ionizing 16,323,130 13,877,729 -14.98 0 0 16,323,130 13,877,729 -14.98 

Radiation-Non-Ionizing $32,614,611 $34,067,458 4.45 $853,796 $173,319 -79.70 $33,468,407 $34,240,777 2.31 

(Continued) 
Table 15.NCI Special Interest Category (SIC) Dollars 

for FY2002— 

 Percent Change from FY2001 (Continued) 

 Special Interest 2001 2002 Percent 2001 2002 Percent 2001 2002 Percent 

 Category (SIC) Grants Grants Change Contracts Contracts Change Totals Totals Change

Radiation-Non-Ionizing Dx or Rx $75,539,731 $87,338,415 15.62 $0 $727,054 $75,539,731 $88,065,469 16.58 

Radiation-UV 30,109,926 31,910,200 5.98 853,796 173,319 -79.70 30,963,722 32,083,519 3.62 

Radiotherapy 186,129,161 215,427,906 15.74 532,160 418,936 -21.28 186,661,321 215,846,842 15.64 

Radon 2,663,660 3,062,288 14.97 0 0 2,663,660 3,062,288 14.97 

Rare Diseases 30,002,699 36,784,776 22.60 879,260 1,854,127 110.87 30,881,959 38,638,903 25.12 

RAS Inhibitors 7,935,689 11,496,118 44.87 606,331 419,867 -30.75 8,542,020 11,915,985 39.50 

Rehabilitation 21,677,142 21,727,475 0.23 2,219,715 2,270,210 2.27 23,896,857 23,997,685 0.42 

Smokeless Tobacco 8,255,406 9,079,157 9.98 0 108,451 8,255,406 9,187,608 11.29 

Resources 334,403,102 387,027,189 15.74 134,425,385 137,814,273 2.52 468,828,487 524,841,462 11.95 

Rural Populations 19,135,158 26,641,779 39.23 14,903,826 14,940,067 0.24 34,038,984 41,581,846 22.16 

Sexually Transmitted Diseases 35,466,974 40,417,819 13.96 3,268,520 1,443,351 -55.84 38,735,494 41,861,170 8.07 

Smoking and Health 104,961,706 128,987,933 22.89 4,398,006 3,193,683 -27.38 109,359,712 132,181,616 20.87 

Smoking Behavior 69,414,259 73,479,632 5.86 2,247,823 898,311 -60.04 71,662,082 74,377,943 3.79 

Smoking, Passive 3,195,135 5,144,280 61.00 78,300 85,026 8.59 3,273,435 5,229,306 59.75 

Structural Biology 271,979,013 300,907,474 10.64 40,059 4,909,708 12156.19 272,019,072 305,817,182 12.42 

Surgery 129,601,515 139,416,973 7.57 1,498,869 1,197,577 -20.10 131,100,384 140,614,550 7.26 

Taxol 65,996,775 73,218,250 10.94 32,166 115,953 260.48 66,028,941 73,334,203 11.06 

Telehealth 89,809,323 78,386,738 -12.72 50,967,918 64,190,845 25.94 140,777,241 142,577,583 1.28 

Therapy 870,131,599 971,888,124 11.69 65,199,968 59,909,897 -8.11 935,331,567 1,031,798,021 10.31 

Tropical Diseases 6,009,550 8,553,908 42.34 104,798 684,611 553.27 6,114,348 9,238,519 51.10 

Tuberculosis 45,302 46,587 2.84 0 0 45,302 46,587 2.84 

Tumor Markers 359,406,893 411,307,341 14.44 12,961,700 13,043,137 0.63 372,368,593 424,350,478 13.96 

Tumor Necrosis Factor 20,937,103 21,666,167 3.48 3,462 0 -100.00 20,940,565 21,666,167 3.47 

Underserved Populations 75,689,392 87,086,363 15.06 15,905,038 15,811,281 -0.59 91,594,430 102,897,644 12.34 

Virus-HHV8 10,517,347 12,455,991 18.43 0 0 10,517,347 12,455,991 18.43 

Virus Cancer Research 175,759,100 176,999,020 0.71 5,796,104 3,660,942 -36.84 181,555,204 180,659,962 -0.49 

Virus-Epstein-Barr 16,983,409 21,842,219 28.61 6,288 0 -100.00 16,989,697 21,842,219 28.56 

Virus-Genital Herpes 980,918 791,268 -19.33 0 0 980,918 791,268 -19.33 

Virus-Herpes 44,719,400 49,648,779 11.02 12,576 0 -100.00 44,731,976 49,648,779 10.99 

Virus-HHV6 63,771 48,563 -23.85 6,288 0 -100.00 70,059 48,563 -30.68 

Virus-HTLV-I 4,585,199 5,817,459 26.87 104,798 684,611 553.27 4,689,997 6,502,070 38.64 

Virus-HTLV-II 282,943 272,629 -3.65 0 0 282,943 272,629 -3.65 

Virus-HTLV-Unspec. 218,552 225,104 3.00 104,798 0 -100.00 323,350 225,104 -30.38 

Virus-Papilloma 37,779,646 38,294,419 1.36 3,149,070 1,203,737 -61.77 40,928,716 39,498,156 -3.50 

Virus-Papova $47,508,362 $48,070,872 1.18 $3,149,070 $1,203,737 -61.77 $50,657,432 $49,274,609 -2.73
Table 16.NCI Organ Site-Specific Dollars for FY2002— 

 Percent Change from FY2001* 

 2001 2002 Percent 2001 2002 Percent 2001 2002 Percent 

Site Category Grants Grants Change Contracts Contracts Change Totals Totals Change

Adrenal $1,835,756 $2,461,533 34.09 $0 $0 $1,835,756 $2,461,533 34.09 

All Sites** 49,817,049 40,369,923 -18.96 26,973,956 39,767,269 47.43 76,791,005 80,137,192 4.36 

Anus 3,771,168 2,830,955 -24.93 0 0 3,771,168 2,830,955 -24.93 

Bladder 21,639,646 26,027,326 20.28 2,051,105 1,274,097 -37.88 23,690,751 27,301,423 15.24 

Blood 1,811,202 973,156 -46.27 35,000 7,518 -78.52 1,846,202 980,674 -46.88 

Bone Marrow 21,391,584 19,677,230 -8.01 0 0 21,391,584 19,677,230 -8.01 

Bone, Cartilage 14,391,897 17,247,451 19.84 0 0 14,391,897 17,247,451 19.84 

Brain 64,438,566 82,797,727 28.49 712,635 1,041,891 46.20 65,151,201 83,839,618 28.68 

Breast 420,581,887 466,221,807 10.85 19,129,296 15,147,918 -20.81 439,711,183 481,369,725 9.47 

Buccal Cavity 4,459,279 4,452,219 -0.16 454,636 776,646 70.83 4,913,915 5,228,865 6.41 

Colon, Rectum 182,552,289 222,963,391 22.14 15,298,482 16,908,463 10.52 197,850,771 239,871,854 21.24 

Central Nervous System 10,799,147 17,456,905 61.65 31,439 155,922 395.95 10,830,586 17,612,827 62.62 

Cervix 55,646,463 56,185,149 0.97 5,888,191 3,859,186 -34.46 61,534,654 60,044,335 -2.42 

Connective Tissue 5,535,330 7,857,870 41.96 0 0 5,535,330 7,857,870 41.96 

Embryonic Tissue, Cells 9,467,501 10,165,631 7.37 0 0 9,467,501 10,165,631 7.37 

Erythrocytes 1,123,696 1,017,898 -9.42 0 0 1,123,696 1,017,898 -9.42 

Esophagus 12,086,969 15,633,684 29.34 3,541,288 558,406 -84.23 15,628,257 16,192,090 3.61 

Eye 1,596,475 2,504,907 56.90 0 0 1,596,475 2,504,907 56.90 

Gall Bladder 169,162 222,092 31.29 0 0 169,162 222,092 31.29 

Gastrointestinal Tract 13,315,454 11,463,853 -13.91 947,158 2,207,704 133.09 14,262,612 13,671,557 -4.14 

Genital System, Female 1,707,350 1,699,401 -0.47 459,865 655,629 42.57 2,167,215 2,355,030 8.67 

Genital System, Male 2,197,552 978,638 -55.47 1,139,865 1,739,438 52.60 3,337,417 2,718,076 -18.56 

Head and Neck 16,535,052 24,867,379 50.39 191,066 1,666,099 772.00 16,726,118 26,533,478 58.64 

Heart 5,244,788 6,253,719 19.24 298,168 380,408 27.58 5,542,956 6,634,127 19.69 

Hodgkins Lymphoma 8,467,163 11,314,840 33.63 4,588 4 -99.91 8,471,751 11,314,844 33.56 

Invertebrate Tissue, Cells 14,585,781 13,247,408 -9.18 0 222,251 14,585,781 13,469,659 -7.65 

Kaposi Sarcoma 18,734,908 16,402,643 -12.45 0 167,574 18,734,908 16,570,217 -11.55 

Kidney 14,319,717 18,754,097 30.97 359,143 475,715 32.46 14,678,860 19,229,812 31.00 

Larynx 1,387,440 1,538,946 10.92 0 0 1,387,440 1,538,946 10.92 

Leukemia 142,979,270 167,559,408 17.19 767,644 1,851,787 141.23 143,746,914 169,411,195 17.85 

Leukocytes 69,241,380 70,161,712 1.33 972,260 1,064,377 9.47 70,213,640 71,226,089 1.44 

Liver 49,439,717 51,157,569 3.47 3,207,659 3,247,716 1.25 52,647,376 54,405,285 3.34 

Lung 178,514,571 206,648,203 15.76 14,782,144 18,114,315 22.54 193,296,715 224,762,518 16.28 

Lymph Node 750,268 678,029 -9.63 0 0 750,268 678,029 -9.63 

Lymphatic System 2,664,440 2,068,357 -22.37 0 0 2,664,440 2,068,357 -22.37 

Melanoma 60,576,181 72,703,068 20.02 2,486,500 2,461,213 -1.02 63,062,681 75,164,281 19.19 

Muscle 8,439,049 9,793,642 16.05 0 0 8,439,049 9,793,642 16.05 

Myeloma 15,062,070 17,356,968 15.24 9,176 761,393 8197.66 15,071,246 18,118,361 20.22 

Nervous System 3,625,268 3,523,660 -2.80 6,288 0 -100.00 3,631,556 3,523,660 -2.97 

Neuroblastoma 13,374,765 16,908,206 26.42 0 0 13,374,765 16,908,206 26.42 

Non-Hodgkins Lymphoma 70,093,377 77,141,012 10.05 2,107,711 2,415,160 14.59 72,201,088 79,556,172 10.19 

Nose, Nasal Passages 1,065,629 2,019,221 89.49 0 0 1,065,629 2,019,221 89.49 

Ovary $66,435,126 $78,133,675 17.61 $5,893,599 $9,597,944 62.85 $72,328,725 $87,731,619 21.30 

(Continued) 

* This table reports funding for research grants and contracts only; training grants and intramural projects are excluded. 

** Research applicable to all sites. 
Table 16.NCI Organ Site-Specific Dollars for FY2002— 

 

 Percent Change from FY2001* (Continued) 

 2001 2002 Percent 2001 2002 Percent 2001 2002 Percent 

Site Category Grants Grants Change Contracts Contracts Change Totals Totals Change

Parathyroid 302,761 144,535 -52.26 0 0 302,761 144,535 -52.26 

Penis 659,708 555,233 -15.84 0 0 659,708 555,233 -15.84 

Pharynx 2,268,913 3,054,679 34.63 0 0 2,268,913 3,054,679 34.63 

Pituitary 1,759,885 2,330,309 32.41 0 0 1,759,885 2,330,309 32.41 

Plant Tissue, Cells 565,847 299,402 -47.09 0 0 565,847 299,402 -47.09 

Platelets 554,711 766,283 38.14 0 0 554,711 766,283 38.14 

Prostate 223,576,342 242,985,186 8.68 14,306,539 16,198,261 13.22 237,882,881 259,183,447 8.95 

Reticuloendothelial System 27,358,067 24,077,970 -11.99 2,629,943 934,837 -64.45 29,988,010 25,012,807 -16.59 

Respiratory System 3,428,953 2,231,189 -34.93 0 0 3,428,953 2,231,189 -34.93 

Retinoblastoma 1,877,505 2,013,370 7.24 0 0 1,877,505 2,013,370 7.24 

Skin 51,157,321 55,643,355 8.77 2,168,240 2,255,975 4.05 53,325,561 57,899,330 8.58 

Small Intestine 1,798,719 1,940,181 7.86 0 0 1,798,719 1,940,181 7.86 

Spleen 346,319 334,096 -3.53 0 0 346,319 334,096 -3.53 

Stomach 3,967,752 6,555,573 65.22 2,010,235 2,097,465 4.34 5,977,987 8,653,038 44.75 

Testis 6,160,001 5,330,602 -13.46 0 105,039 6,160,001 5,435,641 -11.76 

Thymus 1,139,085 1,011,485 -11.20 6,288 0 -100.00 1,145,373 1,011,485 -11.69 

Thyroid 3,330,988 3,948,141 18.53 81,532 0 -100.00 3,412,520 3,948,141 15.70 

Trachea, Bronchus 372,540 386,225 3.67 672,692 393,732 -41.47 1,045,232 779,957 -25.38 

Urinary System 629,770 703,615 11.73 0 0 629,770 703,615 11.73 

Uterus 16,903,933 21,336,142 26.22 835,607 527,039 -36.93 17,739,540 21,863,181 23.25 

Vagina 717,998 690,010 -3.90 0 0 717,998 690,010 -3.90 

Vascular 40,523,773 51,333,578 26.68 374,341 518,142 38.41 40,898,114 51,851,720 26.78 

Wilms Tumor $3,768,844 $4,499,303 19.38 $0 $0 $3,768,844 $4,499,303 19.38 
Table 17.Reviewed Requests for Proposals (RFPs)1

and Master Agreement Announcements (MAAs)2

in FY2002

Announcement Number Announcement Title Workload 

 Round

RFP N01CM27018-45 Early Clinical Trials of Imaging Agents 5/02 

RFP N01-CP-21009-13 Effects of the Chernobyl Accident on Thyroid Cancer and 

 Leukemia and Related Diseases 5/02 

RFP N01-CO-27031-16: Novel Technologies for the Detection, Diagnosis, 

 and Treatment of Cancer (BAA) 5/02 

RFP N01-CM-27004-19 Development of Dosage Forms and Delivery Systems 

 for Anti-tumor Agents 5/02 

Trans-NIH SBIR Omnibus Solicitation Clinical Trials Data 

 Collection Using Hand Held Technologies Area 181 5/02 

RFP SBIR Phase 2 Proposal 5/02 

RFP Loan Repayment Program 5/02 

MAA N01-CP-01003-13 Record Linkage Studies Utilizing Resources in 

 Population-Based Tumor Registries 10/02 

MAA N01-CP-01005-50 Support Services for Studies of Emergent Cancer Issues 10/02 

RFP N01-CN-25005-20 Recompetition: Surveillance, Epidemiology 

 and End Results (SEER) Program 10/02 

RFP N01-BC-27012-74 Early Phase Clinical Trial Protocols to Evaluate Safety 

and Immunogenicity of Human Papilloma Virus VLP Based Vaccines 10/02

1 In terms of review complexity, a single RFP proposal is equivalent to a modest P01, while an MAA proposal is equivalent to 

 an R01. 

2 There were 45 proposals submitted for all MAA, SBIR, and BAA initiatives; 27 proposals were submitted for the RFPs 

 (excluding the BAA); and 79 responses were submitted in response to the Loan Repayment Program.